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Medium and long chain fatty acids exhibit affinity for free-fatty acid receptor 1 (FFA1) 
and 4 (FFA4).  FFA1 and FFA4 are expressed in the pancreas with a third lipid G-
protein coupled receptor, GPR119, and all three GPCRs are also highly expressed by 
gastrointestinal (GI) enteroendocrine L cells, which release glucagon-like peptide 1 
(GLP-1) and peptide YY (PYY).  GLP-1 is a stimulant of insulin secretion 
postprandially, whereas PYY slows GI motility and reduces food intake.  The receptor 
expression patterns raise these receptors’ potential as targets for anti-diabetic and anti-
obesity therapeutics.  This thesis compares the pharmacology and cellular signalling 
of novel FFA1, FFA4 and GPR119 agonists from AstraZeneca, with that of 
commercially available agonists in mouse colonic mucosa.   
Mucosa was mounted in Ussing chambers, voltage-clamped and the resultant short-
circuit current (Isc) was recorded continuously, as a measurement of vectorial epithelial 
ion transport in vitro.  Colonic bead propulsion and charcoal-meal gavage assessments 
were used to measure lower and upper GI transit in vivo, respectively.   
FFA1, FFA4 or GPR119 selective agonism potently inhibited mucosal anion secretion 
via a PYY-Y1 paracrine mechanism.  These anti-secretory responses showed area-
specificity and the descending colon was selected for further interrogation.  Here, 
FFA1 and FFA4 agonists displayed low maximal responses, whereas GPR119 
agonists exhibited partial efficacy in comparison to PSN632408.  All agonists required 
glucose for activity, minimising the potential for hypoglycaemia, a limitation of 
current anti-diabetic drugs.  Furthermore, dual agonism of FFA1, FFA4 or GPR119 
was additive.  The FFA1 antagonist, ANT825 revealed endogenous intestinal FFA1 
tone, and this was inhibited in the presence of the competitive Y1 and Y2 antagonists.  
FFA4 agonism slowed transit in the colon and increased transit in the small intestine, 
whereas FFA1 agonism had no effect on transit in vivo.  As the FFA4 receptor is more 
broadly expressed in the GI tract compared to FFA1 and GPR119, luminal-restricted 
GPR119 agonists in combination with FFA1 agonists should be considered as future 
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PIP2; phosphatidylinositol bisphosphate, 
PKA; protein kinase A, 
PKB; protein kinase B, 
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PKC; protein kinase C, 
PKD; protein kinase D1, 
PLC; Phospholipase C, 
PLD; phospholipase D, 
PepT1; proton-coupled peptide transporter, 
PMD; piecemeal degranulation, 
PP; pancreatic polypeptide, 
po; per os, 
POMC; proopiomelanocortin, 
PPAR; peroxisome proliferator-activator receptor, 
PSN632408; (tert-butyl 4-((3-(pyridin-4-yl)-1,2,4-oxadiazol-5-
yl)methoxy)piperidine-1-carboxylate), 
PVH; paraventricular hypothalamus, 
PVN; paraventricular nucleus, 
PVP; polyvinylpyrrolidone, 
PYY; Peptide YY, 
RNA; ribonucleic acid,  
RYGB; Roux-en Y gastric bypass, 
RT-PCR; reverse transcription polymerase chain reaction, 
s.c; subcutaneous injection, 
SCFA; short-chain fatty acid, 
SDS; sodium dodecyl sulphate, 
SGLT1; sodium-glucose transporter 1, 




SST; somatostatin receptor, 
T2DM; type II diabetes mellitus, 
TA; transit-amplifying cells, 
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TAK1; transforming growth factor β activated kinase 1, 
TAK-875; (6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)biphenyl-3-
yl)methoxy)-2,3-dihydro-1-benzofuran-3-yl)acetic acid hemihydrate, 
TAB1; TGF-β activated binding protein 1, 
TGF-β; transforming growth factor β, 
TLR; toll-like receptor, 
TNF, tumour necrosis factor, 
TNFR; tumour necrosis factor α receptor, 
TRPV1; transient receptor potential cation channel subfamily V member 1, 
TTX; tetrodotoxin, 




UGIT; upper gastrointestinal transit, 
VDCC; voltage dependent calcium channels, 
VIP; vasoactive intestinal polypeptide, 
VMAT; vesicular monoamine transporter, 
VMH; ventromedial hypothalamus, 
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1.1 Obesity and diabetes – a worldwide twin epidemic 
Over the past decade, the prevalence of obesity (defined as having a body mass index 
(BMI) of >30 kg/m2) has grown in severity in all populations.  Today, obesity affects 
more than 650 million individuals globally, and is therefore considered a worldwide 
epidemic (World Health Organisation).  In the UK, 2 in every 3 individuals are 
overweight or obese (Diabetes UK) and in the US, only a third of the population is 
considered to have a normal BMI (Centers of Disease Control and Prevention).  The 
current predicament of obesity is attributed to a Western lifestyle, consisting of highly 
palatable and calorie-dense food and a reduction in energy expenditure (World Health 
Organisation).  Obesity is associated with numerous co-morbidities, the most 
prevalent being Type II diabetes mellitus (T2DM) (Guh et al., 2009).  T2DM is 
associated with a decline in β cell insulin secretion, hyperglycaemia, progressive β cell 
apoptosis and whole-body insulin resistance, resulting in a reduction in glucose uptake 
in the periphery (skeletal muscle, liver and adipose tissue) (Kahn et al., 2006).  The 
term diabesity was coined to express the closely-linked relationship between obesity 
and T2DM (Zimmet et al., 2001).   Both diseases are characterised by peripheral 
insulin resistance and pancreatic β cell insulin deficiency (Verma and Hussain, 2017).  
As early as 1997, it was revealed that for every kg of weight gained, the risk of diabetes 
increased by 4.5 – 9 %, highlighting a potential link between obesity and T2DM (Ford 
et al., 1997).  Today, approximately 90 % of T2DM cases are attributed to excess 
weight gain (World Health Organisation), confirming weight gain as a significant 
contributor to an increased risk of T2DM (Al-Goblan et al., 2014).     
At the start of this PhD (2014), approximately 382 million individuals were diagnosed 
with diabetes.  It is predicted that without concerted action, the number of individuals 
diagnosed is expected to rise to 592 million by 2035, especially in developing 
countries (Guariguata et al., 2014).  The exponential increase in this twin epidemic is 
not only a public health and economical concern, but a challenge in terms of 
discovering improved nonsurgical combinational therapies to curb both diseases.  
Diet, lifestyle and exercise modification, while initially promising, are linked to a high 
failure rate without long-term benefit.  In clinical practise, obese/overweight patients 
only maintained 4.7 % weight loss with intensive behavioural therapy over 2 years 
(Wadden et al., 2011), demonstrating this intervention method was not an adequate 
treatment.  There is only 1 drug available and licenced in Europe (Orlistat) and only 3 
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anti-obesity drugs currently available in the US (Phentermine, Orlistat, Lorcaserin) 
(Yanovski and Yanovski, 2014).  Orlistat is a pancreatic lipase inhibitor which 
prevents lipid hydrolysis and absorption, but only achieves modest weight loss of 2.9 
kg compared to placebo over a one year period (Rucker et al., 2007).  Unfortunately, 
Orlistat is associated with an increase in faecal fat, also known as steatorrhea, and this 
severely limits patient compliance (Douglas et al., 2015).  Previously licenced anti-
obesity therapeutics, Sibutramine (serotonin-noradrenaline reuptake inhibitor) and 
Rimonabant (cannabinoid receptor 1 (CB1) antagonist) were withdrawn due to 
cardiovascular and psychiatric health concerns (Christensen et al., 2007; James et al., 
2010).  The lack of successful anti-obesity therapeutics demonstrates the critical need 
for new efficacious drugs in this field, without adverse effects.  Currently, in the UK 
there are no available combinational drug formulations to treat both obesity and T2DM 
simultaneously.   
The successful surgical treatment of obesity is limited to bariatric surgery, particularly 
Roux-en Y gastric bypass (RYGB).  RYGB achieves efficacious and maintained long 
term weight loss (75 %) (Smith et al., 2008), resolution of T2DM and a reduction in 
mortality and morbidity (Sjöström et al., 2007).  This surgical procedure involves 
sectioning a portion of the stomach, which forms a gastric pouch that is anastomosed 
to the jejunum (alimentary limb).  This creates a diverted passage for ingested material 
to reach a more distal region of the small intestine (Meek et al., 2016).  In the past, 
RYGB was advocated for individuals who were morbidly obese (BMI of 40kg/m2).  
However, due to the steep rise in the obese population and the lack of efficacious anti-
obesity therapeutics, surgery is now available to patients with a BMI >35kg/m2, with 
associated severe T2DM or hypertension (Mayo Clinic, 2017).  The success of RYGB 
has been attributed to the alteration in the milieu of gastrointestinal (GI) hormones 
(e.g. peptide YY(PYY) and glucagon-like peptide 1(GLP-1)) post-surgery (le Roux et 
al., 2006a; Saeidi et al., 2013).  As a result, in the last 10-15 years, targeting the release 
of GI hormones, specifically PYY and GLP-1 from enteroendocrine L cells,  has 
become a major area of interest to emulate post-RYGB GI peptide alterations and 
combat both obesity and T2DM (le Roux et al., 2006a; Meek et al., 2016).  Proven 
GLP-1 mimetics (Exenatide and longer-acting Liraglutide) are market-approved anti-
diabetic therapeutics that mimic the effects of GLP-1, at the glucagon-like peptide 1 
receptor (GLP-1R).  These drugs are well tolerated, robustly increase β cell insulin 
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secretion, improve glucose tolerance and show mild GI adverse effects (Chaudhury et 
al., 2017).  GLP-1 mimetics also cause modest weight loss.  In an earlier study, short-
term Exenatide treatment caused 2.49 kg weight loss in a subset of obese woman, 
compared to 0.43 kg weight gain in the placebo-treated group (Dushay et al., 2012). 
More recently,  Liraglutide induced 5-10 % weight loss compared to placebo (Mehta 
et al., 2017), indicating GLP-1 mimetics possess anti-diabetic and anti-obesity 
activity.  PYY is a potent anorexigenic peptide.  Clinical data indicated that infusion 
of truncated PYY  (also known as PYY(3-36)) reduced food intake in healthy volunteers, 
confirming the robust satiety-inducing effects of this hormone (Degen et al., 2005; le 
Roux et al., 2006b).  These favourable anti-diabetic and anti-obesity effects of L cell-
derived GLP-1 and PYY have facilitated the development of agonists that stimulate 
endogenous GLP-1 and PYY release.  These potential agonists could emulate the 
effects of GLP-1 mimetics, with the added benefit of PYY-induced satiety, and 
therefore provide relief of both diseases (obesity and T2DM), with a single drug 
formulation.  Lipids/lipid metabolites powerfully stimulate PYY (Beglinger and 
Degen, 2006) and GLP-1 release postprandially in humans (Little et al., 2005; Carr et 
al., 2008; Beglinger et al., 2010; Hansen et al., 2011; Mandøe et al., 2015), rodent 
models (Adachi et al., 2006; Xiong et al., 2013; Dailey et al., 2014; Ekberg et al., 
2016; Moss et al., 2016) and primary cultured L cells (Habib et al., 2013; Moss et al., 
2016).  Therefore, in this thesis, the GI L cell lipid receptors, free-fatty acid receptors 
(FFA) 1 (FFA1, previously known as GPR40), FFA4 (GPR120) and the ethanolamide 
receptor, GPR119, were interrogated with novel selective agonists and antagonists. 
 
1.2 Overview of the gastrointestinal tract 
The GI tract is a group of organs from the oral cavity to the rectum (including the 
pharynx, oesophagus, stomach, small intestine, large intestine) and encompasses the 
associated glandular organs (Figure 1.1).  Together, they form the largest endocrine 
organ of the human body, that at its luminal interface consists of a single layer of 
epithelial cells (Reed and Wickham, 2009).  This epithelial layer is in direct contact 
with the external environment and exhibits a large surface area of 100 – 400 m2 
(includes the stomach, small intestine and colon) (Ferraris et al., 1989; MacDonald 
and Monteleone, 2005; Artis, 2008).  Each GI area has a crucial role to play in energy 
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homeostasis, digestion, nutrient (fatty acids, amino acids and monosaccharides) and 
electrolyte absorption and secretion, monitoring the energy status of the body, 
activating and modulating the appropriate physiological responses, protecting the 
body from bacteria and carcinogens and eliminating undigested material (Furness et 
al., 2013).  Ingested material is temporarily stored in the stomach before it is released 
into the small intestine, the primary region of nutrient digestion and absorption.  Here, 
lipids, proteins and carbohydrates undergo enzymatic digestion, providing fatty acids, 
amino acids and monosaccharides, respectively (Hall, 2011).  Absorption of these 
digested nutrients from the intestinal lumen, stimulates the release of a myriad of 
peptides that are key regulators of satiety, GI motility, gastric emptying, 
enteroendocrine and exocrine secretions and overall control of body weight (Perry and 
Wang, 2012).  Finally, the remaining undigested luminal material reaches the large 
intestine, a GI region mainly responsible for reclaiming luminal fluid and electrolytes.  
The undigested material is temporarily stored in the sigmoid colon and rectum, prior 





















Figure 1.1: The structure of the GI tract.  The oral cavity to the anal sphincter, 
including the associated glandular organs (the liver, pancreas and gallbladder). Image 
from Barrett and Raybould (2010).   
 
1.3 The small intestine 
The small intestine constitutes the area from the pyloric sphincter to the ileocaecal 
junction.  In humans, the small intestine is approximately 5 m in length and is divided 
into three regions, the duodenum, the jejunum and the ileum  (Mescher, 2010).  As 
chyme arrives in the duodenum, its acidity is neutralised by bicarbonate ions (HCO3
-) 
secreted mainly by the pancreas and gallbladder, via the pancreatic duct and common 
bile duct, respectively (Reed and Wickham, 2009; Barrett and Raybould, 2010).  
Additionally, duodenal submucosal Brunner glands contribute to the neutralisation of 
chyme by secreting an alkaline fluid (pH 8.1 - 9.3).  This protective mechanism shields 
the mucous membrane and ensures chyme is at an optimum pH for pancreatic enzyme 
activity (Mescher, 2010).  The duodenum and jejunum are responsible for achieving 
complete digestion of lipids, carbohydrates and proteins to allow efficient absorption 
of their digested nutrients (Hall, 2011).  The robust nutrient absorption in these regions 
is attributed to the increased surface area provided by mucosal villi (0.5 to 1.5 mm 
long) that project into lumen and secondly, microvilli (1 µm tall and 0.1 µm in 
diameter) that protrude from the apical cytoplasm of absorptive enterocytes 
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(MacDonald and Monteleone, 2005; Mescher, 2010).  Each enterocyte contains 3000 
microvilli and therefore 1 mm2 of intestinal mucosa is home to 200 million microvilli, 
vastly increasing the area of contact with ingested nutrients, allowing efficient 
absorption (Mescher, 2010). 
 
1.3.1 Digestion of lipids  
As triglycerides enter the small intestine, they are broken down into smaller lipid 
micelles (0.5 µm in diameter) (Carey et al., 1983) and phospholipids by mechanical 
disruption, caused by the frequent contractions of the stomach and small intestine 
(Hall, 2011).  The newly arrived bile, secreted from the gallbladder, contains bile salts 
that prevent reaggregation of the smaller lipids, a process known as emulsification 
(Iqbal et al., 2009) (Figure 1.2).  Due to the amphipathic nature of phospholipids and 
bile salts, the lipolytic enzyme, pancreatic lipase is repelled (Chapus et al., 1975).  To 
combat this, a second pancreatic enzyme, colipase, binds the emulsified lipid droplet 
and provides a binding site for pancreatic lipase (Erlanson-Albertsson, 1992; Lowe, 
1997).  This lipase digests triglycerides, yielding 2-monoglyceride (2-MAG) and two 
FFAs (Mattson and Beck, 1955; Mattson and Volpenhein, 1964; Clément, 1976).  
These lipid metabolites, phospholipids and bile salts aggregate to form micelles.  
Micelles continuously disaggregate and re-form, which enhances their absorption into 
the enterocytes (Clément, 1976; Mu and Høy, 2004).  The lipid nutrients are detected 
and sensed by GI lipid-sensing receptors i.e. FFA1, FFA4 and GPR119 (Ekberg et al., 
2016).  Within the enterocytes, the lipid metabolites, 2-MAG and FFAs re-esterify 
forming chylomicrons (Mattson and Volpenhein, 1964).  Chylomicrons are 














Figure 1.2: Digestion of triglycerides in the small intestine.  Large lipid droplets 
are broken down by mechanical disruption into smaller lipids.  Bile salts released 
from the gallbladder create an emulsification mixture that prevents re-aggregation of 
the small lipids.  Pancreatic lipase digests triglycerides into 2-MAG and two FFAs.  
These lipid metabolites along with phospholipids and bile form micelles.  Finally, 




1.3.2 Digestion of carbohydrates  
Ingested carbohydrates consist of monosaccharides, disaccharides and 
polysaccharides.  Monosaccharides are absorbable and do not require further 
digestion.  In contrast, disaccharides (sucrose) and polysaccharides (e.g. starch) 
require enzymatically degradation before absorption can occur.  The pancreatic 
enzyme, α-amylase digests disaccharides and polysaccharides into shorter chains of 
glucose e.g. maltose, lactose and sucrose (Figure 1.3) (Dahlqvist and Borgstrom, 
1961).  The shorter chains of glucose undergo further digestion by disaccharidases 
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(sucrase, maltase and lactase), found embedded in the intestinal microvilli brush 
border to yield monosaccharides (Holmes, 1971).  Sucrase digests sucrose into glucose 
and fructose.  Maltase yields two glucose molecules from maltose, and lactase splits 
the bond between galactose and glucose (Holmes, 1971; Dahlquist and Semenza, 
1985; Levin, 1994).  Glucose (as well as galactose) is actively transported across 
enterocytes predominantly via the apical-located sodium-glucose transporter 1 
(SGLT1) (Crane, 1962; Wright et al., 2011; Gorboulev et al., 2012), whereas fructose 
is transported across the epithelia via the luminal facilitative transporter, GLUT5 
(Davidson et al., 1992; Miyamoto et al., 1993).  As the glucose concentration 
increases, the facilitative transporter, GLUT2 is trafficked to the luminal membrane to 
facilitate glucose absorption in rodents (Kellett and Helliwell, 2000; Tobin et al., 2008; 
Gorboulev et al., 2012; Mace et al., 2012).  Absorbed glucose, galactose and fructose 
exit the enterocytes and enter the circulation via serosal GLUT2 (Thorens et al., 1990; 


















Figure 1.3: Digestion of carbohydrates in the small intestine.  Polysaccharides 
(starch, glycogen) are digested by pancreatic α-amylase in the intestine into 
disaccharides (maltose, sucrose and lactose).  Disaccharides are further digested by 
disaccharidases (maltase, sucrase, lactase) located in the microvilli brush border into 
monosaccharides.  Image from https://www.pinterest.co.uk/pin/751678994025683223/.  
 
1.3.3 Digestion of proteins 
In the duodenum and jejunum, ingested proteins and polypeptides are digested into 
oligopeptides and amino acids by pancreatic proteolytic enzymes (trypsin, 
chymotrypsin, elastase and carboxypolypeptidase), excreted via the hepatopancreatic 
sphincter.  Trypsin, chymotrypsin and elastin are serine proteases.  Trypsin cleaves 
peptide bonds adjacent to lysine or arginine, whereas chymotrypsin cleaves peptide 
bonds next to hydrophobic amino acids to yield oligopeptides.  Furthermore, elastase 
cleaves elastin and peptide bonds next to alanine, glycine and serine, and 
carboxypolypeptidase digests the carboxyl ends of peptides, releasing free amino acids 
(Figure 1.4) (Whitcomb and Lowe, 2007; Goodman, 2010).  Final protein hydrolyses 
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occurs at the enterocyte brush border membrane by aminopeptidase (hydrolysing the 
amino-terminus) and dipeptidases (cleaves dipeptides into free amino acids) (Tobey 
et al., 1985; Goodman, 2010).  The free amino acids are transported across enterocytes 
into the circulation via several electrogenic amino-acid transporters, while 
approximately 8000 distinct di- and tripeptides are transported via the high 
capacity/low affinity proton-coupled peptide transporter, PepT1 (Liang et al., 1995; 













Figure 1.4: Protein digestion in the small intestine.  Pancreatic proteolytic 
enzymes (trypsin, chymotrypsin, carboxypeptidase) and microvilli brush border 
enzymes (aminopeptidase, carboxypeptidase) digest proteins into di- and tripeptides 
and free amino acids.  The digested proteins are transported across the enterocyte 






1.4 The large intestine 
The large intestine of humans (from the ileocaecal junction to the rectum) spans a total 
length of approximately 1.5 m, and is divided into the caecum, ascending colon, 
hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon 
and the rectum (Geissler and Powers, 2017).  The colon has multiple invaginations 
with flat intercrypt tables (Figure 1.5) and is home to approximately 1200 different 
bacterial species, with 160 microbiota unique to each host (Qin et al., 2010; Schroeder 
and Bäckhed, 2016).  Collectively, the microbial genome is greater than the human 
genome, encoding at least 100 times more genes (Ley et al., 2006; Qin et al., 2010).  
In the intestine, the quantity and diversity of the microbiota increases along the length 
of the GI tract, from the small intestine (duodenum, 101 – 103;  jejunum/ileum, 104 – 
107 per ml of luminal contents) to the large intestine (10
11 – 1013 per ml of luminal 
contents) (Whitman et al., 1998; Eckburg, 2005; O ’hara and Shanahan, 2006; Artis, 
2008; Donaldson et al., 2016; Sender et al., 2016).  The two major phyla systems in 
the distal gut that constitute 90 % of phyla in this region, are Firmicutes and 
Bacteroidetes.  The quantitative ratio between these two phyla vary between hosts 
(Eckburg, 2005).  The complexity increases as differences in mucosal surface-
adherent and lumen microbiota populations have been observed, which also vary in 
aerobic and anaerobic ratios (Eckburg, 2005).  The colonic microbiota critically 
degrade complex indigestible carbohydrates, yielding short-chain fatty acids (SCFA) 
such as acetate, propionate and butyrate (Marchesi et al., 2016).  The SCFAs are 
predominantly absorbed via passive diffusion, however some require active transport 
via various SCFA transporters.  SCFA are also sensed by FFA receptor 2 (FFA2) and 
3 (FFA3) to regulate lipid and glucose metabolism (Brown et al., 2003; Ulven, 2012).  
Oxidation of absorbed SCFAs, particularly butyrate provides 60-70 % of the energy 
supply of colonic enterocytes.  Thus, SCFAs are a fundamental energy source in the 






















Figure 1.5: The structural organisation of the small intestine (A) and colon (B) in 
mouse, shown in the scanning electron micrograph panel on left and in the 
schematic on the right.  The small intestine contains specialised villi and microvilli 
that vastly enhance the surface area of the epithelium and are specifically required for 
efficient absorption of digested nutrients.  Conversely, the colon consists of flat 








1.5 Structural organisation of the intestine 
The structural organisation of the intestine is composed of the mucosa, submucosa, 
submucosal plexus, the muscularis externa, myenteric plexus and the serosa, which 
forms part of the mesentery (Figure 1.6) (Mescher, 2010).     
 
 
Figure 1.6: Transverse section illustrating the anatomy of the small intestine.  
Structural layers of the GI tract include the mucosa (epithelium, lamina propria, 
muscularis mucosa), submucosa with the associated submucosal plexus, muscularis 
externa (constituting circular and longitudinal smooth muscle) and a second neuronal 
plexus, the myenteric plexus lies between the two smooth muscle layers.  The serosa 
is the most outer layer that forms part of the mesentery.  Image from Barrett and 
Raybould (2010).   
 
1.5.1 The intestinal mucosa 
The mucosa is the innermost structural layer of the intestine and is highly adaptable to 
the ever-changing macronutrient environment in the GI lumen.  It provides mucosal 
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immunity against noxious substances, aids digestion and absorption of ingested 
material, maintains mucosal integrity via tight junctions and regulates electrolyte and 
fluid transport, which critically prevents hypo- or hypersecretion states (Hall, 2011).  
The mucosa is segregated from the GI lumen by a single layer of simple columnar 
epithelial cells, surrounded by the lamina propria and muscularis mucosa (Mescher, 
2010).  Here, the different cell populations along the length of the GI tract epithelium 
are organised to meet the functional requirements of specific regions and are linked 
by highly selective intercellular tight junctions.  These tight junctions are composed 
of occludins (Furuse et al., 1993), claudins (Furuse et al., 1998), junctional adhesion 
molecules (Martìn-Padura et al., 1998) and tricellulin (Ikenouchi et al., 2005), which 
together critically regulate cell permeability, paracellular transport of fluid and 
electrolytes and prevent bacterial translocation.  Importantly, these tight junctions 
segregate the luminal and serosal membrane and compartment (Nusrat et al., 2000).  
In this thesis, the segregation of luminal (also known as apical (ap)) and serosal (also 
known as basolateral (bl)) epithelial surfaces imposed by the tight junctions, allowed 
interrogation of various side-specific mucosal receptors with selective agonists.   
In humans, the GI epithelium undergoes a daily cell death of 1011 epithelial cells 
(Potten, 1995), and therefore it is pertinent that the epithelium adapts and self-renews 
to maintain optimum barrier function.  The epithelium is steadily replaced during 
adulthood with newly regenerated cells, originating from 4-6 adult stem cells per 
crypt.  These stem cells are anchored at the base of discrete proliferative invaginations 
(bottle-shaped), known as the crypts of Lieberkühn (Marshman et al., 2002).  Initial 
studies labelled proliferating cells with [3H]thymidine to show cell migration and 
intestinal epithelium renewal.  This revealed stem cells lie at the base of each crypt 
(Cheng and Leblond, 1974).  These pluripotent stem cells give rise to a transient 
population of highly proliferative progenitor cells, known as transit-amplifying cells 
(TA).  These TA cells undergo 2-3 cell divisions and terminally commit to one of four 
linages, while migrating towards the lumen (with the exception of Paneth cells) 
(Cheng and Leblond, 1974) (Figure 1.7).  The four lineages include the absorptive 
cell, enterocytes (80 %) (Karam, 1999; de Santa Barbara et al., 2003) or one of the 
three secretory lineages, nutrient sensing enteroendocrine cells (EECs) (<1 %) (Buffa 
et al., 1978), mucus-secreting goblet cells (5 % in small intestine (de Santa Barbara et 
al., 2003) and 16 % in the colon (Karam, 1999)) and immune Paneth cells.  Cup cells 
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(6 %) (Madara, 1982), tuft cells (0.4 %) (Gerbe et al., 2012), Peyer-patch cells (46 %) 
(Van Kruiningen et al., 2002) and microfold cells (M cells; 5-10 %) (Ohno, 2016) 
have also been identified, but their functions are still poorly defined.  Once the 
terminal differentiated cell types reach the top of small intestinal villi or the colonic 
intercrypt table, they are sloughed off into the lumen, a process occurring every 3-5 
days in mammals (Potten, 1995).  Conversely, Paneth cells migrate towards the base 
of the crypt (Bjerknes and Cheng, 2005). Here, they secrete eosinophilic secretory 
granules containing lysozymes, phospholipase A2 and defensins (Mescher, 2010).  
Initial [3H]thymidine labelling studies in mouse established Paneth cell renewal occurs 
every 18 - 22 days (Cheng et al., 1969).  Later, Ireland et al. (2005) indicated Paneth 
cell turnover occurs every 57 days in mice, three-times long than initial findings.  
Recently, Bohórquez et al. (2015), revealed a similar turnover rate for a population of 
long-lived mouse EECs.  These cells were more resilient and could reside in the 
epithelium for up to 60 days (Bohórquez et al., 2015).  Understanding the longer 
lifespan of these EECs in the epithelial lining while other EECs/enterocytes are 









Figure 1.7: The distribution of various epithelial cell types along the small 
intestine.  Stem cells anchored to the base of crypts of Lieberkühn divide and migrate 
to produce proliferative progenitors also known as TA cells (partially differentiated).  
These TA cells undergo terminal differentiation to produce 1 of 4 lineages: 
enterocytes, goblet cells, EECs or Paneth cells.  Image from Crosnier et al. (2006). 
 
The lamina propria segregates the mucosal epithelium from the submucosa and 
penetrates each intestinal villus.  This layer is primarily composed of loose connective 
tissue, fibroblasts, blood and lymphatic vessels, nerve fibres, lymphoid nodules, 
dendritic cells, antigen presenting cells, immunoglobulin A-secreting plasma cells, 
macrophages and lymphocytes (B cells and T cells) (Reed and Wickham, 2009; 
Mescher, 2010). Surrounding the lamina propria is the outermost layer of the mucosa 
known as the muscularis mucosa.  This layer is composed of elastin fibres and 3-10 
smooth muscle cells (Boudry et al., 2004).  These smooth muscle cells may extend 
into the intestinal villi and their rhythmic contraction is responsible for the movement 
of the villi (Mescher, 2010).   
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In the ileum and colonic lamina propria (and submucosa), aggregates of lymphoid 
follicles (10-200) form Peyer patches, an important component of mucosa-associated 
lymphoid tissue (MALT) (Mescher, 2010).  Together, Peyer patches, mesenteric 
lymph nodes and the appendix are collectively known as gut-associated lymphoid 
tissue (GALT) (Guy-Grand et al., 1974).  The GALT is responsible for 50 % of the 
body’s immune response, providing mucosal immunity against resident bacteria and 
preventing penetration of pathogens from the external environment (Fukatsu and 
Kudsk, 2011). M cells play an important role in GI mucosal immunity.  Simple 
follicle-associated epithelium (FAE), containing M cells lie above Peyer patches.  M 
cells contain specialised apical folds and a basolateral intraepithelial pocket, open to 
underlying aggregates of lymphoid tissue via a porous basement membrane (Neutra 
and Kraehenbuhl, 1992).  These cells sample luminal antigenic ingested material and 
pathogens.  Antigens that bind to M cells are translocated into the intraepithelial 
pocket and are subsequently presented to the underlying immune cells.  This initiates 
an adaptive immune response to neutralise the presented antigens (Neutra and 
Kraehenbuhl, 1992; Neutra et al., 1996).  
 
1.5.2 Submucosal plexus and deep muscular plexus 
The submucosa is a thin layer of loose connective tissue that supports the mucosa and 
consists of blood vessels, lymph vessels and submucosal glands (i.e. duodenal Brunner 
glands) (Barrett and Raybould, 2010).  The blood vessels extend from this region to 
the intestinal villi forming a capillary network just beneath the epithelium.  Venules 
branch off from this network to re-join the submucosal veins.  The lymphatic vessels 
also known as lacteals begin in the intestinal villi, extend to the lamina propria where 
they form a plexus, and eventually are directed to lymphoid nodules in the submucosa 
(Mescher, 2010).  Surrounding the submucosa is an intrinsic neuronal network known 
as the submucosal plexus (also known as Meissner plexus) (Furness and Costa, 1987).  
In humans, this plexus is interconnected with a second submucosal plexus also known 
as Henle’s plexus, located closest to the circular muscle (Hoyle and Burnstock, 1989).  
Encircling the submucosa, is a smooth muscle layer, known as the muscularis externa.  
This muscle layer is made up of two layers of smooth muscle, the inner layer consists 
of circular muscle fibres and the outer layer is composed of longitudinal muscle fibres.  
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In humans, the circular muscle layer is further divided into the inner (more densely 
packed) and outer circular muscle layers (Furness and Costa, 1987). Interspersed in 
the muscularis externa between the circular and longitudinal muscle cells are 
interstitial cells of Cajal (ICC), also known as the pacemaker cells of the muscularis 
externa (Sanders et al., 2006).  ICCs are responsible for generation, modulation and 
propagation of slow wave potentials that regulate GI motility (Farrugia, 2008).  
Between the circular and longitudinal muscle layers is a second intrinsic network 
known as the myenteric plexus (also known as Auerbach plexus).  Together, the 
myenteric plexus and the submucosal plexus form the intrinsic nervous system of the 
GI tract, also known as the enteric nervous system (ENS) (Furness and Costa, 1987; 
Furness et al., 2014).  
 
1.5.3 Serosa 
Surrounding the muscularis externa lies the serosa, a thin layer of squamous 
mesothelial cells and loose connective tissue.  This layer forms part of the mesentery, 
which surrounds the intestine providing protection and support (Barrett and Raybould, 
2010).  
 
1.6 The enteric nervous system  
The ENS of the GI tract forms the third division of the autonomic nervous system 
(ANS) and is composed of an interconnected intrinsic circuit of ganglionated neurons 
(400-600 million in humans) and glial cells (Furness and Costa, 1987; Furness, 2006), 
which are able to function independently of the central nervous system (CNS) (Bayliss 
and Starling, 1899).  While the ENS is often referred to as an autonomous nervous 
system, local enteric reflexes integrate with autonomic reflexes from the CNS, to 
regulate gastric acid secretion, gastric emptying, GI motility, appetite and satiety (also 
known as the gut-brain-axis), local blood flow, fluid and electrolyte secretion, 
expulsion of noxious substances, enteroendocrine secretions, immune responses 
(Furness, 2012), mucosal integrity (Toumi et al., 2003) and defaecation (Furness and 
Costa, 1987; Furness, 2006).  
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The ENS neurons and glia are composed of two main ganglionated plexuses (Brehmer 
et al., 2010), the submucosal plexus (also known as Meissner plexus) located adjacent 
to the mucosal layer, and the myenteric plexus (Auerbach plexus) situated between 
the longitudinal and circular smooth muscle layers of the muscularis externa (Furness 
and Costa, 1987).  The submucosal plexus can be subdivided into two intensively 
interconnected plexuses.  First, the inner plexus which is nearest to the muscularis 
mucosa (Meissner plexus) and a second outer plexus (Schabadasch plexus, also known 
as Henle’s plexus) observed in larger mammals, found adjacent to the circular smooth 
muscle of the muscularis externa (Hoyle and Burnstock, 1989).  Notably, the 
submucosal plexus has been identified in the small and large intestine and is rarely 
seen in the stomach and oesophagus.  In contrast, the myenteric plexus is found 
throughout the GI tract, from the oesophagus to the rectum sphincter (Furness, 2012).  
There are three functional classes of neurons that have been identified in the ENS: 
intrinsic primary afferent neurons (IPANs), motor neurons and interneurons (Furness, 
2000; Furness, 2008; Qu et al., 2008; Furness et al., 2014) (Table 1.1).  Many of the 
initial ENS studies were carried out in guinea pig, attributed to the accessibility of 
large ENS plexuses, of which many of the enteric neurons types (approximately 14) 
have been identified (Furness and Costa, 1987; Furness, 2000).  However, over the 
years the mouse has become the species of choice as genetic manipulation and the 
generation of models of disease are easily accessible (Gershon, 1999).  
Characterisation of the mouse ENS revealed that the neuronal projections, 
morphology, neurochemistry and electrophysiology closely resembled the human and 
guinea-pig ENS, therefore providing a comparative model (Sang and Young, 1996; 
Sang et al., 1997; Sang and Young, 1998; Furness et al., 2004; Nurgali et al., 2004; 







Table 1.1 Different ENS neuronal populations in the mouse small intestine.  Table 
1.1 shows the various types of ENS neurons in the mouse small intestine, including 
the chemical code and the proportion of each neuronal type.  Table from Qu et al. 
(2008). 
 
1.6.1 Intrinsic primary afferent neurons 
In the mouse, Dogiel type II multi-axonal neurons (also known as AH neurons) closely 
resemble the morphology, projections, chemistry coding (Furness et al., 2004) and 
electrophysiological properties (Nurgali et al., 2004) of the guinea pig Dogiel type II 
IPANs.  As a result, mouse Dogiel type II neurons are most likely IPANs (Furness et 
al., 2004; Nurgali et al., 2004).  Mouse IPAN cell bodies are oval-shaped and project 
short and long axons.  IPANs constitute 20.6 % of the total myenteric neuronal 
population in mouse colon (Nurgali et al., 2004) and 26 % in the mouse small intestine 
Mouse small intestine     
Neuronal type Chemical code Proportion 




muscle motor neuron 
NOS/VIP ± NPY 23 % 
Inhibitory longitudinal 
muscle motor neuron 
NOS/VIP 3 % 
Excitatory circular 
muscle motor neuron 
ACh/neurokinins ± calretinin  21 % 
Excitatory longitudinal 
motor neuron 
ACh/calretinin ± neurokinins 13 % 
Descending interneuron ACh/NOS 3 % 
Descending interneuron ACh/5-HT 1 % 
Descending interneuron ACh/SOM/calretinin 4 % 
Ascending interneuron ACh/neurokinins ± calretinin 4 % (estimated) 
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(Qu et al., 2008).  The population of IPANs appears to be negatively correlated to 
species size, with larger mammals possessing fewer IPANs.  Indeed, in humans the 
IPAN population comprises 10 % of the total neuronal population (Weidmann et al., 
2007), approximately half the quantity of IPANs observed in the mouse.   Colonic 
(Furness et al., 2004) and small intestinal (Qu et al., 2008) IPANs project to the 
myenteric ganglia and the mucosa (Furness et al., 2004; Nurgali et al., 2004). 
Similarly, human intestinal IPANs project to the mucosa, which was illustrated 
utilising retrograde transported dye (Dil) (Hens et al., 2001). In an earlier study, 
stimulation of guinea pig small intestine mucosal nerve fibres provided action 
potentials which were recorded from Dogiel type II neurons, confirming IPAN axons 
extend to the mucosa (Bertrand et al., 1998).  In contrast, there appear to be no IPANs 
or IPAN-like neurons in the mouse submucosal layer of the ileum (Mongardi 
Fantaguzzi et al., 2009) or distal colon (Foong et al., 2014).   Small intestinal IPANs 
possess the chemical coding of acetylcholine (ACh)/calbindin/ calcitonin gene-related 
peptide (CGRP)/neurofilament (NF) 145 kDa ± calretinin (Qu et al., 2008) and 
similarly, colonic IPANs are immunoreactive for CGRP/calbindin/ACh/NF±calretinin 
(Furness et al., 2004).  In the guinea pig, IPANs are responsible for sensing mechanical 
distortion of the mucosa, altering enteroendocrine secretions, modulating GI motility, 
regulating local blood flow and fluid, as well as adjusting electrolyte secretion 
(Furness, 2012; Furness et al., 2014).  Thus, as murine IPANs are closely related to 
guinea pig and human IPANs, their functional significance may be similar among 
these species. 
 
1.6.2 Motor neurons 
Motor neurons are Dogiel type I uni-axonal, S-type and receive fast excitatory synaptic 
potentials (Nurgali et al., 2004).  These neurons possess broad lamellar dendritic 
structures, which are less extensive compared to human Dogiel type I neurons (Furness 
and Costa, 1987).  In mammals, motor neurons are divided into excitatory (containing 
ACh and neurokinins) and inhibitory neurons (containing nitric oxide synthase (NOS) 
and vasoactive intestinal polypeptide (VIP)) (Furness, 2006).  In the mouse intestine, 
the ratio of excitatory motor neurons to inhibitory motor neurons in circular smooth 
muscle is 21 %: 23 % (Qu et al., 2008) (guinea pig 12 % :16 % (Furness, 2000)) and 
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in longitudinal smooth muscle, 13 %: 3 % (Qu et al., 2008) (guinea pig 25 %: 2 % 
(Furness, 2000)).   The chemical coding of the excitatory motor neurons are 
ACh/neurokinins ± calretinin (circular muscle) and ACh/calretinin ± neurokinins 
(longitudinal muscle).  Conversely, the chemical coding of inhibitory motor neurons 
is NOS/VIP ± neuropeptide Y (NPY) (circular muscle) (Sang et al., 1997; Qu et al., 
2008) and NOS/VIP (longitudinal muscle) (Qu et al., 2008).  This inhibitory NOS/VIP 
immunoreactivity is similarly observed in humans (Timmermans et al., 1994; Porter 
et al., 1997).   In mammals, NOS and choline acetyltransferase (ChAT) are the rate-
limiting enzymes in the pathways that synthesise the inhibitory neurotransmitters, 
nitric oxide (NO) and the excitatory neurotransmitter, ACh, respectively (Furness, 
2006). Initial mouse studies demonstrated that NOS-containing neurons projected 
anally (Sang et al., 1997), and ACh-containing neurons projected orally (Sang and 
Young, 1998), revealing inhibitory and excitatory neurons, respectively.  Notably, in 
small mammals the predominant motor neuron innervation originates from the 
myenteric plexus, whereas large mammals have a small proportion of motor 
innervation that arises from the submucosal plexus as well (Furness, 2000).   
 
1.6.3 Secretomotor neurons 
In the mouse, there are two functional classes of secretomotor neurons (S-type) (Foong 
et al., 2014), namely cholinergic and non-cholinergic (Furness, 2000; Mongardi 
Fantaguzzi et al., 2009; Foong et al., 2014; Furness et al., 2014).  The proportion of 
cholinergic neurons (contains 2 axons) increases distally in the colon, whereas non-
cholinergic VIP-containing neurons (contains 1 axon) are vastly distributed 
throughout the colon (Foong et al., 2014).   These two neuronal populations project 
their axons to the intestinal mucosa (Foong et al., 2014), and therefore secretomotor 
neurons are intact in the mucosal preparations utilised in this thesis.  Here, 
secretomotor neurons importantly regulate electrolyte secretion to ensure that luminal 
fluid secretion is matched by absorption (Furness, 2000; Furness, 2012; Furness et al., 
2014).  The primary transmitter localised within cholinergic neurons is ACh, a known 
stimulant of electrolyte secretion and vasodilation  (Foong et al., 2014).  In the mouse 
ileum submucosal plexus, VIP non-cholinergic secretomotor neurons constitute 51 % 
of the total neuronal population (Mongardi Fantaguzzi et al., 2009), whereas in the 
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distal colon these neurons make up 80 % of the population. (Foong et al., 2014).  VIP 
causes Gαs-coupled electrolyte and fluid secretion (via vasoactive intestinal 
polypeptide receptors (VPAC)) and induces vasodilation of submucosal arterioles.  
Hyper-secretion induced by VIP causes life-threating diarrhoea and therefore careful 
regulation of fluid secretion is vital to survive and thrive (Foong et al., 2014).  
In the mouse ileum, investigations into the classes of secretomotor submucosal 
neurons revealed three populations: cholinergic secretomotor (30 %: code 
ACh/CGRP/somatostatin (SOM)/calretinin, also small population with NPY), non-
cholinergic secretomotor (20 %: code VIP/NPY/tyrosine hydroxylase(TH)) and non-
cholinergic vasodilator (30 % VIP/NPY/calretinin).  While only approximately 50 % 
of cholinergic neurons were CGRP immunoreactive in the ileum (Mongardi 
Fantaguzzi et al., 2009), all of the cholinergic neurons in the colon were CGRP 
immunoreactive (Foong et al., 2014). This suggests two populations of cholinergic 
neurons exists in the ileum (Mongardi Fantaguzzi et al., 2009) and only one population 
exists in the colon (Foong et al., 2014).  
 
1.6.4 Interneurons 
In the ENS, uni-directional interneurons (S-type) transmit GI signals between motor 
neurons, providing a passage for each signal to travel over the length of the GI tract.  
In the mouse, there appears to be four classes of interneurons, one ascending and three 
descending.  Moreover, the chemical coding of these interneurons is strikingly similar 
to the guinea pig interneuron coding (Furness, 2000; Qu et al., 2008).  Together, the 
interneurons make up approximately 10 % of the ENS neurons.  The ascending 
interneurons (estimated 4 %) are immunoreactive for ACh/neurokinins ± calretinin.  
In contrast, three populations of descending interneurons exist: ACh/NOS (3 %), 
ACh/serotonin (5-HT) (1 %) (Sang and Young, 1996; Sang et al., 1997; Sang and 
Young, 1998; Qu et al., 2008) and ACh/SOM/calretinin (4 % (Van Op Den Bosch et 
al., 2008)) (Sang and Young, 1996; Qu et al., 2008).  Interneurons are involved in local 
propulsion reflexes, regulate secretomotor and motility reflexes and modulate 
propagation of the migrating motor complex (MMC, also known as the migrating 
myoelectric complex).  In mammals, the MMC describes the rostro-claudal GI 
contractions during the interdigestive state that passes through the lumen, from 
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stomach to ileum every 80-120 min.  The MMC facilitates the movement of 
undigested material to the descending regions of the GI tract (Furness, 2006; Furness, 
2012; Furness et al., 2014).  This clears the intestinal lumen and prevents bacterial 
overgrowth.  
 
1.6.5 Vagal innervation of the GI tract and intestinofugal GI neurons 
The human vagus contains 40 000–50 000 axons, 90 % of which are afferent processes 
(Furness et al., 2014).  Together, afferent axons and efferent axons form a bidirectional 
signalling pathway between the gut and the brain.  The pre-ganglionic vagal 
innervation creates a rostro-caudal gradient in the GI tract, with the largest vagal 
innervation found in the upper GI tract (oesophagus, stomach, pancreas and 
gallbladder) and sparse innervation in the small and large intestine (Berthoud et al., 
1991).  Parasympathetic vagal afferents are low threshold tension detectors, which 
modulate normal GI function (Andrews, 1986).  Their main functions include, 
relaxation of the oesophagus sphincter, propagation and propulsion of ingested 
material within the oesophagus, increasing gastric capacity and facilitating antral 
stomach contractions to relax the pylorus, increasing gastric acid secretion, contracting 
the gallbladder and also stimulating pancreatic enzyme secretion (Furness and Costa, 
1987; Stakenborg et al., 2013; Furness et al., 2014).   
Intestinofugal neurons are mechanosensory and form a distinct set of myenteric 
ganglia that modulate normal GI function.  The cell bodies of these neurons are present 
in the GI wall and their axons are arranged in parallel to circular muscle fibres (Figure 
1.8).  Intestinofugal neurons are activated by stretch/distension of circular muscle or 
the presence of fatty acids in the distal intestinal region.  Activation of intestinofugal 
neurons initiates entero-enteric reflexes that modulate proximal intestinal function 
(Szurszewski et al., 2002). Activated intestinofugal neurons project their afferent 
axons to sympathetic prevertebral ganglia and synapse with post-ganglionic 
sympathetic fibres.  The sympathetic fibres project back to the GI tract via entero-
enteric pathways to inhibit fluid secretion and intestinal motility, in the proximal 
intestine (Furness, 2006).   Taken together, the entero-enteric reflex is an essential 















Figure 1.8: Schematic illustrating the intestinal GI tract is subject to local and 
central innervation.  The GI tract responds to nutrients, toxic metabolites, bacteria 
and hormones by signalling via ENS local signalling pathways or via the CNS.  The 
central signalling pathways include vagal pathways, spinal innervation, and 
intestinofugal pathways involved in entero-enteric reflexes.  Image from Furness et al. 
(2013). 
 
1.7 Gastrointestinal nutrient sensing and the enteroendocrine L cell 
The nutrient-rich luminal content is sensed by EECs.  In the GI tract, there are at least 
10 different types of EECs, that together secrete over 20 different peptides (Polak et 
al., 1971; Pearse and Bussolati, 1972; Buffa et al., 1975; Polak et al., 1975; Buffa et 
al., 1976; Alumets et al., 1977; Helmstaedter et al., 1977; Böttcher et al., 1984; Lewin 
et al., 1998; Date et al., 2000) (Table 1.2).  Together, these peptides coordinate 
complex physiological responses and are critical regulators of GI function and 




Table 1.2: The various types of EECs in the GI tract.  The table shows the different 
types of EECs in the GI tract and the various peptides they each secrete.  It also 
includes the location(s) of each EEC and the major functions of their released peptides.  
Table from Mace et al. (2015). 
 
Together, these various EECs (listed in Table 1.2) constitute <1 % of the total GI 
mucosal epithelial population and are distributed individually throughout the mucosal 
epithelium, surrounded by absorptive enterocytes (Buffa et al., 1978).  This 
interspersed nature of EECs is attributed to the lateral inhibition of adjacent cells 
differentiating into EECs, via a Notch signalling pathway (Schonhoff et al., 2004).  
The morphology of most EECs in Table 1.2 (with the exception of ghrelin-containing 
EEC  Peptide(s) Location(s) Major function of peptide(s) 
X/A Ghrelin stomach Food intake, appetite control 
D SOM stomach, small 
intestine 
Gastrin release, 
inhibit insulin release 
G Gastrin stomach (pyloric 
antral) 
Gastric acid release 
I Cholecystokinin (CCK) proximal small 
intestine 
Gallbladder contraction, 
stimulate release of pancreatic 
enzymes 




Insulin release  




distal small intestine, 
colon 
GI motility, reduce food 
intake, stimulates insulin 
release, slows gastric 
emptying 
M Motilin small intestine Regulation of MMC and 
motility 
N NTS distal small intestine, 
colon 
Gastric acid secretion, 
intestinal mucosal growth 
P Leptin stomach Food intake 
S Secretin  proximal small 
intestine 




cells) are open-type, cone-shaped and their microvilli  project optimally into the 
lumen, to achieve maximal nutrient sensing (Shakhlamov and Makar’, 1985).  In 
contrast, the ghrelin-containing X/A cells are closed type and unable to sense luminal 
macronutrients.  These X/A cells are activated from the underlying serosal side 
(paracrine or neurocrine) and subsequently release ghrelin, a powerful appetite 
stimulant in mouse (Asakawa et al., 2001) and human (Wren et al., 2001).   
One of the most relevant EEC cells of interest in anti-diabetic and anti-obesity 
therapeutics is the L cell.  The latter is attributed to the anorectic peptides (namely 
PYY and oxyntomodulin (OXM)) and the incretin peptide (GLP-1) secreted by this 
cell type (Albrechtsen et al., 2014).  The L cell has an open type morphology and 
serosal basal processes (Shakhlamov and Makar’, 1985).  These basal processes have 
recently been termed neuropods (Bohórquez et al., 2014; Bohórquez et al., 2015).  In 
their study, neuropods projected from the L cell and were escorted by enteric glia to 
nerve fibre neurite axonal projections.  These findings potentially established direct 
communication between the L cell and the surrounding enteric and CNS neurons 
(Bohórquez et al., 2014; Bohórquez et al., 2015).  In mammals, the frequency of  L 
cells increases along the length of the GI tract, with a preponderance of L cells 
observed in the distal colon (Figure 1.9) (Sundler et al., 1993).  L cells located in the 
colon co-secrete PYY, GLP-1, GLP-2, and OXM (Böttcher et al., 1984; Böttcher et 
al., 1986; Cho et al., 2015).  Additionally, peptide mRNA encoding gastric inhibitory 
polypeptide (GIP), cholecystokinin (CCK) and neurotensin (NTS) (Egerod et al., 
2012; Habib et al., 2012) has also been identified in small intestinal L cells.  The 
murine L cell has been described as glucose-sensitive (Reimann et al., 2008).  
Therefore, selective activation of the L cell could protect against hypoglycaemia, 
unlike current T2DM therapeutics i.e. sulphonylureas (van Staa et al., 1997; Stahl and 











Figure 1.9: Endocrine/paracrine cell types, their peptide localisation and 
distribution in the mammalian GI tract.  The width of the bars represents the density 
of each cell population.  Enteroendocrine L cells (yellow) increase in abundance along 
the length of the colon, with highest abundance in the descending colon and rectum 
(adapted from Sundler et al. (1993) by Tough IR). 
 
1.7.1 RYGB surgery increases postprandial PYY and GLP-1 plasma concentrations 
and therefore the L cell is an attractive anti-obesity and anti-diabetic target  
RYGB bypass surgery has been classified as the most common and efficacious 
treatment option of obesity (Smith et al., 2008).  The alterations in GI peptides 
observed postprandially after surgery has been attributed to the successful weight loss 
and the improvement in glucose tolerance seen in patients (Miras and le Roux, 2013).  
Before surgery, obese individuals display a blunted postprandial PYY and GLP-1 
response, whereas patients who have undergone RYGB surgery, present with 
postprandial plasma PYY and GLP-1 levels that are vastly superior to lean controls 
(Figure 1.10) (Borg et al., 2006; le  Roux et al., 2006).  Well before successful weight 
loss is achieved post-surgery, patients exhibit an improvement in insulin resistance, 
insulin production and GLP-1 responses, which may be implicated in the observed 
T2DM remission and the cessation of anti-diabetic medication (Pournaras et al., 2010).   
Pories et al. (1995) revealed that out of 298 obese individuals with pre-existing T2DM, 
91 % of these subjects achieved an improvement in glucose tolerance after RYGB 
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(Pories et al., 1995).  Therefore, it has been postulated that the successful weight loss 
and improvement in glucose tolerance observed post-RYGB, may be attributed to the 
increase in L cell derived peptides, GLP-1 (Peterli et al., 2009) and PYY (Korner et 
al., 2006; Karamanakos et al., 2008) postprandially (le Roux et al., 2006a; le Roux et 
al., 2007).   
 
 
Figure 1.10: Post-RYGB surgery alterations in postprandial GLP-1 and PYY 
plasma concentrations (pmol/L).  The GLP-1 (pmol/L) and PYY (pmol/L) 
responses to a test meal (420 kcal) in humans who have undergone RYGB (▲, n=6), 
or gastric band (■, n=6) compared with lean (◊, n=15), and obese controls (O, n=12) 
(le Roux et al., 2006a).   
 
To emulate post-RYGB PYY and GLP-1 alterations, L cell signalling mechanisms 
have been investigated with selective agonists.  Specifically, agonism of L cell-
enriched lipid sensing G-protein coupled receptors (GPCRs) including, GPR119 
(Overton et al., 2006; Chu et al., 2007; Chu et al., 2008; Cox et al., 2010; Patel et al., 
2014), FFA1 (Itoh et al., 2003; Edfalk et al., 2008) and FFA4 (Hirasawa et al., 2005).  
These GPCRs vary in expression patterns along the length of the GI tract, and are 
responsible for sensing lipid metabolites in the lumen (Spreckley and Murphy, 2015).  
Lipid are powerful stimulants of L cell secretion via activation of FFA1, FFA4 and 
GPR119 (Ekberg et al., 2016).  Activation of these GPCRs release L cell-derived 
peptides, that together have the ability to regulated whole body glucose, increase 
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insulin release, modulate intestinal mucosal epithelial integrity, slow GI motility and 
enhance central satiety and appetite (Itoh et al., 2003; Hirasawa et al., 2005; Overton 
et al., 2006; Chu et al., 2007; Chu et al., 2008; Edfalk et al., 2008; Engelstoft et al., 
2008; Cox et al., 2010).  At the start of this PhD, in comparison to GPR119, little was 
known about the pharmacology, functional significance, L cell signalling mechanisms 
and intestinal and colonic motility effects of FFA1 and FFA4 agonism in the mouse.  
Knowing FFA1, FFA4 and GPR119 were enriched in L cells, agonism of these three 
receptors was interrogated with novel selective compounds (synthesised by 
AstraZeneca (AZ)) to investigate L cell signalling mechanisms.    
 
1.8 The FFA1 (GPR40) receptor 
In 2003, GPR40 was deorphanised  as the first G-protein coupled FFA receptor (Itoh 
et al., 2003), which was activated by medium-long chain saturated and unsaturated 
FFAs (MCFA and LCFA, respectively) (Briscoe et al., 2003; Itoh et al., 2003; 
Kotarsky et al., 2003).  Briscoe et al. (2003) demonstrated in human embryonic kidney 
(HEK) 293 cells expressing GPR40, measuring intracellular calcium ([Ca2+]i), that a 
range of medium-long chain saturated and unsaturated FFAs (with a carbon length 
chain greater than 6) activated GPR40.  This included linolenic acid, linoleic acid, 
eicosapentaenoic acid, palmitic acid, oleic acid, pentadencanoic acid and 
docosahexaenoic acid (DHA) (all EC50s > 1 µM).  The potency of saturated FFAs (not 
unsaturated FFAs) was dependent on chain length, with a carbon chain less than 10 or 
greater than 14, showing little activity (Briscoe et al., 2003).   Later in 2008, GPR40 
was renamed FFA1 (Stoddart et al., 2008).  The mouse FFA1 gene encoded a class A, 
rhodopsin GPCR, which has 83 % homology to the human FFA1 receptor (Table 1.3). 
The expression of FFA1 was first identified in rat and mouse pancreatic β cells (Itoh 
et al., 2003).  Here, FFA1 activation results in glucose-stimulated insulin secretion 
(GSIS) (Itoh et al., 2003).  Later, FFA1 was also identified in human pancreatic islets 
(Tomita et al., 2005). As a result, soon after FFA1 was deorphanised, it was fast-
tracked as a relevant therapeutic target for T2DM.  Since its discovery in β cells, FFA1 
expression has also been identified in mouse enteroendocrine L cells (Edfalk et al., 
2008), CCK-secreting I cells (Liou et al., 2011; Sykaras et al., 2012), GIP-secreting K 
cells (Parker et al., 2009), pancreatic α cell islets (Flodgren et al., 2007) and taste cells 
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(Cartoni et al., 2010).  More recently, FFA1 has also been found in the CNS.  In one 
study, utilising in situ hybridisation, FFA1 mRNA was identified in mouse 
hippocampal and motor cortex neurons (Zamarbide et al., 2014), whereas in another 
study, immunohistochemical analysis revealed FFA1 expression in the mouse spinal 
dorsal horn and dorsal root ganglion neurons (Karki et al., 2015).  FFA1 expression in 
the brain appears to be involved in descending pain pathways (Karki et al., 2015; 
Nakamoto et al., 2015).   
 
 
Table 1.3: The total number of amino acids (αα) in the GPR119, FFA1 and FFA4 
receptor sequences.  The table includes the % of amino acids conserved between Mus 
Musculus (mouse), Rattus Norvegicus (rat) and Homo-Sapien (human) (created using 
BLASTp, www.blast.ncbi.nlm.nih.gov). 
 
1.8.1 FFA1 signal transduction in enteroendocrine L cells and pancreatic β cells 
Since the deophanisation of FFA1, many studies have interrogated FFA1 signalling 
mechanisms in various species and assays.  The initial FFA1 study demonstrated that 
activation of mouse/human FFA1 expressed in Chinese Hamster Ovary (CHO) cells 
or pancreatic β MIN6 cells, resulted in a classic Gαq/11-mediated Ca2+ response (Itoh et 
al., 2003).  Since then, FFA1-mediated Gαq-signalling has been displayed in many 
different studies utilising various assays (Briscoe et al., 2003; Briscoe et al., 2006; 
Christiansen et al., 2008; Negoro et al., 2010).  In the L cell, the Gαq-protein dissociates 
and activates phospholipase Cβ (PLC).  Hydrolysis of the membrane lipid 
 Mus 
Musculus 
Rattus Norvegicus Homo-Sapiens 






GPR119 335 468 96 335 82 
FFA1 300 300 96 300 83 
FFA4 361 361 98 Short isoform: 361 





phosphatidylinositol bisphosphate (PIP2) yields inositol triphosphate (IP3) and 
diacylglycerol (DAG).  IP3 immobilises calcium ions (Ca
2+) from the endoplasmic 
reticulum (ER) and this triggers the release of secretory vesicles, containing L cell-
derived peptide hormones.  Simultaneously, DAG activates protein kinase C (PKC) 
and protein kinase D1 (PKD) stimulating F-active remodelling, which contributes to 
the release of L cell secretory vesicles (Figure 1.11) (Edfalk et al., 2008).  Two 
independent studies have linked FFA1 activation to GLP-1 release in vivo.  First, 
Edfalk et al. (2008) revealed loss of plasma GLP-1 release in FFA1-/- mice, in response 
to a high fat diet (HFD), compared to the control (Edfalk et al., 2008).  Later, Xiong 
et al. (2013) also revealed loss of GLP-1 release to corn oil (containing linolenic and 
linoleic acid) in FFA1-/- mice (Xiong et al., 2013).  Together, these studies confirm 













Figure 1.11: Schematic of L cell signalling of FFA1, FFA4 and GPR119.  FFA1 
and FFA4 signal via the Gαq pathway.  Activation of this signalling pathway stimulates 
PLC, which in turn yields IP3 and DAG.  IP3 activates IP3 receptors (not shown) 
expressed in the ER, which increases [Ca2+]i and causes consequent peptide release.  
DAG activates PKC/PKD, which contributes to peptide release.  GPR119 is Gαs-
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coupled and activates adenylate cyclase (AC), increasing cyclic adenosine 
monophosphate (cAMP), which activates protein kinase A (PKA) and the exchange 
protein directly activated by cAMP (Epac), resulting in the release of secretory 
vesicles within L cells.  Image adapted from Hauge et al. (2015). 
 
As plasma glucose rises postprandially, glucose is taken up by the β cell (via GLUT2) 
and this initiates glycolysis.  This mechanism creates adenosine triphosphate (ATP) 
and causes the closure of ATP-sensitive potassium channels (KATP), depolarising the 
β cell.  This depolarisation causes the influx of Ca2+ via L-type voltage dependent 
calcium channels (VDCC), which consequently results in insulin release (Fu et al., 
2013) (Figure 1.12).  GSIS is augmented by activation of β cell FFA1 Gαq/11 PLC 
pathway (Fujiwara et al., 2005; Shapiro et al., 2005), leading to phosphorylation of 
PKD1 (Ferdaoussi et al., 2012) and insulin release (Latour et al., 2007; Tan et al., 
2008) (Figure 1.12).  FFA1 agonism has been shown to amplify β cell GSIS in the 
presence of high glucose (11 mM and 22 mM) compared to low glucose (5.5 mM), in 
a MIN6 cell line transfected with FFA1.  This indicated FFA1-induced GSIS was 
glucose-sensitive (Itoh et al., 2003).  In another study, Schnell et al. (2007), revealed 
that numerous saturated FFAs and mono- and polyunsaturated FFAs increased the 
mobilisation of [Ca2+]i and caused an influx of Ca
2+ via VDCC in primary mouse β 
cells, classic characteristics of Gαq-signalling.  This mechanism was abolished in the 
presence of a specific-FFA1 small interfering ribonucleic acid (siRNA), confirming 
that this signalling pathway was FFA1-dependent in primary mouse β cells (Schnell 





Figure 1.12: Schematic showing various mechanisms of β cell insulin secretion.  
As the glucose levels rise after a meal, glucose is transported into the pancreatic β cell 
via the GLUT2 glucose transporter.  The cell undergoes glycolysis which releases 
ATP.  The rise in ATP shuts ATP-sensitive potassium channels (KATP), depolarising 
the β cell, which causes an influx of Ca2+ via VDCC.  This rise in [Ca2+]i triggers 
insulin secretion.  The β cell is enriched with FFA1 and GPR119 receptors that 
augment insulin secretion via Gαq and Gαs signalling pathways, respectively.  
Activation of the GLP-1R and the gastric inhibitory polypeptide receptor (GIP-R) with 
GLP-1 and GIP respectively, also enhances insulin release via a Gαs-stimulatory 
pathway.  Image adapted from Li et al. (2016).  
 
1.8.2 FFA1 polymorphisms 
The polymorphism Arg211His was identified in the FFA1 gene as a missense variant 
(Haga et al., 2002).  A study carried out in healthy Japanese men demonstrated that 
subjects with the homozygous Arg/Arg variant, showed decreased serum insulin, β 
cell function and basal insulin sensitivity.  In the same study, there were no clear 
differences observed in genotype and allele frequency between the healthy population 
and a T2DM cohort.  This study concluded that this gene variant may contribute to a 
variation in insulin secretion capacity, which could ultimately lead to β cell 
dysfunction and T2DM.  However, further in vitro and in vivo experimentation was 
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advised (Ogawa et al., 2005).  On the contrary, Hamid et al. (2005) revealed that the 
Arg211His polymorphism does not contribute to dysregulation of FFA1 signalling in 
vitro or insulin secretion in healthy and T2DM volunteers (Hamid et al., 2005).  Two 
other rare FFA1 polymorphisms have been discovered, Asp175Asn (Hamid et al., 
2005) and Gly180Ser (Vettor et al., 2008).  Gly180Ser and Asp175Asn caused a 
decrease in receptor function in HeLa cells (measuring oleic-induced increase in 
[Ca2+]i) (Vettor et al., 2008) and COS-7 cells (measuring 5,8,11-eicosatriynoic acid-
induced [3H]‐myo‐inositol turnover), respectively (Hamid et al., 2005).  However, 
thorough pharmacological investigations undertaken by Smith et al. (2009) failed to 
observe any functional difference between these three polymorphic variants 
(Arg211His, Gly180Ser and Asp175Asn) expressed in HEK293 cells (Smith et al., 
2009).   The inconsistencies indicate that there were no clear findings to suggest that 
these FFA1 polymorphisms were detrimental to FFA1 receptor function.  
 
1.8.3 FFA1-/- studies   
In 2003, Itoh et al. demonstrated that 50 % of the FFA-induced GSIS response in 
MIN6 cells was abolished in the presence of FFA1 siRNA in vitro, indicating FFA1 
agonism was a major contributor to FFA-induced GSIS (Itoh et al., 2003).   The first 
study to utilise FFA1-/- mice, showed these mice were protected against obesity-
induced hyperglycaemia, glucose intolerance, hyperinsulinemia, fatty liver 
development, increased hepatic glucose and hypertriglyceridemia (Steneberg et al., 
2005).  In the same study,  overexpression of FFA1 in mice, impaired β cell function, 
caused hypoinsulinemia and resulted in diabetes in vivo (Steneberg et al., 2005).  In 
this way, an FFA1 antagonist appeared to be advantageous as a therapeutic for obesity 
and diabetes.  Conversely, Latour et al. (2007) showed that FFA1-/- mice have normal 
glucose tolerance and insulin secretion in response to a glucose stimulus.  However, 
the insulin response to Intralipid (fat emulsion) was attenuated by 50 %.  This 
suggested that 50 % of the GSIS response was FFA1-mediated (Latour et al., 2007), 
as shown previously (Itoh et al., 2003).  Therefore, an FFA1 agonist was proposed as 
a potential anti-T2DM therapeutic.  Similarly, Lan et al. (2008) and Alquier et al. 
(2009) revealed 50 % and 60 % loss of the GSIS response respectively, in FFA1-/- 
mice in vivo.  Additionally, Lan et al. (2008) demonstrated that when these FFA1-/- 
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mice were introduced to a HFD (60 % calories from fat), they were not protected 
against the adverse effects associated with a HFD.  Both wild-type (WT) and FFA1-/- 
mice were obese, developed insulin resistance and a fatty liver (Lan et al., 2008).  This 
suggested loss of FFA1 does not provide protection against HFD.  Similarly, Kebede 
et al. (2008) showed that FFA1-/- mice fed a HFD (60 % for 11 weeks) also displayed 
fasting hyperglycaemia,  became obese, glucose intolerant and insulin resistant with 
associated fatty liver disease, and their insulin secretory responses were blunted 
compared to WT (Kebede et al., 2008).  Notably, Nagasumi et al. (2009) demonstrated 
that overexpression of human FFA1 in pancreatic β cells improved glucose tolerance 
and enhanced GSIS in mice, in an oral glucose tolerance test (OGTT).  As FFA1 
agonism stimulates GSIS (Itoh et al., 2003) and 50-60 % of this response was 
abolished in FFA1-/- mice in vivo (Latour et al., 2007; Lan et al., 2008; Alquier et al., 
2009), a selective FFA1 agonist rather than a FFA1 antagonist might be beneficial in 
future T2DM therapeutics.  
 
1.8.4 FFA1 agonists 
Since the deorphanisation of FFA1, many FFA1 agonists have been synthesised to 
interrogate FFA1 signalling mechanisms in various assays.  In this next section, only 
the FFA1 agonists (TAK-875, JTT and TUG424) and the dual FFA1 and FFA4 
agonists (GW9508 and pinolenic acid) used in this thesis will be described.  
TAK-875 (produced by Takeda) also known as Fasiglifam (Negoro et al., 2010; 
Negoro et al., 2012a; Negoro et al., 2012b), was the first FFA1 agonist to enter clinical 
trials as an orally available, potent and selective agonist.  Pre-clinical studies 
demonstrated TAK-875 enhanced GSIS in rat and human pancreatic islets in vitro 
(Yashiro et al., 2012).  Furthermore, TAK-875 (at 10 mg/kg) elevated plasma insulin 
and fasting hyperglycaemia in male Zucker T2DM rats in vivo, without the risk of 
hypoglycaemia (Tsujihata et al., 2011).  Attributed to the success of TAK-875 in 
preclinical studies, this agonist progressed into clinical development.  The first Phase 
I clinical trial in healthy volunteers showed TAK-875 was well tolerated and rapidly 
absorbed (Naik et al., 2012).  In a Phase II study, multiple ascending doses in diabetic 
volunteers, improved their glucose tolerance without dose-related adverse effects 
(Leifke et al., 2012).  The success of Phase I and II studies allowed TAK-875 to 
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proceed to phase III clinical trials.  A phase III trial in T2DM Japanese patients found 
TAK-875 significantly reduced glycosylated haemoglobin A1c (HbA1c, measurement 
of blood glucose over 2-3 months) compared to the placebo, improved glycaemic 
control and possessed a minimal risk of hypoglycaemia  (Kaku et al., 2015).  
Unfortunately, in Phase III trials TAK-875 induced liver toxicity and therefore the 
clinical trial was terminated.  TAK-875 was resynthesised by AZ and this selective 
FFA1 agonist was used in this thesis. 
Recently, the crystal structure of the FFA1 receptor was discovered utilising the 
selective FFA1 ligand, TAK-875.  TAK-875 bound the FFA1 receptor via the lipid 
bilayer, between the seven-transmembrane helix 3–5 and the extracellular loop 2.  The 
carboxylate of TAK-875 interacted with two critical residues, Arg183 and Arg258, 
within the binding pocket.  A third important residue, Asn244 formed a hydrogen bond 
with Arg258.  Once TAK-875 bound to the FFA1 receptor, it protruded outside of 
transmembrane domains III and IV (Srivastava et al., 2014).  An earlier study 
suggested there may be multiple binding sites within the FFA1 receptor, including two 
allosteric sites and one orthosteric site (Lin et al., 2012).  TAK-875 and most other 
synthetic FFA1 agonists appear to bind the FFA1 allosteric site, and their carboxylate 
tails interact with the two Arg residues (Hassing et al., 2016b).  Indeed, TAK-875 has 
been termed a partial agonist on its own and a positive allosteric modulator when used 
in combination with γ-linolenic acid, resulting in robust amplification of GSIS in 
mouse pancreatic islets (Yabuki et al., 2013). 
JTT-851 was synthesised by Japan Tobacco.  This FFA1 agonist progressed to clinical 
trials and in 2013 the phase II study (NCT01699737) was completed.  Since 2013, no 
further development has been reported.  JTT-851 was resynthesised by AZ, as a 
selective and potent FFA1 agonist and henceforth it will be referred to as JTT.  
TUG424, a potent FFA1 full agonist (compound 20; (Christiansen et al., 2008)) from 
the alkyne agonist series, significantly increased GSIS (2-fold) in a glucose-dependent 
manner, in a rat insulin-secreting β cell line (INS-1E) and in islets from WT mice.  
This elevation in insulin secretion was absent in islets retrieved from FFA1-/- mice, 
suggesting the  GSIS effect was FFA1-mediated (Christiansen et al., 2008).  TUG424, 




1.8.5 Dual FFA1 and FFA4 agonists 
GW9508 was discovered during a GlaxoSmithKline (GSK) chemical collection in 
2006, and was marketed as a dual FFA1 and FFA4 agonist (Briscoe et al., 2006).  
Notably, GW9508 had a 100-fold greater selectivity and a 70-fold higher potency for 
FFA1 than FFA4.   Due to the lack of FFA1 selective agonists in many of the initial 
FFA1 studies, GW9508 was the preferred agonist of choice.  In the initial studies, 
GW9508 increased [Ca2+]i and promoted glucose-dependent GSIS in FFA1 or FFA4 
transiently transfected HEK293 cells and MIN6 insulinoma cells, respectively 
(Briscoe et al., 2006).   GW9508, which is commercially available was used in this 
study as a dual FFA1 and FFA4 agonist.   
Pine nut oil (PNO) from the Korean pine (Pinus koraiensis), is commonly used in food 
preparation and condiments worldwide.  PNO is composed of 92 % poly- and 
monounsaturated FFAs including oleic acid, linolenic acid and pinolenic acid (Xie et 
al., 2016).  Pinolenic acid constitutes 15-20 % of PNO and has recently been identified 
as a FFA1 and FFA4 dual agonist (Christiansen et al., 2015).  In the past, many studies 
have examined the beneficial effects of PNO.  In these studies, PNO reduced weight 
gain and intramuscular lipid accumulation in mice (Lee et al., 2004); provided 
protection against hypercholesterolaemia, thrombosis and hypertension in rats 
(Sugano et al., 1994) and had apparent appetite suppressant effects in postmenopausal 
women, which was attributed to an increase in GI peptides, namely GLP-1 and CCK-
8 (Pasman et al., 2008).  Pinolenic acid, which is commercially available was used in 
this thesis as a dietary dual FFA1 and FFA4 agonist.  
 
1.8.6 FFA1 antagonists 
FFA1 antagonists have limited therapeutic value in T2DM, however they are pertinent 
pharmacological tools.  The first FFA1 antagonist synthesised was GW1100.  It 
selectively inhibited GW9508-stimulated Ca2+ elevation and GSIS in HEK293 cells 
and MIN6 cells transfected with FFA1, respectively (Briscoe et al., 2006).  To date, 
GW1100 is still used as the most common selective commercially available FFA1 
antagonist.  Over the years, two other FFA1 antagonists have been synthesised, 
namely ANT203 and ANT825 (also known as compound 39) (Waring et al., 2015).  
According to AZ, ANT203 and ANT825 exhibit identical pharmacology (D. Smith 
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and M. Schindler, personal communication).  Notably, while acute exposure of FFAs 
prompt GSIS, chronic exposure of FFAs (i.e. palmitate) are associated with β cell 
apoptosis, which impairs insulin secretion (Zhou and Grill, 1995).  In obese 
individuals, prolonged elevation of FFAs appears to be linked to insulin resistance and 
T2DM (Kashyap et al., 2003).  Kristinsson et al. (2013) demonstrated that the FFA1 
antagonist, ANT203, significantly reduced the deleterious effects of palmitate on β 
cells.  This revealed a role for FFA1 in palmitate-induced β-cell apoptosis, but this 
was dependent on the presence of extracellular FFAs.   Thus, Kristinsson et al. (2013) 
concluded that only in the absence of chronically high levels of circulating FFAs was 
FFA1 agonism advantageous, stimulating GSIS.   More recent studies have shown 
FFA1 agonism (TUG-469, 3 and 10 µM) caused GSIS, protected β cells and abolished 
palmitate-induced β cell apoptosis in murine islets and rat INS-1E cells (Wagner et 
al., 2013; Panse et al., 2015).  Conversely, the FFA1 antagonist, TUG-761 (10 µM) 
induced apoptosis and this effect was absent in islets from FFA1-/- mice (Wagner et 
al., 2013).  Taken together, these studies further confirm FFA1 agonism may be 
advantageous for future T2DM therapeutics.  Recently, the FFA1 antagonist, ANT825 
(80 mg/kg) reduced non-esterified fatty acid (NEFA)-induced insulin secretion by 
approximately 70 %, in male insulin resistant Zucker fa/fa rats.  Thus, while FFA1 
antagonists are not beneficial as T2DM therapeutics, they may be valuable in the 
treatment of hyperinsulinemia or insulin resistant states, where insulin levels are 
elevated due to GSIS (Waring et al., 2015).  The commercially available FFA1 
antagonist, GW1100 and the selective AZ supplied FFA1 antagonist, ANT825 were 
use in this PhD study. 
 
1.9 The FFA4 (GPR120) receptor 
GPR120, now designated FFA4 (Davenport et al., 2013) was isolated from human 
genomic deoxyribonucleic acid (DNA) fragments and deorphanised in 2005, as the 
second FFA GPCR for LCFAs (Hirasawa et al., 2005).  FFA4, a seven-transmembrane 
class A rhodopsin-like receptor is activated by a range of medium-long chain saturated 
and polyunsaturated fatty acids (C12-C22; particularly omega-3 and omega-6 FFAs) 
(Hirasawa et al., 2005).    
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Initial FFA4 studies revealed FFA4 mRNA expression was abundant in mouse and 
human intestine, lung (Hirasawa et al., 2005; Miyauchi et al., 2009; Little et al., 2014; 
Mizuta et al., 2015) and adipose (Gotoh et al., 2007; Miyauchi et al., 2009).  Hirasawa 
and colleagues also demonstrated that FFA4 mRNA was colocalised with GLP-1 in 
GLP-1-producing human colonic cells i.e. enteroendocrine L cells, utilising in situ 
hybridisation and a GLP-1 antibody.  This was confirmed using reverse transcription 
polymerase chain reaction (RT-PCR), which showed an abundance of FFA4 mRNA 
in GLP-1 positive cells and a minor detection of FFA4 mRNA in GLP-1 negative cells 
(Hirasawa et al., 2005).  Since this study, the FFA4 receptor has been widely expressed 
in intestinal enteroendocrine K cells (Iwasaki et al., 2015), I cells (Sykaras et al., 
2012), gastric ghrelin cells (Koyama et al., 2016) and gastric somatostatin cells 
(Egerod et al., 2015).  FFA4 expression has also been identified in murine pancreatic 
delta cells (Stone et al., 2014), clonal β cells (Moran et al., 2014), immune 
macrophages (Oh et al., 2010), taste cells (Cartoni et al., 2010) and in hypothalamic 
microglia (Dragano et al., 2017).  In this way, FFA4 is more widely expressed 
compared to the FFA1 receptor.  
There are two splice variants of the human FFA4 receptor, a short isoform (GPR120S) 
and a long isoform (GPR120L), while only one variant exists in rodents and 
cynomolgus monkey.  The human GPR120S is homologous to the FFA4 receptor 
found in rodents and cynomolgus monkey (Moore et al., 2009), and 86 % of its amino 
acid sequence is conserved when compared with the mouse FFA4 receptor sequence 
(Table 1.3).  Notably, the GPR120L has an insertion of 16 amino acids in the third 
intracellular loop and this region of the long isoform, is important for G-protein and 
β-arrestin recognition and association.  Recently, the differential signalling of the two 
human isoforms was investigated in HEK293 cells (Watson et al., 2012).  Watson et 
al. (2012) revealed that activation of the short isoform (GPR120S) with the dual FFA1 
and FFA4 synthetic agonist, GW9508 increased [Ca2+]i
 (EC50 3.2 µM (1.6 – 6.3)) and 
also recruited β-arrestin 2.  Conversely, activation of the long isoform (GPR120L) 
recruited β-arrestin 2 but was unresponsive in the Ca2+ mobilisation assay, identifying 
signalling bias between the two human FFA4 isoforms (Watson et al., 2012).  Further 
studies are required to understand the importance of the FFA4 long isoform in humans.  
In most human FFA4 studies in the literature, the GPR120S isoform has been utilised 
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(Suckow and Briscoe, 2016), and therefore these studies are comparable with murine 
FFA4 receptor studies. 
The expression of FFA4 varies between lean and obese humans.  As BMI increased, 
the expression of duodenal FFA4 was upregulated (Little et al., 2014). This 
corresponded to data from Paulsen et al. (2014), which showed FFA4 expression was 
elevated in the distal ileum in diet-induced obese (DIO) rats, when compared with 
diet-resistant (DR) rats (Paulsen et al., 2014).  Conversely, Fam et al. (2015), revealed 
a decrease in FFA4 expression in DIO mouse ileum (Fam et al., 2015).  This suggests 
FFA4 expression may be regulated differently in different DIO rodents (Paulsen et al., 
2014; Fam et al., 2015).  Nevertheless, the upregulation of FFA4 in DIO rat ileum 
(Paulsen et al., 2014) was more comparable with changes observed in human (obese) 
duodenum (Little et al., 2014).   
 
1.9.1 FFA4 signal transduction in enteroendocrine L cells 
The first FFA4 study showed that α-linolenic acid stimulated a rise in [Ca2+]i in a 
concentration-dependent manner, in HEK293 cells stably expressing the murine 
GPR120-Gα16 fusion protein.  In the same study, FFA4 agonism had no effect on 
cAMP, therefore indicating that FFA4 activation was Gαq-mediated and does not 
couple to Gαs (Hirasawa et al., 2005).  Thus, in enteroendocrine L cells FFA4 agonism 
generates IP3 and DAG, which stimulate the release of L cell-derived peptides (Figure 
1.11).  Many in vitro studies have recapitulated FFA4-Gαq signalling revealing an 
increase in [Ca2+]i (Hara et al., 2009; Watson et al., 2012; Hudson et al., 2013).   More 
recently the promiscuity of FFA4 signalling was revealed, with reports showing FFA4 
couples to the Gαi-protein in mouse gastric somatostatin cells (Egerod et al., 2015), 
gastric ghrelin A/X cells (Koyama et al., 2016) and pancreatic somatostatin delta cells 
(Stone et al., 2014).  In this way, FFA4 agonism in different EEC types leads to the 






1.9.2 FFA4 signal transduction in macrophages 
In macrophages, activation of the toll-like receptor (TLR) 4 by lipopolysaccharides 
(LPS) and activation of a second receptor, tumour necrosis factor α receptor (TNFR) 
by tumour necrosis factor (TNF) α, cause activation of pro-inflammatory signalling 
(Figure 1.13, right side).  Activation of FFA4 leads to receptor phosphorylation by 
GPCR kinases.  The phosphorylated FFA4 binds β-arrestin 2 which induces 
internalisation of the FFA4-β-arrestin 2 complex.  This complex binds TGF-β 
activated binding protein 1 (TAB1), which prevents the formation of a complex 
consisting of TAB1 and transforming growth factor β (TGF-β) activated kinase 1 
(TAK1).  This ultimately inhibits downstream pro-inflammatory pathways involving 
IKB kinase (IKK)/ nuclear factor (NF)-KB and mitogen-activated protein kinase 
kinase 4 (MKK4)/c-Jun NH2-terminal kinase (JNK) (Oh et al., 2010; Oh et al., 2014).  
This pro-inflammatory pathway was inhibited by the selective FFA4 agonist, TUG891 
(IC50 1.4 µM (0.7 – 2.7)) in murine RAW264.7 macrophages (Hudson et al., 2013).  
Li et al. (2013) further interrogated this anti-inflammatory mechanism in RAW264.7 
cells and demonstrated that the omega-3 FFA, DHA inhibits cyclooxygenase 2 (COX-
2) (downstream of (NF)-KB) and subsequent prostaglandin E2 synthesis, via a FFA4 
mechanism (Li et al., 2013).  Unlike FFA4 L cell signalling,  the FFA4 mechanism in 
macrophages appears to be β-arrestin 2 dependent and independent of Gαq/11 (Oh et al., 








Figure 1.13: Differential FFA4 signalling pathways in adipocytes (left) and 
macrophages (right).  In adipocytes, activation of FFA4 stimulates Gαq-coupled 
signalling and leads to the activation of phosphatidylinositol-4,5-bisphosphate 3-
kinase (PI3K) and a downstream protein kinase B (PKB, also known as Akt) pathway.  
This increases the glucose transport into adipocytes by inserting GLUT4 into the 
plasma membrane, which enhances adipogenesis.  In macrophages, FFA4 activation 
leads to phosphorylation of FFA4, and the subsequent binding of β-arrestin 2 causes 
internalisation of the FFA4 receptor.  Image adapted from Li et al. (2016). 
 
1.9.3 FFA4 signal transduction in adipocytes 
The expression of FFA4 mRNA has been identified in four types of human adipose 
tissue, namely subcutaneous, perirenal, mesenteric and epidydimal tissue (Gotoh et 
al., 2007).  FFA4 mRNA increases during adipocyte differentiation and is strongly 
expressed in mature adipocytes (Gotoh et al., 2007).  Activation of the FFA4 receptor 
in adipocytes leads to the activation of phosphatidylinositol-4,5-bisphosphate 3-kinase 
(PI3K) and a downstream protein kinase B (PKB; also known as Akt) pathway (Figure 
1.13, left side).  This results in translocation of vesicles containing the glucose 
transporter, GLUT4 to the plasma membrane, and this enhances glucose uptake, 
adipogenesis and insulin sensitivity (Katsuma et al., 2005; Oh et al., 2010; Hudson et 
al., 2013).  In STC-1 cells, the presence of a PI3K inhibitor prevented Akt activation, 
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and thus FFA4-induced anti-apoptotic effects were abolished (Katsuma et al., 2005).  
This confirmed the FFA4-induced anti-apoptotic effects were Gαq-PI3K mediated in 
adipocytes.  Later in 2010, Oh et al. demonstrated that the polyunsaturated FFA, DHA 
enhanced glucose uptake and GLUT4 transport to the plasma membrane.  This 
mechanism was FFA4-, GLUT4- and Gαq-dependent in 3T3-L1 adipocytes, and was 
also independent of β-arrestin 2 involvement (Oh et al., 2010).  These insulin-
sensitising effects of FFA4 agonism (Oh et al., 2010) are thought to contribute to 
combatting insulin resistance and fasting hyperglycaemia, which are observed in 
FFA4-/- mice on HFD (Ichimura et al., 2012).   
 
1.9.4 The FFA4 polymorphism 
FFA4 receptor dysfunction caused by a single nucleotide mutation (p.R270H) in the 
long isoform of the receptor (designated R254H in the short FFA4 isoform), has been 
associated with an increased risk in obesity in humans (European population, minor 
allele frequency of ~2 %).  Expression of this missense non-synonymous mutation, 
p.R270H in HEK293 cells significantly reduced the elevation of [Ca2+]i to α-linolenic 
acid, compared to cells expressing non-mutant FFA4.  Furthermore, ALA stimulated 
GLP-1 release and this was ablated in human intestinal cells (NCI-H716) transfected 
with the variant p.R270H, compared to the control (Ichimura et al., 2012).  This study 
demonstrated that the presence of the FFA4 variant, p.R270H was not only associated 
with obesity in humans but also caused FFA4 signalling dysfunction in vitro.  This 
low-frequency allele was associated with an increased fasting hyperglycaemia in a 
European population but was not linked to an increased risk of T2DM (Bonnefond et 
al., 2015).  Recently, Vestmar et al. (2016) revealed that the presence of R270H in 
HEK293 cells also reduced FFA4 surface expression, basal FFA4 constitutive activity 
and Gαq signalling, but did not affect β-arrestin signalling in vitro.  As FFA4 signalling 
is Gαq-mediated in L cells and β-arrestin dependent in macrophages, the lack of Gαq 
but not β-arrestin signalling, implicates a possible risk for intestinal metabolic 
disruption but not macrophage inflammatory dysfunction.  Despite the observed 
dysfunctional FFA4 signalling in vitro, this did not predispose a Danish population to 
an increase risk of obesity or obesity related metabolic disorders (Vestmar et al., 
2016).    The presence of R270H/R254H appears to disrupt FFA4 signalling in vitro 
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and in vivo.  However, further studies are required to determine whether this 
predisposes individuals to obesity and obesity-related disorders in vivo. 
 
1.9.5 FFA4-/- studies  
Typically, FFA4-/- mice on a normal chow diet are glucose-intolerant, possess insulin 
resistance and are obese with increased inflammation (Oh et al., 2010).  When 
introduced to a HFD (60 %, 15-20 weeks), FFA4-/- mice were unable to respond to 
omega-3 FFAs, whereas WT mice (+HFD) given omega-3 FFAs showed an 
improvement in glucose tolerance, insulin sensitivity and a reduction in inflammation.  
This study demonstrated the beneficial insulin-sensitising effects of FFA4 activation 
(Oh et al., 2010).  Ichimura et al. (2012) also observed insulin resistance in FFA4-/- 
mice, as seen previously by Oh et al. (2010).  Conversely, these mice only displayed 
glucose intolerance and an increased body weight when on a HFD (60 %), not on 
normal chow (Ichimura et al., 2012).  At odds with these studies, Suckrow et al. (2014) 
demonstrated FFA4-/- mice were hyperglycaemic, hyperinsulinemia, possessed an 
increased body weight and were glucose-intolerant, but not insulin resistant (Suckow 
et al., 2014).  Together, data from these three studies show clear discrepancies, which 
have been attributed to possible differences in animal backcrossing, housing or 
knockout strategies.  
 
1.9.6 FFA4 agonists 
The polyunsaturated FFAs, omega-3 and omega-6, are potent activators of FFA4 and 
are provided by dietary fish oil and supplements.  However, the quantity of fish oil 
that would need to be consumed, to chronically activate FFA4 is impractical and 
therefore activating FFA4 with a proven, potent small molecule agonist may be more 
practical and beneficial long term (Hirasawa et al., 2005).  The search for FFA4 
selective agonists has been challenging, as most endogenous fatty acids are 
nonselective and activate both FFA1 and FFA4 (Hudson et al., 2011).  This is 
surprising as only 10 % of their amino acid sequences are conserved between these 
two receptors.  Since the discovery of FFA4, many FFA4 agonists have been 
generated.  However, none of these agonists have progressed to clinical development.  
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The first natural FFA4 ligands, grifolin acid and grifolin methyl ether were isolated 
from the fruiting bodies of the plant, Albatrellus ovinu.  However, these grifolin 
derivatives only provided modest efficacy (Hara et al., 2009).  In 2010, the initial lead 
synthetic FFA4 agonists, including NCG21 (Suzuki et al., 2008), were derived from 
peroxisome proliferator-activator receptor (PPAR) γ agonists.  Unfortunately, these 
agonists only provided modest selectivity (10-15 fold) and efficacy over FFA1, and 
micromolar concentrations (µM) were required to induce FFA4 signalling (Sun et al., 
2010).  Hence, the development of a potent and selective FFA4 agonist was critical to 
interrogate the pharmacology and function of the FFA4 receptor.  In the section that 
follows, I shall focus on the agonists used in this PhD, namely TUG891, Met-36 and 
AZ423. 
In 2013, TUG891 was described as the first potent and selective agonist for human 
and murine FFA4 (Shimpukade et al., 2012; Hudson et al., 2013).  TUG891 increased 
[Ca2+]i
 in HEK293 cells expressing the human (EC50 117.5 nM (100.0 – 138.0) or 
mouse FFA4 receptor (EC50 128.8 nM (104.7 – 158.5)).  Notably, TUG891 exhibited 
poor selectivity between the mouse FFA4 and FFA1 receptors (EC50 389.0 nM (323.6 
– 467.7)) in a calcium mobilisation assay, indicating TUG891 possibly exerts dual 
FFA1 and FFA4 agonism, in this species.  Furthermore, TUG891 induced β-arrestin 2 
recruitment (HEK293T cells) in a bioluminescence resonance energy transfer (BRET) 
assay, 288-fold and 61-fold more potently at human and mouse FFA4 respectively, 
compared to the FFA1 receptor.  Furthermore, TUG891 possessed only 3-fold 
selectivity between the FFA4 receptor and the FFA1 receptor, in a Ca2+ assay in 
HEK293 cells.  This revealed TUG891 exhibited poor selectivity between murine 
FFA4 and FFA1 in this assay.  In the same study, TUG891 robustly secreted GLP-1 
in STC-1 and GLUTag EEC lines, enhanced [3H]deoxyglucose uptake in 3T3-L1 
adipocytes and inhibited TNF-α secretion in RAW264.7 macrophages (IC50 1.4 µM 
(0.7 – 2.7)).  Thus, TUG891 enhanced adipogenesis and inhibited pro-inflammatory 
responses.  TUG891 was used in this thesis as a commercially available selective 
FFA4 agonist (Hudson et al., 2013).  
The FFA4 agonists, Metabolex-36 (Ma et al., 2010) and AZ423 (McCoull et al., 2017) 
are 100-fold selective for FFA4 over FFA1.  Stone et al. (2014) demonstrated these 
two agonists inhibited glucose-dependent somatostatin secretion via a FFA4-
meditated inhibitory Gαi-signalling pathway, in pancreatic delta cells.  Apart from this 
68 
 
study, there has been limited information regarding the function of Metabolex-36 and 
AZ423, in vitro or in vivo.  Recently, AZ423 (also known as compound 34, McCoull 
et al. (2017)), significantly reduced glucose excursions after a glucose load, an effect 
that was absent in FFA4-/- mice (McCoull et al., 2017).  Thus, showing for the first 
time that AZ423 improves glucose tolerance via an FFA4-mediated mechanism.  
Metabolex-36 was resynthesised by AZ and in this thesis, it has been abbreviated to 
Met-36.   
 
1.9.7 The FFA4 antagonist 
To date, the only commercially available FFA4 antagonist is AH-7614 (previously 
known as compound 39, Sparks et al. (2014)).  In 2014, this FFA4 antagonist was 
discovered as a xanthene derivative of a diarylsulfonamide based FFA4 agonist 
(Sparks et al., 2014).  AH-7614 inhibited the ability of linoleic acid to stimulate [Ca2+]i 
in U2OS cells transfected with mouse (IC50 7.9 nM) or human FFA4 (IC50 79.4 nM).  
In the same study, this FFA4 antagonist inhibited agonist (GSK137647A)-induced 
GSIS in MIN6 cells and GLP-1 secretion in the human intestinal cell line, NCI-H716 
(Sparks et al., 2014).  AH-7614 is commercially available and was used in this PhD 
study as a selective FFA4 antagonist.  
 
1.10 The GPR119 receptor 
In 2003, GPR119 was deorphanised using a bioinformatics approach of the human 
genome.  This receptor appeared to be a class A GPCR that did not closely resemble 
FFA1 or FFA4 (Fredriksson et al., 2003).  The GPR119 mouse gene encodes a 335 
amino-acid sequence and this has 82 % homology to the human receptor (Table 1.3).  
Like FFA1, the GPR119 receptor was fast-tracked as a relevant therapeutic target for 
diabetes and obesity, due to its enrichment in mouse and human pancreas (Chu et al., 
2008; Odori et al., 2013) (specifically the islets (Chu et al., 2007)) as well as the GI 
tract (stomach, duodenum, jejunum, ileum and colon) (Soga et al., 2005; Chu et al., 
2007; Chu et al., 2008).  Initial studies conducting in situ hybridisation analysis 
revealed GPR119 was expressed in rat pancreatic islets, specifically in β cells (Chu et 
al., 2007).  Additionally,  GPR119 mRNA was identified in preproglucagon-
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expressing cells of mouse proximal colon i.e. GLP-1 secreting L cells (Chu et al., 
2008).  This was later confirmed in mouse and human L cell cell-based assays (mouse 
GLUTags and human NCI-H716) (Lauffer et al., 2009).  Furthermore, the expression 
of GPR119 in the human brain was low, which strengthened the safety profile of this 
receptor (Soga et al., 2005; Chu et al., 2008).  Theoretically, the expression of GPR119 
in β cells could increase insulin secretion directly (Figure 1.12), while L cell GPR119 
agonism (Figure 1.11) could stimulate the release of the incretin, GLP-1 and thus cause 
insulin secretion via β cell GLP-1R (Chu et al., 2008) (Figure 1.12).  In previously 
published mouse mucosal studies, GPR119-induced anti-secretory responses that 
increased along the length of the GI tract, and the greatest response was observed in 
the descending colon (Cox et al., 2010).  This response profile correlated with the 
initial murine GPR119 mRNA expression pattern (Chu et al., 2008).  In humans, the 
greatest GPR119 mRNA expression was observed in the pancreas (Soga et al., 2005; 
Chu et al., 2008), followed by the GI tract (Chu et al., 2008).  In the human intestine, 
GPR119 expression was greatest in the duodenum, whereas expression levels in the 
jejunum, ileum and colon were similar in each region (Chu et al., 2008; Odori et al., 
2013). Similarly, Patel et al. (2014) revealed human GPR119 expression was uniform 
along the GI tract, with a slight elevated GPR119 expression level in the duodenum 
(Patel et al., 2014).  The expression of GPR119 receptor in mouse has also been 
identified in pancreatic polypeptide (PP) cells (Sakamoto et al., 2006), duodenal CCK-
I cells (Sykaras et al., 2012), upper small intestine GIP-K cells (Parker et al., 2009) 
and pancreatic α cells (Odori et al., 2013).  In this way, GPR119 and the FFA1 and 
FFA4 receptors are similarly expressed in intestinal L, K and I cells. 
 
1.10.1 GPR119 endogenous agonists  
The GPR119 endogenous ligands are thought to include the ethanolamide derivative, 
oleoylethanolamide (OEA); the fatty acid derivatives, 2-MAG and oleoyl-glycerol (2-
OG) (Hansen et al., 2011); the lysophospholipids, lysophosphatidylcholine (LPC) 
(Soga et al., 2005) and 5 hydroxyl-eicosapentaenoic acid (5-HEPE) (Kogure et al., 
2011).  
In 2005, Soga et al. identified the first GPR119 endogenous agonist, LPC.  Ingested 
material and bile (recently arrived from the gallbladder) generates lysophospholipids, 
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namely oleic acid, palmitic acid, stearic acid and phosphatidylcholine.  
Phosphatidylcholine is converted by phospholipase A2, yielding a potent endogenous 
GPR119 agonist, LPC in the lumen (Soga et al., 2005).  LPC (5µM or 10µM) 
promoted GSIS in a mouse pancreatic β cell line, NIT-1 transfected with GPR119.  
This functional effect was partially lost in the presence of GPR119 siRNA.  This study 
suggested LPC was an endogenous GPR119 agonist, which stimulated insulin 
secretion in mouse NIT-1 cells (Soga et al., 2005).  
The ethanolamine derivative, OEA was identified as a lipid mediator that potently 
reduced food intake and body weight, and additionally enhanced satiety in rats 
(Rodríguez de Fonseca et al., 2001).  These OEA (administered via intraperitoneal 
injection, i.p.) satiety-inducing effects were apparently PPARα receptor-mediated in 
mice (Fu et al., 2003).  In 2006, OEA was described as a full endogenous GPR119 
agonist, which was more potent (EC50 3.2 ± 0.33 µM) than LPC (EC50 >30 µM) at the 
human GPR119 receptor, in a yeast fluorometric assay (Overton et al., 2006).  
Furthermore, OEA (EC50 2.9 ± 0.46 µM) upregulated cAMP levels in HEK293 cells 
transfected with human GPR119, and this response was GPR119-mediated (Overton 
et al., 2006).  OEA (30 mg/kg, i.p.) also induced hypophagia in rats, and Overton et 
al. (2006) proposed this may be attributed to GPR119.   Later, in 2009, OEA (30 
mg/kg, i.p.) suppressed food intake in GPR119 WT and GPR119-/- mice, confirming 
this anorexigenic effect was GPR119-independent (Lan et al., 2009).  OEA is found 
in small quantities in the diet and is also synthesised on demand from phospholipids 
within the membrane lipid bilayer, via the N-acyl phosphatidylethanolamide (NAPE) 
phospholipase D (PLD) pathway.  OEA can undergo further enzymatic hydrolysis by 
the intracellular membrane bound fatty acid amide hydrolase (FAAH), to provide oleic 
acid and ethanolamine (Cravatt et al., 1996).  Lauffer et al. (2009) demonstrated that 
OEA (10 µmol/l) increased basal GLP-1 in murine GLUTag cells (2.1 ± 0.2-fold), 
which was augmented in the presence of the FAAH inhibitor, URB597 (to 3.2 ± 0.4-
fold of control).  This functional effect was GPR119-dependent.  As a result, OEA-
induced GLP-1 release was GPR119-mediated and also limited by FAAH (Lauffer et 
al., 2009).  More recently, Moss et al. (2016) showed OEA stimulated GLP-1 release 
in mouse duodenum/jejunum/colonic primary cultures, and this functional effect was 
abrogated in GPR119-/- colonic cultures, but not duodenum/jejunum cultures.  This 
suggested OEA induced GLP-1 release was GPR119-mediated in the colon and was 
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GPR119-independent in the duodenum/jejunum.  This indicated regional differences 
exist in OEA-GPR119 signalling  (Moss et al., 2016).   5-HEPE is generated from the 
hydrolysis of the LCFA, eicosapentaenoic acid by the enzyme 5-hypoxgenase.  In 
2011, Kogure et al. (2011) showed that 5-HEPE and OEA were equipotent activators 
of GPR119 and suggested 5-HEPE as another endogenous GPR119 agonist.  In this 
study, both OEA and 5-HEPE caused GPR119-dependent insulin release from MIN6 
insulinoma cells.  While 5-HEPE may be a GPR119 endogenous agonist, it is rarely 
synthesised unless a large quantity of fish oil is consumed (Kogure et al., 2011).    
Trioleoylglycerol digestion by pancreatic lipase yields 2-OG and 2-MAG (e.g. oleic 
acid) (Hansen et al., 2012).  Approximately 5-7 g of 2-OG is yielded per meal in the 
intestinal lumen.  As 2-OG was structurally related to OEA, it was thought to be 
another potential endogenous GPR119 ligand (Hansen et al., 2012).  Initial 
investigations showed 2-OG (EC50 2.5 µM) amplified cAMP less potently than OEA 
(EC50 0.2 µM) in COS-7 cells transfected with human GPR119, and both responses 
were GPR119-mediated.  In a human trial, a bolus of 2 g 2-OG (via a duodenal tube) 
resulted in a rise in plasma GLP-1 and GIP, but not PYY (Hansen et al., 2011).  More 
recently, Hassing et al. (2016a) demonstrated that 2-OG mediated GLP-1 release, and 
this was GPR119-dependent in vitro and in ex vivo primary colonic cultures (Hassing 
et al., 2016a). These studies suggest 2-OG may be another endogenous ligand at 
GPR119, and activation of this receptor causes the release of GLP-1 and GIP in man 
(Hansen et al., 2011).   
N-oleoyldopamine (OLDA) was discovered in the peripheral mesenteric tissue as a 
lipid derivative of dopamine and was also thought to be a GPR119 endogenous 
agonist.  Chu et al. (2010) revealed OLDA was similarly potent to OEA, promoting 
insulin release in insulinoma cell lines (NIT-1 (mouse), RIN-5F (rat), HIT-T15 
(hamster)) expressing human GPR119.  Furthermore, OLDA stimulated GIP release 
and improved glucose-tolerance in mice in vivo and these effects were impaired in 
GPR119-/- mice (Chu et al., 2010).  This suggested OLDA was a strong contender as 
a GPR119 endogenous agonist.  Tyrosine hydroxylase and dopacarboxylase were 
known enzymes responsible for synthesising dopamine from tyrosine, and further N-
acylation of newly synthesised dopamine by oleic acid was thought to form OLDA.  
However, when RNA levels of tyrosine hydroxylase and dopacarboxylase were 
analysed by RT-PCR, Chu et al. (2010) observed low levels in all small intestinal 
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regions and was unable to detect any RNA in mouse colon, suggesting 
dopamine/OLDA were not synthesised here via this pathway.  Recently, Tough et al. 
(2018b) demonstrated OLDA anti-secretory responses were no different between WT 
and GPR119-/- mouse descending colon mucosa.  This indicated OLDA anti-secretory 
PYY-mediated responses were GPR119-independent (Tough et al., 2018b).  Taken 
together, these studies demonstrate that OLDA is unlikely to be an endogenous agonist 
of the GPR119 receptor in the colon.     
 
1.10.2 GPR119 signal transduction in enteroendocrine L cells and pancreatic β cells 
Initial studies demonstrated that the potential GPR119 endogenous agonist, LPC 
elevated GSIS (in 16.8 mM glucose) in an isolated pancreas perfused rat model and a 
mouse pancreatic β cell line (NIT-1).  These responses were inhibited in the presence 
of the AC inhibitor, MDL12330A implicating LPC-stimulated release was coupled to 
Gαs and was AC/glucose-dependent.  In the same study, LPC increased cAMP (EC50 
1.5 ± 0.17) in RH777 rat hepatoma cells transfected with GPR119, but not in mock-
transfected cells, suggesting the LPC Gαs signalling was GPR119-mediated (Soga et 
al., 2005).  Chu et al. (2007) were the first group to show GPR119 was constitutively 
active, a characteristic of many rhodopsin-like GPCRs (Behan and Chalmers, 2001).  
In their study, a significant rise in cAMP was observed upon expression of the GPR119 
receptor in HEK293 cells, compared with cells transiently expressing an empty-vector.  
This confirmed the GPR119 receptor coupled to Gαs and was constitutively active (Chu 
et al., 2007).  Recently, the high constitutive activity of the GPR119 receptor was 
characterised in COS-7 cells (determined by an ELISA) (Engelstoft et al. 2014).  
Engelstoft et al. (2014) revealed GPR119 constitutive activity was 37 ± 0.8 % of the 
Emax of the cAMP response to GPR119 agonism (AR231453) (Engelstoft et al., 2014).   
The two most widely published GPR119 synthetic agonists that have been utilised to 
interrogate the pharmacology and signalling of the GPR119 receptor, were 
PSN632406 (Overton et al., 2006) and AR231453 (Semple et al., 2008).  In 2006, 
PSN632408 (developed by Prosidion) was selected during a high throughput screen 
of small molecules.  This small molecule was assessed in a yeast-based assay 
expressing mouse (EC50 7.9 ± 0.7 µM) or human (EC50 5.6 ± 0.1 µM) GPR119 
isoforms.  This selective full agonist was as efficacious as OEA and an equipotent 
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activator of GPR119.  PSN632408 increased cAMP (EC50 1.9 ± 0.14 µM) in HEK293 
cells transfected with human GPR119.  This response was abrogated in cells 
transfected with an empty vector, and this suggested that activation of the GPR119 
receptor leads to Gαs signalling (Overton et al., 2006). Similarly, Ning et al. (2008) 
revealed PSN632408 triggered Gαs-cAMP accumulation in HEK293 cells and GSIS 
in mouse MIN6c4 insulinoma cells (Ning et al., 2008).  Theoretically, as the GPR119 
receptor couples to Gαs, this could result in a rise in cAMP formation, activating PKA 
and the exchange protein directly activated by cAMP (Epac), to cause release of L cell 
peptide hormones (Figure 1.12).   Notably, PSN632408 has suppressed food intake 
and reduced body weight and adiposity in rats  (Overton et al., 2006).  Furthermore, 
PSN632408 (and OEA) increased the number of β cells in mouse islets in vitro and in 
a transplanted graft in diabetic mice in vivo, which improved glycemia after 4 weeks 
(Gao et al., 2011).  This demonstrates GPR119 activation may also be involved in 
regulating food intake, body weight and β cell protection in vivo.  The commercially 
available GPR119 full agonist, PSN632408 was selected as a proven GPR119 full 
agonist in this PhD study.   
AR231453 (developed by Arena Pharmaceuticals) was discovered in 2008 as the first 
orally potent subnanomolar (≤ nM) agonist for the human and mouse GPR119 
receptor.  Initial studies revealed AR231453 elevated cAMP (EC50 5.7 ± 1.6 nM) in 
HEK293 cells transfected with human GPR119.  In the same study, AR231453 also 
triggered GSIS in β cell lines and mouse islets (the glucose concentration ranged from 
8-17 mM).  This indicated GPR119-mediated insulinotropic effects were glucose-
dependent.  Chu et al. (2008) showed that AR231453 potently induced secretion of 
GLP-1 in GLUTag cells in vitro.  This effect was enhanced in the presence of a 
dipeptidyl peptidase-4 (DPPIV) inhibitor, sitagliptin and abrogated in the presence of 
a GLP-1R antagonist, exendin (Ex)9-39 (Chu et al., 2008).  This confirmed the 
response was GLP-1-mediated and limited by DPPIV activity in vivo.  Furthermore, 
AR231453 also improved glucose tolerance and enhanced GSIS in C57BL/6J (and 
diabetic) mice, and these effects were eliminated in GPR119-/- mice in vivo.  Thus, the 
beneficial effects of this agonist, AR231453 were GPR119-mediated in mice (Chu et 
al., 2008).   
The phenotype of GPR119-/- mice appeared normal, but the GSIS response to a 
selective GPR119 agonist was impaired (Chu et al., 2008).  Similarly, in another study, 
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GPR119-/- mice were healthy and fertile and no change was observed in behaviour, 
body weight, leptin, insulin, plasma glucose, morphology of the islets and insulin 
content (Lan et al., 2009).  Thus, whole-body deletion of GPR119 was not detrimental, 
suggestive of compensatory mechanisms.  
Both PSN632408 (Cox et al., 2010) and the more selective GPR119 agonist, PSN-
GPR119 (Patel et al., 2014) have elicited anti-secretory responses in mouse and human 
mucosa.  These responses were mediated via a paracrine PYY-Y1 mechanism and were 
glucose-sensitive (Cox et al., 2010; Patel et al., 2014).  This glucose-sensitivity of 
GPR119 signalling could provide protection against hypoglycaemia in clinical 
practise.    
 
1.10.3 Other GPR119 agonists 
Compound 16 (EC50 68 nM) (Scott et al., 2014) and compound 42 (EC50 56 nM) (Scott 
et al., 2012) were identified as potent GPR119 agonists in independent cAMP assays, 
in HEK293S cells overexpressing mouse GPR119.  In an OGTT in C57BL/6J mice, 
compound 16 and compound 42 both enhanced glucose disposal and induced GLP-1 
secretion.  These effects were enhanced in the presence of a DPPIV inhibitor, 
sitagliptin and abrogated in GPR119-/- mice.  This study revealed selective GPR119 
activation triggered GLP-1 release and this response was limited by DPPIV activity.  
Compound 16 and 42 were synthesised by AZ and in this thesis, have been abbreviated 
to Cpd.16 and Cpd.42.  
Two GPR119 agonists have progressed into clinical trials, JNJ-28630368 (synthesised 
by Johnsson and Johnsson Pharmaceutical Research) and GSK1292263 (developed by 
GSK).  However, both clinical investigations were terminated.  The JNJ-28630368 
clinical trial was terminated due to an unknown reason (Semple et al., 2011), and the 
GSK1292263 investigations were thought to have terminated due to tachyphylaxis 
(Nunez et al., 2014).  Cornall et al. (2013, 2015) revealed that GPR119 agonism in 
skeletal and cardiac muscle cell lines may be detrimental to fatty acid metabolism and 
oxidation.  This study suggested careful analysis and in vivo experiments would be 
required to investigate the safety of  GPR119 agonism in cardiac and skeletal tissue, 
in order to prevent the failure of future GPR119 clinical compounds (Cornall et al., 
2013; Cornall et al., 2015).  These findings suggested targeting GPR119 may not be 
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as safe as originally thought and this may have impeded the progress of many GPR119 
projects in the pharmaceutical industry.   
There are currently no GPR119 antagonists commercially available.  
 
1.11 Colonic L cell-containing peptides and their physiological significance 
1.11.1 Peptide YY and the neuropeptide Y family 
PYY, a 36 amino-acid peptide was first isolated in a chemical assay that identified 
COOH-terminal amides and measured tyrosine-amide release after peptide 
degradation with trypsin or thermolysin, in porcine small intestine.  It was designated 
PYY, as tyrosine (Y) was present at both terminals (COOH and NH2 ends) of the 
amino acid sequence (Tatemoto and Mutt, 1980; Tatemoto, 1982).  PYY along with 
NPY and PP are members of the pancreatic polypeptide family, and all three peptides 
share a conserved tertiary structure known as the PP hairpin-fold motif.  The PP fold 
is U-shaped with an extended polyproline helix and an α-helix linked to a β-turn 
(Larhammar, 1996a).  PYY, NPY and PP bind NPY receptors denoted as Y receptors, 
which belong to the rhodopsin class I GPCR family.  To date, five distinct mammalian 
Y receptors have been cloned and characterised, Y1, Y2, Y4, Y5 and y6.  The Y receptors 
are GPCRs that couple to the pertussis-toxin sensitive G-protein, Gαi and cause 
inhibition of AC and cAMP elevation (Michel et al., 1998).  In mammals, PYY and 
NPY exhibit the highest affinity for Y1, Y2 and Y5.  These three Y receptors possess 
very low amino acid sequence homology, approximately 27 - 31 % (Larhammar et al., 
2001).    The Y4 receptor preferentially binds PP (Bard et al., 1995) and the y6 receptor 
is a pseudogene in primates (Matsumoto et al., 1996), but is a functional receptor in 
mouse (Weinberg et al., 1996) and rabbit (Matsumoto et al., 1996).  The existence of 
a sixth Y receptor subtype, Y3 was thought to be NPY-preferring, but has not been 
cloned and therefore will not be mentioned further (Glaum et al., 1997; Lee and Miller, 
1998).  There are two major circulating forms of PYY including, PYY(1-36) and its 
truncated form, PYY(3-36) (Eberlein et al., 1989).  As PYY(1-36) is released, 40 % is 
converted to PYY(3-36) (Grandt et al., 1992).  PYY(3-36) is the predominant postprandial 
circulating form (Grandt et al., 1994) and is yielded during degradation of PYY(1-36) 
by the exopeptidase, DPPIV (Mentlein et al., 1993a) and aminopeptidase-P (Medeiros 
and Turner, 1994).  DPPIV exists in two isoforms, a membrane-anchored form and a 
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soluble circulating form (Mulvihill and Drucker, 2014).  In the GI tract, DPPIV 
expression has been identified in the epithelium microvilli brush border and capillary 
endothelium (Hansen et al., 1999).   Enzyme degradation of PYY(1-36) to PYY(3-36) does 
not abolish this peptide’s affinity for Y receptors, however the pharmacology of the 
truncated peptide is altered.  The full peptide, PYY(1-36) is selective for Y1, Y2 and Y5.  
In contrast, PYY(3-36) is more selective as it exhibits a higher affinity for Y2 and also 
binds the Y5 receptor, but with less affinity (Grandt et al., 1992; Grandt et al., 1994).  
PYY was localised in 50 % of EECs in the mouse (Arantes and Nogueira, 1997) and 
human intestinal mucosa (Adrian et al., 1985).  The immunoreactivity of PYY 
increased in frequency along the length of the GI tract, and was found in largest 
abundance in the terminal ileum, colon and rectum (Adrian et al., 1985; Ekblad and 
Sundler, 2002).  Sparse PYY immunoreactivity was identified in enteric and CNS 
neurons in comparison to intestinal enteroendocrine PYY immunoreactivity (Ekblad 
and Sundler, 2002).  In enteroendocrine colonic L cells, PYY was co-expressed and 
co-packaged alongside glicentin (includes OXM), GLP-1 and GLP-2 (Böttcher et al., 
1984; Böttcher et al., 1986; Cho et al., 2015).  In small intestinal L cells, PYY was co-
expressed with mRNA for NTS (Egerod et al., 2012), GIP and CCK (Habib et al., 
2012).   
Circulating PYY(3-36) rises as early as 15 min after a meal.  However, the majority of 
PYY containing L cells are expressed in the large intestine.  This suggests a neuronal 
signalling mechanism exists, transmitting a signal from the small intestine to the large 
intestine (Lin et al., 2000), to cause the plasma levels of PYY(3-36) to rise swiftly after 
a meal.  PYY(3-36) peaks again at 90–120 min after a meal, an indicator of 
macronutrients arriving in the distal regions of the intestine.  Notably, the quantity of 
PYY release is dependent on the size of a meal and the type of macronutrients present 








1.11.2 Y1 receptor 
The Y1 receptor was the first Y receptor cloned, utilising rat complimentary 
deoxyribonucleic acid (cDNA) (Eva et al., 1990; Krause et al., 1992).  Later, Y1 
receptor clones were also identified in human (Herzog et al., 1992; Larhammar et al., 
1992), mouse (Eva et al., 1992) and frog (Xenopus laevis) (Blomqvist et al., 1995).  
The Y1 receptor sequence is highly conserved between the mouse and rat (98 %) and 
between rodents and human (94 %) (Larhammar, 1996b).  In humans, Y1 receptor 
mRNA expression has been identified in the intestine, kidney, blood vessels, ganglia 
in the ENS plexuses (Wharton et al., 1993) and the brain (cerebral cortex and striatum) 
(Caberlotto et al., 1997).  In the human intestine, the Y1 receptor was identified in 
PYY-negative enterocytes (Mannon et al., 1999).  Mannon et al. (1999) revealed the 
Y1 receptor was trafficked to the basolateral membrane, suggesting PYY released from 
enteroendocrine L cells may act via a paracrine pathway, to activate Y1 receptors 
expressed in the surrounding PYY-negative enterocytes.  In the mouse, Y1 mRNA was 
also found in the intestine and in pancreatic β cells, adipose, heart, kidney, spleen, 
skeletal muscle, lung and brain (Nakamura et al., 1995).  
NPY and PYY were identified as the most potent and efficacious endogenous ligands 
of the human Y1 receptor, whereas PP had no affinity at physiological concentrations 
(Herzog et al., 1992; Larhammar et al., 1992).  In mouse (Cox et al., 2001; Tough et 
al., 2006) and human (Cox and Tough, 2002) colonic mucosa, PYY, NPY and human 
PP have decreased enterocyte epithelial ion transport, revealing Gαi-signalling.  The 
PYY anti-secretory response was TTX-insensitive and 90 % inhibited by the Y1 
competitive antagonist, BIBO3304 (Wieland et al., 1998) (IC50 25.4 nM (16.2–39.7 
nM), (Cox et al., 2001)).  BIBO3304 revealed basal Y1 tone in human colonic mucosal 
preparations and inhibited PYY(1-36), but not human PP or PYY(3-36) anti-secretory 
responses (Cox and Tough, 2002).  Hence, PYY anti-secretory responses were 
predominantly Y1-mediated and epithelial in origin, which was suggestive of a 
paracrine PYY-Y1 mechanism, that was also tonically active (Cox et al., 2001; Cox 
and Tough, 2002; Hyland et al., 2003).  
The function of the Y1 receptor in the GI tract includes PYY-induced inhibition of GI 
motility (Spiller et al., 1984; Pironi et al., 1993; Lin et al., 1996; Tough et al., 2011).  
Pedrazzini et al. (1998) demonstrated Y1
-/- mice possessed an increased body weight 
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and a decreased food intake, compared to WT (Pedrazzini et al., 1998).  This 
implicates the involvement of the Y1 receptor in central mechanisms modulating body 
weight and food intake (Pedrazzini et al., 1998; Kanatani et al., 2000). 
 
1.11.3 Y2 receptor 
In 1997, the Y2 receptor was cloned from human SMS-KAN cells and human brain 
cDNA libraries, while studying the hydrolysed forms of PYY and NPY (Rose et al., 
1997).  Despite showing only 31 % homology to the Y1 receptor, the Y2 receptor was 
similarly activated by NPY and PYY.  However, the truncated forms of NPY and PYY 
possessed higher affinity for the Y2 receptor.  In contrast, human PP exhibited the 
lowest potency for the Y2 receptor (Michel et al., 1998; Cox et al., 2001; Cox and 
Tough, 2002; Hyland et al., 2003).  Like Y1 signalling, activation of the Y2 receptor 
led to inhibition of AC and cAMP accumulation (Michel et al., 1998).  Y2 receptor 
expression has been identified mainly in brain pre-synaptic neurons, where it appears 
to be an autoreceptor (Colmers et al., 1991), and was rarely observed in the periphery 
(Gehlert et al., 1996).  In human colonic mucosa, the Y2 antagonist, BIIE0246 (Doods 
et al., 1999) revealed Y2 tone and inhibited PYY(3-36), not human PP or PYY(1-36) anti-
secretory responses.  Furthermore, PYY(3-36) anti-secretory responses were 
tetrodotoxin (TTX)-sensitive.  Together, this data indicated that PYY(3-36) responses 
were neuronally-mediated and not epithelial in origin (Cox and Tough, 2002).  A year 
later, Hyland et al. (2003) demonstrated that PYY(3-36) displayed an EC50 of 10.1 nM 
(male) and 10.2 nM (female) in Y2
+/+ mouse colonic mucosa and these anti-secretory 
responses were lost in Y2
-/- mucosa.  Additionally, the Y2 antagonist (BIIE2046) 
revealed Y2 tone, which was also lost in Y2
-/- mucosa, revealing tonic endogenous Y2 
activity.  Hyland et al. (2003) also revealed the Y2 receptor was prejunctional in 
mucosa and post-junctional in longitudinal smooth muscle.  Centrally, PYY(3-36) is a 
major anorexigenic mediator and its effects appear to be mediated by the Y2 receptor 
(Batterham et al., 2002; Batterham et al., 2003; Abbott et al., 2005).  These 
mechanisms will be introduced in section 1.14.  The phenotype of Y2
-/- mice was lean 
and showed a reduction in body weight gain (larger reduction in females), adiposity, 
elevated PP levels and an increased food intake, implicating the involvement of the Y2 
receptor in appetite and body weight modulation (Sainsbury et al., 2002).  
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1.11.4 Y4 receptor  
In 1995, the Y4 receptor was cloned utilising the human genomic library (Lundell et 
al., 1995) and was closely related to the Y1 receptor (42 % amino-acid sequence 
homology) (Darby et al., 1997).  In humans, this receptor was localised in the small 
intestine and colonic mucosa, stomach, pancreas and prostrate (Bard et al., 1995).  In 
the mouse, Y4 was observed in the heart, intestine and brain (Michel et al., 1998).  In 
1975, PP was isolated from avian pancreas, released from pancreatic endocrine F cells 
(approximately 10 % of pancreatic islets) (Kimmel et al., 1975).   PP possessed the 
highest affinity for Y4, followed by PYY and NPY for the human Y4 receptor in COS-
7 cells (Bard et al., 1995).  PP was observed relatively rarely in the mouse or human 
small intestine/colon and was not co-localised with PYY (Ekblad and Sundler, 2002).  
In human colonic mucosa, Y4 receptors were expressed in epithelia as Y4 agonism was 
TTX-insensitive (Cox and Tough, 2002).  In 2006, Tough et al. established rat PP 
induced anti-secretory responses resembling Gαi-signalling in mouse colonic mucosa, 
and these responses were abolished in Y4
-/- mice, further demonstrating a role for Y4 
in colonic epithelial ion transport (Tough et al., 2006).  The phenotype of Y4
-/- mice 
show a reduced food intake and body weight gain, thus validating the involvement of 
Y4 receptors in feeding (Sainsbury et al., 2010).  
 
1.11.5 Y5 receptor  
In 1996, Y5 was cloned from a hypothalamic rat cDNA library (Gerald et al., 1996; 
Hu et al., 1996) and possessed 30 - 33 % amino acid sequence homology to Y1, Y2  
and Y4 (Hu et al., 1996).  Initial studies revealed that the rat Y5 receptor couples to Gαi 
in HEK293 cells (Gerald et al., 1996).  In two independent studies, NPY and PYY 
activated the Y5 receptor with similar potencies, whereas PP exhibited the lowest 
potency (Gerald et al., 1996; Hu et al., 1996).  Y5 was predominately expressed in the 
CNS, where it strongly regulated appetite and was observed sparsely in the periphery 
(Gerald et al., 1996).  In humans, Y5 expression has not been observed in the small 
intestine or colon (Michel et al., 1998).  Furthermore, the Y5 agonist ([Ala31, 
Aib32]NPY) (Cabrele et al., 2000) had no effect on epithelial ion transport in human 
mucosa (Cox and Tough, 2002).  Moreover, this Y5 agonist was only responsive at 
micromolar concentrations (µM) in mouse descending colon mucosa (Cox et al., 
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2001).  These studies suggested Y5 is not involved in electrolyte transport in human 
intestine and appears to have no role in mouse mucosa.   Y5
-/- mice remain healthy but 
develop late onset obesity around 30 + weeks, and this was attributed to increased food 
intake and body weight gain (Kushi et al., 1998).  More recently, Ishihara and 
colleagues examined the effects of a selective Y5 antagonist in mice on a HFD.   These 
mice displayed a reduction in fat pad weight, insulin-levels and an inhibition of diet-
induced body weight gain, compared to untreated mice (Ishihara et al., 2006). These 
studies implicate the Y5 receptor as a critical regulator of appetite, satiety and body 
weight.  
 
1.11.6 y6 receptor  
The y6 receptor was initially cloned from murine genomic DNA (Weinberg et al., 
1996).  Later, in man (and primates) this receptor was identified as a pseudogene 
attributed to a frameshift mutation (single-base mutant) in the third intracellular loop, 
which encoded a non-functional truncated protein (Matsumoto et al., 1996; Michel et 
al., 1998).  As a result, this receptor was designated a lower-case y.  Despite the non-
functionality of this receptor (y6) in man, it shares 50 % sequence homology with Y1 
and Y4 (Wraith et al., 2000).    In humans, y6 has been identified in the small intestine, 
colon, skeletal muscle and cardiac muscle (Matsumoto et al., 1996).  The murine y6 
receptor was functional and localised in the small intestine and was sparsely expressed 
in embryonic colon and brain (Weinberg et al., 1996).  The agonist potency rank at the 
murine y6 receptor has been controversial between studies.  One study showed a rank 
of PP > PYY ≥ NPY (similar to Y4 receptor) (Gregor et al., 1996) whereas, another 
study displayed the opposite order NPY = PYY > PP (similar to the Y1 receptor) 
(Weinberg et al., 1996).  The potency rank was reinvestigated in HEK293 cells 
expressing mouse y6.  Mullins et al. (2000) revealed PYY and NPY exhibited 
equipotent binding affinities at the mouse y6 receptor in HEK293 cells.  Both agonists 
inhibited cAMP accumulation showing Gαi-signalling (Mullins et al., 2000) and thus, 
their potency rank was similar to that observed in an earlier study (Weinberg et al., 
1996).  Taken together, while y6 appears to be functional in the mouse, the 
pharmacology of this receptor has not been well defined.  Furthermore, Mullins et al. 
(2000) did not suggest a role for y6 in feeding or appetite regulation.  
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1.12 Glucagon-like peptides  
GLP-1 and GLP-2 are co-encoded within the proglucagon gene.  Proglucagon 
undergoes differential tissue-specific post-translational processing, in pancreatic α 
cells and GI enteroendocrine L cells, yielding various bioactive products (Baggio et 
al., 2004) (Figure 1.14).  In the L cell, proconvertase (PC)-1/3 cleaves the proglucagon 
gene to form GLP-1, GLP-2,  intervening peptide-2 (IP-2) and glicentin.  Glicentin is 
cleaved further creating glicentin-related pancreatic polypeptide (GRPP) and OXM.  
In pancreatic α cells, PC-2 yields glucagon, intervening peptide-1 (IP-1) and GRPP 
(Holst, 2007).  Like PYY, the quantity of GLP-1/GLP-2 release is dependent on the 
calorie intake amount and the type of macronutrients.  The GLP-1/GLP-2 peptides are 
secreted in a 1:1 ratio (Lim and Brubaker, 2006).  On average, plasma levels of GLP-
1/GLP-2 increase 2-5-fold after a meal (Xiao et al., 1999; Nauck et al., 2011).  The L 
cell postprandial GLP secretion is biphasic.  The first phase is rapid, peaking within 
15-30 min and has been attributed to neuronal signals arriving from the proximal 
intestine.  The second phase of GLP-1 plasma levels peak 90-120 min later and is 








Figure 1.14: Tissue-specific differential posttranslational processing of 
proglucagon in the pancreas, gut and brain.  The numbers indicate amino acid 
positions in the proglucagon sequence (total 160 amino acids).  The vertical lines 
illustrate specific cleavage sites.  GRPP, glicentin-related pancreatic polypeptide; IP-
1, intervening peptide-1; IP-2, intervening peptide-2 (Holst, 2007). 
 
1.12.1 Glucagon-like peptide 1 
GLP-1 is a member of the incretin glucoregulatory family and constitutes a 36 amino-
acid peptide sequence, that is highly conserved among mammals (Kreymann et al., 
1987; Mojsov et al., 1987).  The two discovered circulating forms of human GLP-1 
were GLP-1(7-37) and GLP-1(7-36) amide (Ørskov et al., 1994).  Once released, these 
circulating forms were rapidly degraded (cleaving two NH2-terminal amino acids) 
within 1-2 min by DPPIV, yielding inactive GLP-1(9-36) amide and GLP-1(9-37) in 
human (Mentlein et al., 1993b).   The truncated GLP-1(9-36) amide was the major 
circulating form of GLP-1 (Deacon et al., 1995).  Hansen et al. (1999, 2000) revealed 
that less than 25 % of active GLP-1 leaves porcine ileum in vitro (Hansen et al., 1999; 
Hansen et al., 2000).  In the liver, active GLP-1 can be further degraded (about 40-50 
%) before entering the systemic circulation (Deacon et al., 1995).  Therefore, 
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approximately 10 – 15 % of released active GLP-1 may be measured in the circulation.  
Similarly, in human intestine, 80 % of active GLP-1 was amidated (GLP-1(7-36) amide) 
as it entered the circulation (Ørskov et al., 1994).  
GLP-1 is an incretin i.e. a GI hormone released in response to orally ingested 
macronutrients and subsequently amplifies insulin secretion.  Postprandial GLP-1 
release was a powerful stimulant of pancreatic β cell insulin secretion (Fehmann and 
Habener, 1992).  Additionally, GLP-1 protected the β cell by enhancing β cell mass, 
proliferation,  inhibiting apoptosis and decreasing α cell mass (Farilla et al., 2002). 
Hence, GLP-1 was a highly relevant peptide of interest in anti-diabetic therapeutics.  
Unfortunately, the rapid half-life of GLP-1 limited the therapeutic value of this 
peptide.  As a result, successful GLP-1 mimetics were synthesised to recapitulate the 
physiological effects of the endogenous GLP-1 peptide.  Clinically proven GLP-1 
mimetics, like Exenatide (Kendall et al., 2005) or the longer acting, Liraglutide 
(Zinman et al., 2009) have revolutionised the diabetic therapeutic field, and are the 
most efficacious drugs currently on the market to treat T2DM.  These GLP-1 mimetics 
improve glycaemic control and promote weight loss (Dushay et al., 2012; Mehta et 
al., 2017).  DPPIV inhibitors e.g. sitagliptin are often given as adjunctive T2DM 
therapeutics to prevent endogenous peptide degradation (i.e. GLP-1 and PYY), with 
the added benefit of partial weight loss (Drucker and Nauck, 2006) 
In the GI tract, GLP-1 slowed GI motility via GLP-1R (Amato et al., 2010; Halim et 
al., 2018), may be involved in the ileal brake (Giralt and Vergara, 1999), decreased 
gastric acid (and pancreatic) secretion (Imeryüz et al., 1997) and slowed gastric 
emptying (Nauck et al., 2011).  Together, these GLP-1-mediated GI effects may 
enhance central satiety.  Indeed, studies have shown GLP-1 decreases food and fluid 
intake in rats (Tang-Christensen et al., 1996) and humans (healthy and obese) (Flint et 
al., 1998; Näslund et al., 1998; Gutzwiller et al., 2004).  Furthermore, in healthy 
individuals, GLP-1 enhanced gastric accommodation, which correlated with a 
significant decrease in the feeling of hunger  (Delgado-Aros et al., 2002; Andrews et 
al., 2006).  The anorectic effect of GLP-1 appeared to be mediated by vagal and 
brainstem feeding pathways in the rat, as this anorectic effect was absent following 
vagotomy (Imeryüz et al., 1997).  Therefore, GLP-1 has anorexigenic properties and 
most likely contributes to the augmentation of satiety in animal models and humans.  
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1.12.2 GLP-1 receptor 
In 1992, the GLP-1R was cloned using cDNA from rat pancreatic islets (Thorens, 
1992), and this was followed by the cloning of the homologous human GLP-1R  
(Thorens et al., 1993).  GLP-1R is a class 2 GPCR, joining the glucagon, GIP and 
secretin receptor family (Mayo, 2003).  Activation of GLP-1R (with GLP-1(7-37)) 
resulted in the stimulation of the Gαs-stimulatory cAMP pathway and the elevation of 
[Ca2+]i, in COS-7 cells expressing rat GLP-1R (Wheeler et al., 1993).  The expression 
of mouse (Campos et al., 1994) and human GLP-1R (Wei and Mojsov, 1995) has been 
identified in pancreatic islets, stomach, intestine, heart, kidney and the brain 
hypothalamus.  In 1991, Ex4 was isolated from Heloderma suspectum (Glia monster) 
venom, and it displayed structural similarity (53 %) to mammalian GLP-1.  Initial 
studies demonstrated that Ex4 exhibited 125IGLP-1(7-36) displacement at the GLP-1R.  
This indicated Ex4, like GLP-1, selectively activated the GLP-1R.  In a separate study, 
Ex4 triggered cAMP accumulation in rat insulinoma RINm5F cells, suggestive of Gαs 
signalling.  Ex4 also increased GSIS in rat islets and a mouse insulinoma cell line, and 
these effects were suppressed by the truncated form of the Ex4, also known as Ex(9-
39) amide (Göke et al., 1993).  This study demonstrated Ex4 mimicked the action of 
GLP-1 and was thus a GLP-1R agonist.  Furthermore, Ex(9-39) amide was a selective 
GLP-1R antagonist.  The discovery of Ex4 pioneered the field and led the way forward 
in the creation of GLP-1 mimetics.  Ex4 and Ex(9-39) were key pharmacological tools 
used in this thesis.   
Ablation of the GLP-1R in mice has demonstrated the importance of this receptor in 
glucose tolerance.  GLP-1R-/- mice present with mild fasting hyperglycaemia and 
glucose intolerance, which have been attributed to a reduction in postprandial insulin-
release and abnormal glucose excursions.  These mice also display normal body 
weight and feeding regulation (Scrocchi et al., 1996), and thus reveal alternative 
compensatory mechanisms to control feeding and appetite.  
 
1.12.3 Glucagon-like peptide 2 
In 1996, glucagon-like peptide 2 (GLP-2) was isolated from mammalian proglucagon 
DNA, as a 33-amino acid intestinotrophic peptide.  In this initial study, Drucker et al. 
(1996) demonstrated that mice treated with GLP-2 for 4-6 days presented with a 50 % 
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increase in small bowel weight, enhanced crypt cell proliferation and an increase in 
mucosal thickness in the proximal small intestine.  The increase in mucosal thickness 
was attributed to a narrowing of intestinal cells, elongated microvilli and an inhibition 
of intestinal crypt enterocyte apoptosis (Drucker et al., 1996).  Drucker et al. (1997) 
investigated the intestinotrophic effects of GLP-2 in rodents.  Here, GLP-2 stimulated 
elongation of intestinal villus height in mice and rats.  Further investigations revealed 
GLP-2 was unable to increase intestinal villus height in DPPIV-/- mice, demonstrating 
DPPIV limits the intestinotrophic effects of GLP-2 (Drucker et al., 1997).  Notably, 
compared to GLP-1, GLP-2 was less susceptible to degradation by the DPPIV enzyme,  
in both the GI tract and vasculature (Drucker et al., 1997).   In humans, GLP-2(1-33) is 
hydrolysed into GLP-2(3-33) within 7.2 mins.  In this way, most of the released GLP-2 
is still intact and efficacious by the time it reaches the circulation (Hartmann et al., 
2000).   
Unlike GLP-1, GLP-2 is not an incretin.  The main physiological functions of GLP-2 
are maintenance and protection of the intestinal integrity and morphology (Brubaker 
et al., 1997; Scott et al., 1998), inhibition of crypt cell apoptosis (Boushey et al., 2001), 
increasing crypt cell proliferation (Drucker et al., 1996; Drucker et al., 1997) and 
reducing GI epithelium inflammatory states (Drucker et al., 1999; Sigalet et al., 2007). 
This includes a reduction in paracellular epithelial tight-junction permeability, which 
strengthens epithelium barrier function (Benjamin et al., 2000).   The activity of 
epithelium disaccharidases (maltase, sucrase, lactase) was enhanced by GLP-2 
treatment (10 days) in mice.  This increased activity of disaccharidases may facilitate 
and enhance the absorption of disaccharides (Brubaker et al., 1997).  Certainly, the 
absorption of the amino acid, leucine and the triglyceride, triolein was increased 
(Brubaker et al., 1997).  More recently, GLP-2 enhanced leucine absorption in mice 
in vivo (Lee et al., 2017), and this implicated the involvement of GLP-2 in the 
facilitation of nutrient absorption.  Having established the effects of GLP-2 in rodent 
models, investigations were extended to human trials.  In humans with short-bowel 
syndrome (subjects present with no ileum (or colon) and malabsorption), GLP-2 
(administered twice daily, subcutaneous injection (s.c) for 35 days) provided 
beneficial intestinotrophic effects, slowed gastric emptying and improved the 
nutritional state of these individuals (Jeppesen et al., 2001).  The effect of GLP-2 
administration on gastric motility has been assessed in mouse and humans.  In WT 
86 
 
mice, GLP-2 (0.15 µg/g body weight) slowed upper intestinal transit (by 29 %) in 
response to a charcoal meal (oral gavage), but was less potent than GLP-1 (55 %) in 
vivo (McDonagh et al., 2007).  In humans, the effects on motility have been 
controversial.  In healthy volunteers, Schmidt et al. (2003) observed no effect of GLP-
2 (0.75 and 2.25 pmol kg body wt −1 min −1)  on the motility of a solid meal (omelette) 
and suggested GLP-2 had no role to play in the ileal brake.  In another study GLP-2 
administration (0.5 and 1.0 pmol kg body wt −1 min −1) resulted in a dose-dependent 
slowing of antral emptying to a liquid meal (lukewarm beef tea) in healthy volunteers 
(Nagell et al., 2004) as previously observed (Jeppesen et al., 2001).  While it appears 
GLP-2 slows GI motility in mice, the motility effect in humans remains unresolved.  
The main beneficial effects of GLP-2 in rodents and humans appears to be 
intestinotrophic and mucosal protective.  
 
1.12.4 GLP-2 receptor  
The glucagon-like peptide 2 receptor (GLP-2R) was cloned from rat intestinal and 
hypothalamic cDNA libraries.  The rat GLP-2R clone was utilised to identify the 
human GLP-2R (Munroe et al., 1999).  Like the GLP-1R, the GLP-2R belongs to the 
7-transmembrane class 2 GPCR family (Mayo, 2003).  Activation of GLP-2R 
amplified AC activity and increased cAMP (EC50 0.58 nM) signalling (stimulatory Gαs 
pathways), in COS-7 cells expressing rat GLP-2R (Munroe et al., 1999).  Human GLP-
2R was expressed in the stomach, intestine and brain (Yusta et al., 2000).   In the 
mouse, GLP-2R was identified in the stomach, duodenum, jejunum, colon, 
hypothalamus, brain stem and lung (Yusta et al., 2000). More specifically, GLP-2R 
has been localised in subepithelial myofibroblasts (Ørskov et al., 2005), in enteric 
neurons, vagal afferents (Guan et al., 2006), in intestinal PYY- and GLP-1-containing 
EECs (Yusta et al., 2000), the hypothalamus, hippocampus and the 
nucleus tractus solitarius (Lovshin et al., 2001).  
The GLP-2R-/- mice possess normal glucose regulation in various ranges of glycemia 
and no clear phenotype (Bahrami et al., 2010).  However, a GLP-2R deficiency in 
diabetic ob/ob mice revealed an amplification of α cell mass, a diminished β cell mass, 
hyperglycaemia, elevated glucagon secretion and glucose intolerance.  This 
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demonstrated that the adaptive trophic features associated with GLP-2R activation 
were critical in metabolic stress (Bahrami et al., 2010).   
 
1.13 Oxyntomodulin  
In the early 1980’s OXM (previously known as enteroglucagon) was isolated and 
characterised from porcine jejuno-ileum (Bataille et al., 1982), as a 37 amino-acid 
peptide that resembled glucagon.  OXM was also isolated in rat (Bataille et al., 1981; 
Collie et al., 1994) and human intestine (Ghatei et al., 1983).  This peptide was 
produced in preproglucagon-containing cells and was processed similarly to GLP-1 
and GLP-2 (Mojsov et al., 1986).  The preproglucagon precursor is cleaved by PC 1/3, 
creating OXM, a peptide formed of glucagon and an octapeptide extension, also 
known as IP-1 (Figure 1.14) (Holst, 1997).  OXM is co-released with GLP-1, GLP-2 
and PYY from enteroendocrine L cells (Böttcher et al., 1984; Böttcher et al., 1986). 
Two independent studies revealed OXM exhibited affinity for the GLP-1R (Gros et 
al., 1993) and the porcine glucagon receptor  (GCGR) (Baldissera et al., 1988), 
implicating OXM as a dual agonist.  At each receptor, OXM was 10 - 100 fold less 
potent than the cognate ligands, GLP-1 and glucagon (Baldissera et al., 1988; Gros et 
al., 1993).  Despite OXM engaging the same receptor as GLP-1, peripheral 
administration of OXM and GLP-1 has resulted in differential region-specific 
hypothalamic neuronal activity (Chaudhri et al., 2006).  Utilising manganese-
enhanced magnetic resonance imaging, Chaudhri et al. (2006) revealed that OXM 
reduced neuronal activity in the arcuate nucleus (ARC), paraventricular nucleus 
(PVN) and supraoptic nuclei.  In contrast, GLP-1 suppressed neuronal signalling in 
the PVN and enhanced signalling in the ventromedial hypothalamus (VMH).  This 
suggested that while OXM and GLP-1 both bind the GLP-1R, an uncharacterised 
OXM receptor may exist.  In this way, the observed differences in hypothalamic 
neuronal signalling (Chaudhri et al., 2006) may be attributed to the activation of this 
uncharacterised OXM receptor.  To date, no specific OXM receptor has been 
identified or sequenced. 
OXM appears to be an anorectic peptide in rodents and humans.  
Intracerebroventricular (icv) administration of OXM into the PVN suppressed food 
intake in rats (Dakin et al., 2001; Dakin et al., 2002).  This anorectic effect was reduced 
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in the presence of the GLP-1 antagonist, Ex(9-39), suggestive of a GLP-1R-mediated 
mechanism (Dakin et al., 2001).  In another study, OXM (icv) transiently inhibited 
food intake, and this effect was absent in GLP-1R-/-, not GCGR-/- mice.  This 
confirmed the OXM-induced anorectic effect was GLP-1R-dependent (Baggio et al., 
2004).  This anorectic effect was also displayed in healthy subjects (Cohen et al., 
2003).  OXM (i.p.) decreased food intake and suppressed the levels of the appetite 
stimulant peptide, ghrelin.  These anorectic effects of OXM extended to obese and 
overweight volunteers (Cohen et al., 2003).  In another study, self-administration of 
OXM (s.c, 3 times daily) resulted in a suppressed energy intake, enhancement in 
activity-induced energy expenditure and lower body weight in overweight and obese 
volunteers (Wynne et al., 2006).  More recently, the reduction in body weight was also 
shown to be mediated by the GCGR receptor in mice (Kosinski et al., 2012).  Together, 
these studies demonstrated that combined agonism of GLP-1R and GCGR with OXM 
induced beneficial anorectic effects.  OXM also increased insulin secretion from 
murine islets in vitro, improved glucose tolerance and enhanced glucose disposal in 
WT (Maida et al., 2008) and DIO mice in vivo (Parlevliet et al., 2008).  These effects 
were GLP-1R-mediated (Maida et al., 2008; Parlevliet et al., 2008).  Other benefits of 
OXM agonism include protection of β cell mass apoptosis in mice (Maida et al., 2008), 
reduction of gastric acid/pancreatic exocrine secretions and inhibition of gastric 
emptying in humans (Schjoldager et al., 1989).  Furthermore, OXM had no effect on 
gastric motility in mice (Maida et al., 2008).   
 
1.14 Control of appetite in the hypothalamic arcuate nucleus and the role of PYY(3-36) 
The hypothalamus, located in the mediobasal section of the brain and the brainstem 
are the main centres of energy and appetite regulation (Murphy and Bloom, 2006).  
The basal region of the hypothalamus forms the ARC.  The ARC encloses the third 
ventricle and is a modified region of the blood-brain barrier (semi-permeable) and is 
anatomically above the median eminence.  This region of the hypothalamus serves as 
a privileged first sensor of the peripheral energy status of the whole organism, allows 
entry of peripheral peptides and critically integrates neuronal and endocrine signals 
(Peruzzo et al., 2000).   The ARC consists of two populations of nuclei that either 
enhance appetite (orexigenic) or inhibit (anorexigenic) food intake (Figure 1.15) 
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(Cone, 2005).  ARC neurons project onto second order neurons in higher hypothalamic 
regions, the VMH, the paraventricular hypothalamus (PVH) and the lateral 
hypothalamus area (LHA), to regulate satiety, appetite and energy expenditure 




Figure 1.15: Two populations of first order neurons regulate feeding and appetite 
in the hypothalamic arcuate nucleus (ARC).  Stimulated proopiomelanocortin 
(POMC) neurons in the ARC, release α melanocyte-stimulating hormone (α-MSH).   
α-MSH activates MC3/MC4 receptors expressed on second-order neurons, in the 
paraventricular nucleus (PVN).  This enhances satiety by reducing food intake and 
stimulating energy expenditure.  The second population of neurons in the ARC, are 
agouti-related peptide (AgRP)/NPY neurons.  When stimulated, AgRP, an 
endogenous antagonist of the MC4 (and MC3) receptor, is released and blocks the 
effects of α-MSH, to increase food intake and reduce energy expenditure.  Ingested 
macronutrients stimulate the release of GI peptides e.g. PYY and GLP-1 from 
enteroendocrine L cells.  These hormones activate hypothalamic nuclei and the brain 
stem vagal afferents, to regulate feeding and satiety.  Therefore, the ARC integrates 
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neuronal and endocrine signals from the periphery and brainstem.  Image from Sam et 
al. (2012).  
The lateral located anorexigenic neurons in the ARC, coexpress cocaine and 
amphetamine-related transcript (CART) (Koylu et al., 1997; Kristensen et al., 1998) 
and proopiomelanocortin (POMC) neurons (Elias et al., 1998).  These neurons are 
powerful suppressants of food intake and body weight.  POMC is cleaved by PC 1/2 
within these neurons, yielding α melanocyte-stimulating hormone (α-MSH) 
(Jacobowitz and O’Donohue, 1978; Cone et al., 1996).  α-MSH binds central G-
protein coupled melanocortin receptors (MC3 (Roselli-Rehfuss et al., 1993) and MC4 
(Cone et al., 1996)), to inhibit feeding and enhance energy expenditure (Fan et al., 
1997).  Notably, MC4 is highly expressed in the hypothalamic PVN (Mountjoy et al., 
1994).  Target deletion of MC4 results in hyperphagia and obesity in mice (Huszar et 
al., 1997) and humans (Vaisse et al., 1998; Yeo et al., 1998).  Conversely, the medially 
located orexigenic neurons that coexpress AgRP (Shutter et al., 1997; Haskell-
Luevano et al., 1999) and NPY (Broberger et al., 1998) stimulate food intake.   AgRP 
is a potent endogenous MC3 and MC4 competitive antagonist (Lu et al., 1994; Ollmann 
et al., 1997) that inhibits the effect of α-MSH, which stimulates feeding and decreases 
energy expenditure (Broberger et al., 1998; Hahn et al., 1998; Hagan et al., 2000).  The 
regulation and balance between the orexigenic and anorexigenic neuronal populations 
ensures food intake and energy expenditure is maintained. 
Ingested macronutrients stimulate the release of numerous GI peptides.  Initial studies 
suggested acute peripheral PYY(3-36) administration reduced food intake in rodents 
(Batterham et al., 2002) and humans (healthy and obese) (Batterham et al., 2003).  
However, these studies were controversial as many laboratories were unable to repeat 
these findings.  The inconsistencies between studies have been attributed to animal 
stress, and the importance of prior acclimatisation (i.e. animal handling) of each 
experimental animal to the methodology and environment (Tschöp et al., 2004).  
Batterham et al. (2002) demonstrated the reduction in food intake was mediated via 
the ARC, as peripherally administered PYY(3-36) increased c-fos expression in this 
region.  In this study, PYY(3-36) hyperpolarised non-POMC neurons (which were 
assumed as orexigenic NPY neurons) and this caused disinhibition, and thus 
depolarisation of anorexigenic POMC neurons.  The anorectic effect of PYY(3-36) was 
absent in Y2
-/- mice, indicating this PYY(3-36)-induced anorectic effect was Y2-
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mediated (Batterham et al., 2002).  Subsequent studies, have confirmed PYY(3-36) 
elicited an acute reduction in food intake in mice (Challis et al., 2003; Pittner et al., 
2004; Adams et al., 2006), rats (Abbott et al., 2005; Chelikani et al., 2006) and rhesus 
monkeys (Moran et al., 2005) in vivo.  Abbott et al. (2005) demonstrated food intake 
was inhibited in mice treated with the Y2R antagonist, BIIE2046 in vivo (Abbott et al., 
2005).  Taken together, these studies show that inhibition of food intake by PYY(3-36) 
was Y2-mediated, which resulted in the suppression of ARC orexigenic NPY neurons 
and an increased neuronal activity of anorexigenic POMC neurons. 
 
1.15 PYY slows the colonic and ileal brakes 
Initial intestinal motility investigations have described the slowing of small bowel 
transit to an ileal perfusion of a lipid emulsion in human subjects (Read et al., 1984; 
Spiller et al., 1984; Spiller et al., 1988).  These studies revealed the existence of an 
inhibitory intestino-intestinal feedback mechanism, whereby unabsorbed nutrients in 
the ileum delayed proximal intestinal motility (Read et al., 1984).  This mechanism, 
designated the ileal brake (Spiller et al., 1988) was critical to slow the motility of 
luminal macronutrients, to optimise digestive and absorptive processes.  The 
companion brakes include, the duodenal brake, jejunal brake and the colonic brake 
(Van Citters and Lin, 1999).  PYY was a major inhibitory mediator of intestinal 
motility, as studies showed a positive correlation between PYY release and reduced 
intestinal motility following a lipid stimulation in humans (Pironi et al., 1993).  The 
use of a polyclonal PYY antibody abolished the PYY-induced inhibition of intestinal 
transit, confirming PYY was the primary mediator of the ileal brake (Lin et al., 1996).  
In another study, PYY also slowed colonic motility in cats (Lundberg et al., 1982).  
The ability of distal released PYY to inhibit proximal intestinal motility most likely 
involves activation of the intestinofugal nerve pathway, which passes through the 
sympathetic prevertebral ganglia (Figure 1.8) (Furness et al., 2013).    Lin et al. (2000) 
showed that distal PYY release was dependent on proximal CCK release.  This 
suggested that newly arrived chyme in the small intestine stimulated upper intestinal 
I cells to release CCK, and this in turn signalled distal L cells to secrete PYY (Lin et 
al., 2000).  In this way, PYY initiated the ileal brake (and the associated compound 
brakes), which slowed small intestinal motility to allow optimal absorption of 
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nutrients.  Furthermore,  serotonergic, opioid (Lin, 2004) and β-adrenergic pathways 
(Lin et al., 2003) were also thought to contribute to the inhibition of intestinal transit 
by PYY in canines.    
While PYY is a critical regulator of GI motility, normal peristalsis also requires 
functional circular and longitudinal smooth muscle, the ENS/CNS innervation, and 
ICCs to generate peristaltic slow waves (Bornstein et al., 2004).  Dysfunction in any 
of these three components also result in abnormal or defective GI motility.  Indeed, 
the importance of the ENS is observed in Hirschsprung disease.  Infants with this 
disorder lack ENS development in the distal intestine, and therefore this region of the 
intestine is unable to propel chyme appropriately (Furness, 2012).  Prolonged and 
abnormal peristalsis is also observed in mice with an impaired ICC intestinal network 
(Ward et al., 1994; Der–Silaphet et al., 1998) and in mice lacking the contractile 
activity of intestinal smooth muscle cells (Angstenberger et al., 2007).  Taken together, 
these studies reveal the importance of the ENS, ICCs, smooth muscle and PYY to 
modulate intestinal motility and optimise nutrient absorption.   
 
1.16 Intestinal epithelial ion transport  
1.16.1 Intestinal epithelial ion absorption 
In humans, 1.3-1.8 L electrolyte-rich fluid is absorbed daily, with 90 % of this 
occurring in the proximal intestine (Debongnie and Phillips, 1978).  The intestinal 
epithelium consists of predominantly absorptive/secretory enterocytes (Figure 1.16).  
Enterocytes in the intestinal crypt region are highly secretory compared to surface 
epithelial enterocytes, that are primarily absorptive (Köckerling et al., 1993; 
Hermiston and Gordon, 1995).  Glucose and amino acids are actively absorbed and 
co-transported into enterocytes with Na+.  Once in the cell, these nutrients exit the 
serosal side, independent of ion movement (Field, 2003).  The predominate apical 
absorption of Na+ and Cl- in the intestine is electroneutral (via Na+/H+ (NHE) and Cl-
/HCO3
- exchangers) (Rajendran and Binder, 1990; Rajendran et al., 1995) and 
electrogenic (via apical amiloride-sensitive ENac channels) (Kunzelmann and Mall, 
2002).  In humans, the proximal colon absorption is mainly electroneutral, and 
absorption in the distal colon is primarily electrogenic (Levitan et al., 1962).  
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In the colonic enterocytes, there are three types of NHEs, NHE1, which is located in 
the serosal membrane, whereas NHE2 and NHE3 are in the luminal epithelial 
membrane (Figure 1.16).  Most electroneutral Na+ absorption occurs via NHE3 (Ikuma 
et al., 1999).  Upregulation of cAMP inhibits electroneutral NaCl reabsorption, an 
effect that was absent in mice lacking the predominant luminal Cl- channel, also 
known as cystic fibrosis transmembrane conductance regulator (CFTR).  This 
implicates a regulatory role of CFTR in electroneutral NaCl absorption in the intestine 
(Clarke and Harline, 1996).  Electroneutral absorption of Cl- occurs via surface 
epithelium luminal Cl-/HCO3
- or Cl-/OH- exchangers (also present in crypt cells).  
Furthermore, a third Cl-/HCO3
- exchanger is located in the serosal membrane, 
providing a passage for Cl- to enter the circulation (Rajendran et al., 2000).  As Cl- 
exits, HCO3
- enters the cytosol and is secreted via the luminal Cl-/HCO3
- exchanger, 
creating an alkaline intestinal region (Seidler et al., 2000).   
Electrogenic transport of Na+ occurs via luminal ENac channels and this generates an 
electrochemical gradient (Canessa et al., 1993; Garty and Palmer, 1997).  ENac does 
not appear to be located in crypt cells, further confirming crypt enterocytes are most 
likely secretory (Greger et al., 1997).  Studies have revealed that ENac also appears to 
be regulated by CFTR.  A larger Na+ conductance was observed in colonic mucosa 
from individuals with cystic fibrosis (Mall, 1999).  Furthermore, CFTR-/- mice show 
an increased amiloride-sensitive short circuit current (Isc) compared to WT, 
implicating normal CFTR function inhibits ENac absorption (Clarke and Harline, 
1996).  The ouabain-sensitive serosal electrogenic 3Na+/2K+ ATPase removes 3Na+ 
from the cytosol and allows entry of 2K+.  This generates an electrochemical gradient 
and a negative cell voltage that drives Na+ absorption (Kunzelmann and Mall, 2002).  
The transport of Na+ into the intercellular space, is followed by Cl- and this initiates 
fluid movement (Greger et al., 1997).  The intercellular Cl- exits via serosal Cl- 
channels or the Cl-/HCO3
- exchanger.   
Fluid movement from the lumen into the general circulation occurs via paracellular 
shunting or transcellular movement via luminal and serosal aquaporins (AQP) (Wang 
et al., 2000).  Three types of AQPs exist in the colonic mucosa, AQP3, AQP4, AQP8 
(Ma and Verkman, 1999).  Studies in transgenic mice have shown that loss of AQP4 
results in 50 % loss of water permeability and increased stool water content (Wang et 
al., 2000).  Conversely, loss of AQP3 (Ma et al., 2000) or AQP8 (Yang et al., 2005), 
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has no effect on colonic water permeability.  Thus, AQP4 appears to be the primary 
AQP responsible for fluid absorption in the mouse.  
 
Figure 1.16: Intestinal epithelial ion transport in absorptive/secretory 
enterocytes.  Left cell: Absorption of ingested organic solutes (glucose and amino 
acids) enter enterocytes via co-transporters, that couple to a sodium ion (Na+).  These 
nutrients exit the serosal membrane independent of ion transport.  Electroneutral 
transport of Na+ and chloride ions (Cl-) occurs via Na+/H+ (NHE) and Cl-/HCO3
- 
exchangers.  Na+ is also absorbed via the epithelial sodium channel (ENac).  In the 
serosal membrane, the 3Na+/2K+ ATPase is electrogenic and uses ATP to drive 
transport of ions against their electrochemical gradient.  Serosal potassium ion (K+) 
channels open allowing exit of K+ ions to prevent cell swelling.  Water is absorbed via 
paracellular shunting or transcellular via AQPs.  Right cell: The secretagogue, VIP, 
activates VPAC receptors that are Gαs-coupled.  This leads to an increase in cAMP 
accumulation and encourages the opening of CFTR channels, to cause Cl- secretion.  
The loss of Cl- facilitates electroneutral inward flux of Na+, K+ and 2Cl- via the 





1.16.2 Intestinal epithelial ion secretion 
Fluid secretion and absorption are balanced to prevent diarrhoea/constipation and also 
to maintain hydration and mucus secretion (Kunzelmann and Mall, 2002).  Activation 
of secretory cells in the intestine with a secretagogue (e.g. VIP) increases cAMP 
activation and this drives the probability of CFTR opening, to cause Cl- secretion 
(Figure 1.16) (Field, 2003).  The CFTR channel is a member of the ATP-binding 
cassette protein family and dysfunction of the channel leads to cystic fibrosis (Riordan 
et al., 1989).  Utilising in situ hybridisation, studies have shown CFTR mRNA 
expression was graded along the crypt-villus axis, with lowest expression observed at 
the villus tip in rat (Trezíse and Buchwald, 1991) and human (Strong et al., 1994).  
Thus, crypt enterocytes are predominantly secretory.  CFTR is activated by Gαs or Gαq 
pathways to cause secretion of Cl- (Mall et al., 1998; Barrett and Keely, 2000).  In this 
way, CFTR has dual function in the intestine a) in the crypt enterocytes, the main 
function of CFTR is Cl- secretion, and b) in the surface epithelium enterocytes, CFTR 
is also an important regulator of ENac and electroneutral NaCl absorption.  CFTR Cl- 
secretion is dependent on the serosal Na+K+2Cl- co-transporter (NKCC1) (Haas and 
Forbush III, 2000).  Loss of NKCC1 in mice (NKCC1-/-) ameliorated colonic Cl- 
secretion, demonstrating NKCC1 as a key regulator of Cl- secretion (Flagella et al., 
1999) (Figure 1.16).  Newly arrived intercellular K+ from NKCC1 prevents cell 
shrinkage (Lang et al., 1998) and is recycled back into the circulation via serosal K+ 
channels (cAMP dependent- or Ca2+) or electroneutral serosal K+/Cl- co-transporters, 
to prevent cell swelling (Kunzelmann and Mall, 2002).  This recycling of K+ prolongs 
Cl- secretion and NaCl absorption (Field, 2003).   
 
1.16.3 Y receptor signalling inhibits epithelial ion transport and upper intestinal 
transit is increased in PYY-/- mice 
In 1988, Cox and Cuthbert revealed PYY and NPY inhibited basal Isc and VIP-induced 
secretory responses in rat jejunum and descending colon mucosa.  These responses 
were absent in unstripped tissue, demonstrating the circular and longitudinal muscle 
provided a barrier to exogenous peptides.  These anti-secretory responses were 50 % 
inhibited by piretanide, a NKCC1 inhibitor, suggesting the movement of Na+, K+ and 
2Cl- partially mediated the anti-secretory responses (Cox et al., 1988).   Furthermore, 
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36Cl- and 22Na+ flux studies demonstrated the anti-secretory responses were attributed 
to the attenuation of Cl- anion secretion (from serosal to mucosal side) via luminal 
anion channels (presumably CFTR channels) (Cox et al., 1988).  Indeed, Hubel and 
Renquist (1986) demonstrated activation of Y receptors (Gαi-coupled), reduced cAMP 
production and PKA activity in enterocytes.  This was attributed to the attenuation of 
Cl- secretion via luminal CFTR channels and the reduction of K+ conductance, causing 
an anti-secretory response (Hubel and Renquist, 1986).   
In early GI electrophysiology studies, the rat or guinea pig were used as the preferred 
species of choice.  Today, the mouse is the most commonly utilised species due to the 
availability of transgenic and knockout mice lacking a single Y receptor, which has 
revealed detailed analysis of specific genes, receptors and their pharmacology and 
physiology (Gershon, 1999).  As a result, Cox et al. (2001) investigated the effects of 
NPY, PYY and hPP in the mouse.  PYY, NPY and hPP inhibited VIP-induced anion 
secretion in descending colon mucosa (Cox et al., 2001), as observed previously in the 
rat (Cox et al., 1988).  The receptor selectivity of these three agonists were investigated 
using Y1 (BIBO3304 or BIBP3226) an Y2 (BIIE2046) competitive antagonists.  PYY, 
NPY and hPP responses were Y1-, Y2- and Y4-mediated, respectively (Cox et al., 2001; 
Tough et al., 2006).  These findings were similar to those observed in descending 
human colon mucosa (Cox and Tough, 2002), and were confirmed by the loss of 
selective agonism in Y2
-/-- (Hyland et al., 2003) and Y4
-/- mouse tissue (Tough et al., 
2006).   Studies carried out by Hyland et al. (2003) demonstrated Y2 receptors were 
located pre-junctionally in neurons in mouse and human descending colonic mucosa, 
whereas Y2 receptors were post-junctional in longitudinal smooth muscle (Hyland et 
al., 2003).  Additionally, PYY(3-36) Y2 responses were also 90 % inhibited in the 
presence of TTX, demonstrating a predominant neuronal component, and a relatively 
minor epithelial post-junctional proportion of Y2-mediation.  Importantly, Y1, Y2 and 
Y4 signalling in the mouse and human colonic mucosa was identical, and therefore the 
mouse was chosen as the preferred species to use in further studies (Cox et al., 2001; 
Cox and Tough, 2002; Hyland et al., 2003; Tough et al., 2006). The competitive Y 
receptor antagonists (BIBO3304 and BIIE2046) also revealed basal Y1 and Y2 tone in 
mouse and human colonic mucosa, implicating tonic PYY-Y1 and NPY-Y2 activity 
(Hyland et al., 2003; Hyland and Cox, 2005; Tough et al., 2011).  Utilising various 
knockout mice (NPY-/-, PYY-/- and NPY/PYY -/-) and human mucosa, Tough et al. 
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(2011) revealed Y1 tone was predominantly TTX-insensitive mediated by Y1 receptors 
(90 %) and the residual 10 % was Y2-mediated and TTX-sensitive.  Conversely, Y2 
tone was primarily Y2-mediated and attenuated in the presence of TTX (Cox, 2008; 
Tough et al., 2011).  Taken together, these studies showed that in the mouse, Y1 and 
Y4 responses were mainly epithelial in origin and Y2 responses were predominantly 
neuronally-mediated.  Thus, revealing differential expression of these three Y 
receptors in the intestine. 
The effect of Y-receptor signalling on colonic motility in vitro and upper GI transit 
(UGIT) in vivo has been assessed.  The Y1 antagonist (BIBO3304) appeared to 
increase colonic transit, whereas the Y2 antagonist (BIIE2046) appeared to slow 
colonic transit, in isolated colon in vitro.  However, these effects were not significant.  
UGIT was significantly faster in PYY-/- mice and the transit rate in the double 
knockout NPY/PYY -/- mice was similar to WT, indicating loss of NPY negates the 
inhibitory effects of PYY (Tough et al., 2011).  Therefore, PYY slowed colonic and 
upper GI transit as shown previously (Savage et al., 1987; Lin et al., 1996), presumably 
via the Y1 receptor (Tough et al., 2011), whereas NPY increased colonic transit as 
shown previously (Chen et al., 1997; Monnikes et al., 2000).  This NPY-induced 
increase in colonic motility was Y2-mediated in vivo (Tough et al., 2011).  
More recently, Cox et al. (2010) showed that activation of the ethanolamide receptor 
GPR119, with the selective GPR119 agonist, PSN632408 (Cox et al., 2010) or PSN-
GPR119 (Patel et al., 2014) was PYY Y1-mediated and glucose-sensitive in mouse 
and human mucosa, and improved glucose tolerance in mice.  These key GPR119 
studies demonstrated the benefit of targeting L cell GPR119, as a relevant therapeutic 
target in T2DM.   This thesis further investigated GPR119 signalling and additionally 
interrogated novel FFA1 and FFA4 signalling in the mouse, using selective agonists 








1.17 Thesis aims  
At the start of this PhD, the pharmacology of the FFA1, FFA4 and GPR119 receptors 
in native tissue was unclear, and very few functional studies had been performed 
interrogating their intestine mechanisms.  The first aim of this study was to determine 
the potencies and efficacies of novel selective agonists received from AZ (FFA1 
agonists: JTT, TAK-875; FFA4 agonists: AZ423, Met-36; GPR119 agonists: Cpd.16, 
Cpd.42) and compare them with commercially available agonists (FFA1 agonist: 
TUG424; FFA4 agonist: TUG891; FFA1 and FFA4 dual agonist: GW9508; GPR119 
agonist: PSN632408).  Next, a tissue survey was undertaken to investigate the GI 
regional variations in FFA1, FFA4 and GPR119 agonism, and this allowed selection 
of an optimal area for future functional studies.   
In descending colon mucosa, the selectivity of the FFA1-preferring antagonist, 
GW1100 and the FFA4 antagonist, AH-7614 was established, comparing them with 
the selective AZ FFA1 antagonist, ANT825.  The relative abilities of each antagonist 
to reveal tonic FFA1 or FFA4 activity was evaluated.  Additionally, each antagonist 
was utilised to validate the selectivity of the chosen agonists.  The involvement of 
endogenous PYY in FFA1, FFA4 and GPR119 agonism was determined by blocking 
endogenous PYY activity pharmacologically, with the competitive Y1 antagonist 
(BIBO3304) and Y2 antagonist (BIIE2046).  The glucose-sensitivity of these 
responses was evaluated as hypoglycaemia is a common adverse effect of some T2DM 
therapeutics, namely sulphonylureas and insulin.   Moreover, the TTX-sensitivity of 
FFA1, FFA4 and GPR119 agonism was assessed to determine the enteric neuronal 
involvement in their mucosal responses. 
As GLP-1 responses were not observed in FFA1, FFA4 or GPR119 agonism in the 
descending colon mucosal Ussing chamber studies, another tissue survey was 
undertaken to identify the area of colon that provided the greatest GLP-1-mediated 
response.  In this region, GPR119 agonism was assessed in the presence of a DPPIV-
inhibitor (sitagliptin), as the GPR119 receptor has a significant role in GLP-1 release 
in primary colonic crypt cultures and in mice in vivo, compared to the FFA1 and FFA4 
receptors (Ekberg et al., 2016). 
Physiologically, lipid metabolites from the diet concomitantly activate all three lipid-
sensing receptors, FFA1, FFA4 and GPR119.  Thus, potential synergistic effects of 
99 
 
co-agonism and triple agonism was evaluated in the descending colon.  L cell triple 
receptor agonism was studied utilising dietary pinolenic acid, a newly characterised 
dual FFA1 and FFA4 agonist, and this was applied with a commercial or AZ supplied 
GPR119 agonist.  As PYY is a known mediator of the ileal and colonic brakes, the 
effect of FFA1 and FFA4 agonism on upper intestinal motility and colonic motility 
was assessed in vivo.   
A summary of the selective AZ compounds and commercially available agonists used 
in this thesis is shown in Table 1.4.  Furthermore, the AZ in-house potency and 
selectivity data of each AZ compound is shown in Table 1.5.   
 
 
Table 1.4: Synthetic agonists and antagonists used in this thesis, which were 
either received from AstraZeneca or commercially bought.  The table includes 
compound receptor target(s), other names, international non-proprietary names and 
the abbreviated names used in this thesis. 
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 Table 1.5: AstraZeneca in-house potency and signalling data of compounds used in this 
thesis. Abbreviations: 5-HT, serotonin; AChE, acetyl cholinesterase; cAMP, cyclic adenosine monophosphate; CB1, cannabinoid 
receptor 1; CB2, cannabinoid receptor 2; CHO, Chinese Hamster Ovary; FFA1, free-fatty acid receptor 1; FFA4, free-fatty acid 
receptor 4; FLIPR, fluorometric imaging plate reader; HEK, human embryonic kidney; NPY, neuropeptide Y; PPAR, peroxisome 



























2.1 Mucosal preparation and measurement of vectorial ion transport (short-circuit 
current (Isc)) 
Mice (C57BL/6J, 12-20 weeks old, 20-30 g, female or male) were procured from 
Charles River Laboratories (Margate, UK) had free access to standard chow (Rat and 
Mouse No 3 breeding diet, Special Diets Service, Braintree, UK) and water ad libitum.  
This species and strain was used because the Y1, Y2 and Y4 expression patterns in 
colonic mucosa is the same as that observed in human (Cox and Tough, 2002; Hyland 
et al., 2003; Tough et al., 2006; Tough et al., 2011).  Mice were housed in a convention 
unit, in open top conventional cages with Lignocel poplar bedding material along with 
the appropriate environment enrichment.   A maximum of five mice were housed in a 
single cage.  Housing rooms were maintained at 20-24 ◦C, humidity 55 % ± 10 % and 
12/12 h light and dark cycles, with lights on from 07.00 am.  All animal care and 
experimental procedures complied with the Animals (Scientific procedures) Act 1986 
and were approved by the local ethics committee.  Mice were killed by cervical 
dislocation and the whole colon or specific area of GI tract was dissected (noting the 
proximal and distal regions) and placed in fresh Krebs-Henseleit (KH), with the 
following composition (in mM); NaCl 118, KCl 4.7, NaHCO3 25, KH2PO4 1.2, 
MgSO4 1.2, CaCl2 2.5, and D-glucose 11.1.   
First, the mucosal sheets were prepared by cutting along the mesenteric line and 
carefully removing luminal contents.  The tissue was carefully pinned (mucosal side-
down) and the overlying smooth muscle layers (both circular and longitudinal muscle 
with the associated myenteric plexus) were removed by micro-dissection.  The 
mucosal preparation was cut into adjacent pieces (~0.5 cm); the descending colon (i.e. 
transverse-distal colon to rectum) routinely provided 6 adjacent pieces and the 
ascending colon (i.e. cecal junction to transverse colonic regions)  providing 4 
preparations.   Each mucosal preparation was mounted between two halves of an 
Perpex Ussing chamber (exposed area, 0.14 cm2) within 30 mins of excision from the 
mouse, bathed in 5 ml of oxygenated KH (95 % O2/ 5 % CO2) on each side of the 
reservoir at 37 ˚C, voltage clamped at 0 mV and the resultant basal Isc was measured 
(in µA.cm-2) continuously on a chart recorder (Kipp and Zonen, Lincoln, UK), as 
described previously (Cox et al., 2010) (Figure 2.1).  The Ussing chambers, DVC1000 
and the amplifiers were purchased from WPI UK, Hitchin, Herts, UK.   The mounted 
mucosal preparations, consisting of mucosa, submucosa and submucosal innervation, 
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created a barrier between the ap and bl sides of the reservoir.  This orientation of the 
mucosal preparation allowed measurement of net electrogenic anion secretion, as an 
increase in Isc.  
Once the Isc had stabilised (15 min), a 1 mV pulse was applied and the Isc deflection 
was evaluated to measure the transepithelial resistance (Ω.cm2), calculated using 
Ohms law (transepithelial resistance = voltage/current).  Once the mucosal 
preparations had equilibrated and the basal Isc had stabilised, agonist or antagonist 























Figure 2.1: The Ussing chamber set-up.   A mucosal sheet is mounted in the middle 
of the Ussing chamber, voltage-clamped at 0 mV and bathed in 5 ml of oxygenated 
KH, on each side of the reservoir.  This set-up allows interrogation of receptors on the 
apical (ap) and basolateral (bl) sides of the mucosa.  The resultant change in Isc from 







2.2 Sidedness, potency and efficacy of the FFA1, FFA4 and GPR119 agonists 
Descending colon mucosal preparations were pretreated with VIP (30 nM unless 
otherwise stated, bl) to provide a degree of vectorial epithelial ion secretion upon 
which subsequent anti-secretory signalling was more readily observed (as optimised 
previously; Tough et al. 2006; Cox et al. 2010).  Once VIP responses reached a 
maximum, the commercial available FFA1 agonist (TUG424), FFA4 agonist 
(TUG891) or the dual agonist (GW9508) was added to either reservoir, to determine 
the sidedness of these responses.   
Single apical additions of the commercially available FFA1, FFA4 and GPR119 
agonists (namely TUG424, TUG891, GW9508, PSN632408) and the selective 
agonists received from AZ (JTT, TAK-875, Met-36, AZ423, Cpd.16 and Cpd.42) 
were used to construct single addition concentration-response curves, comparing the 
commercial and selective agonists.  The single EC50 values for each agonist were 
calculated.  The non-linear regression formula used to fit each curve was as follows; 
y = min response + (max response – min response/ 1 + 10^(LogEC50 – x) * Hill slope), 
where y = response and x = Log10[agonist](M).   For each curve the minimum response 
was set to 0µA and the Hill slope was allowed to vary.  Overall range of Hill slopes 
were -1.6 to -0.4; the commercial GPR119 agonist, PSN632408 possessed the most 
negative cooperativity (Hill slope of -1.6).  PYY (10 nM unless otherwise stated, bl) 
was added finally as an internal control for 10 min.  Changes in Isc to each agonist 
were pooled and converted to µA.cm-2.   
Utilising an EC80 concentration of the selected FFA1 agonist, TAK-875 (200 nM); the 
FFA4 agonist, Met-36 (100 nM) and the GPR119 agonist, Cpd.42 (100 nM), the 
sidedness of their responses was assessed in descending colon mucosa. Agonists were 
applied to the ap or bl sides of the reservoir after VIP, and these responses were 
recorded for 20 min, followed by the addition of PYY.   
 
2.3 Tetrodotoxin-sensitivity of FFA1, FFA4 and GPR119 responses and their regional 
variation in the GI tract, on basal Isc and in the presence of VIP  
Once the EC50 values were established, the FFA1 (TAK-875), FFA4 (Met-36) and 
GPR119 (Cpd.42) agonists were selected to use in further studies.  To determine 
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whether their responses were neuronally-mediated or epithelial in origin, EC80 
concentrations of each agonist were selected.  The descending colon mucosal 
preparations were pretreated with the voltage-gated sodium channel neurotoxin, TTX 
(100 nM, bl) or vehicle (distal water, dH2O), 15 min prior to VIP.  Subsequently, the 
agonists were added, and their responses were monitored for 20 min, followed by 
PYY.   
In the next experiment, the region of the GI tract that provided the greatest FFA1 
(TAK-875), FFA4 (Met-36) or GPR119 (Cpd.42) response on basal Isc and after VIP 
was identified.  Responses were evaluated in the mid-ileum, terminal-ileum, ascending 
colon, and descending colon.  Finally, exogenous PYY was used as an internal control.  
 
2.4 Regional variation of Ex4-mediated GLP-1 responses in the colon  
The colon was cut into eight equal sized pieces from the caecal junction, providing 
ascending colon (AC1-AC3), transverse colon (designated as ascending-transverse 
colon, ATC and descending transverse colon, DTC) and descending colon (DC3-
DC1).  DC1 was closest to the rectum.  The mucosae were pretreated with the GLP-1 
antagonist, Ex(9-39) (1 µM, bl) or vehicle (dH2O) for 20 mins, prior to a single 
concentration of the GLP-1 agonist, Ex4 (100 nM, bl).  The internal controls, VIP and 
PYY were added at the end of the experiment to increase and lower the Isc, 
respectively.   
 
2.5 Evaluating GPR119 agonism in the presence of the DPPIV inhibitor, sitagliptin in 
the ascending and descending colon 
The ascending colon (AC1 - AC2) and the descending colon (DC2 – DC1) were 
pretreated with sitagliptin (1 µM, bl) or vehicle control (dH2O) for 15 mins.  After 
VIP, the PSN632408 (10 µM, ap) response was assessed in the presence and absence 
of sitagliptin.  These latter responses were recorded for 20 mins, followed by the 





2.6 Establishing the selectivity of FFA1, FFA4 and GPR119 agonism using FFA1 and 
FFA4 antagonists 
Once the basal Isc levels had stabilised, varying concentrations (1 nM–10 µM) of the 
FFA1 antagonist, ANT825 or FFA4 antagonist, AH-7614 (1 nM–10 µM) were added 
to each descending colon mucosal preparation for 10-15 min.  To establish IC50 values 
of ANT825 and AH-7614, VIP was applied followed by the FFA1 agonist, JTT (300 
nM, ap) or FFA4 agonist, Met-36 (100 nM), respectively.  The consequent reductions 
in Isc were recorded and converted to µA.cm
-2.  PYY was added as an internal control.   
To show FFA1 selectivity, the mucosae were pretreated with the commercially 
available FFA1 antagonist (GW1100), or the AZ FFA1 antagonist (ANT825) or 
vehicle (0.1 % dimethyl sulfoxide (DMSO)) for a 10 min period, prior to VIP 
application.  The commercially available agonists, TUG424 (100 nM), TUG891 (100 
nM) and GW9508 (1 µM) were tested initially in the presence or absence of each 
FFA1 antagonist.  Later, the selectivity of the AZ agonists, TAK-875 (200 nM), Met-
36 (100 nM) and Cpd.42 (100 nM) were examined.   
To investigate FFA4 selectivity, the descending colon mucosa was pretreated with a 
combination of the FFA1 (ANT825, 10 µM, ap) and FFA4 antagonists (AH-7614, 10 
µM, ap) or the respective vehicle control for 10-15 min, followed by VIP.  The 
selectivity the dual agonist, GW9508 (1 µM, ap) was assessed and its response was 
recorded for 20 min.  Furthermore, the TAK-875 response (FFA1, 200 nM, ap) was 
evaluated in the presence of AH-7614 alone.  The ability of AH-7614 (10 µM) and 
ANT825 (10 µM) to reveal tonic FFA1 and FFA4 activity was assessed on basal Isc 
(over a 20 min period) in the presence of the combined competitive Y1 antagonist 
(BIBO3304 (300 nM)) and Y2 antagonist (BIIE2046 (1 µM)), or vehicle (0.013 % 
DMSO) in descending colon mucosal preparations.  
 
2.7 Y1 and Y2 receptor antagonist (BIBO3304 and BIIE0246) studies 
Descending colon mucosal preparations were pretreated with previously optimised 
concentrations of the Y1 antagonist, BIBO3304 (BIBO, 300 nM, bl) or the Y2 
antagonist, BIIE0246 (BIIE, 1 µM, bl) or both, and their respective DMSO (0.003-0.1 
%) controls.  After 10-15 min, VIP was applied and once this response had stabilised, 
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a single apical concentration of the FFA1, FFA4 or GPR119 agonist was added, and 
the consequent reductions in Isc were converted to µA.cm
-2.  PYY and the α2-
adrenoceptor agonist, UK14,304 (1 µM) were used as internal controls. 
 
2.8 Mucosal glucose-sensitivity of FFA1, FFA4 and GPR119 agonism 
Excised whole colon was placed in fresh glucose-free KH with the following 
composition (in mM); NaCl 118, KCl 4.7, NaHCO3 25, KH2PO4 1.2, MgSO4 1.2, 
CaCl2 2.5, and D-mannitol 11.1.  Descending colon mucosal preparations were micro-
dissected as described above (section 2.1), placed in Ussing chambers and were bathed 
in KH containing glucose on both sides (control) or in KH containing the glucose 
replacement, D-mannitol (at 11.1 mM) on the ap side only.  Mucosal basal Isc levels 
were allowed to stabilise before the addition of VIP.  Subsequently, a single apical 
addition of the FFA1, FFA4 or GPR119 agonist was added and consequent reductions 
in Isc were recorded and converted to µA.cm
-2.  Phloridzin (50 µM, ap) was used as an 
internal control to block apically located SGLT1, and this electrogenic activity should 
be impaired when mannitol replaces glucose apically.  When investigating FFA1 and 
FFA4 agonism in the presence of low or high glucose; the glucose concentration was 
altered (5 mM or 25 mM glucose in the KH) on both the ap and bl sides 
simultaneously. 
 
2.9 Inhibition of mucosal glucose transport via blockade of SGLT1 and GLUT2 
Descending colon mucosal preparations were pretreated with a combination of the 
SGLT1 inhibitor, phloridzin (50 µM, ap) and the GLUT2 inhibitor, phloretin (0.1 mM, 
ap + bl) or vehicle (dH2O) for 15 mins.  Phloretin blocks apical and basolateral 
expressed GLUT2 (Gorboulev et al., 2012; Mace et al., 2012).  After VIP, the FFA1 
agonist (TAK-875, 200 nM, ap), the FFA4 agonist (Met-36, 100 nM, ap) or the 
GPR119 agonist (Cpd.42, 100 nM, ap) was added and their responses were recorded 




2.10 Co-agonism of L cell FFA1, FFA4 or GPR119 receptors using the selective AZ 
agonists 
First, the Isc was raised with VIP in the descending colon mucosal preparations.  Next, 
agonism of FFA1, FFA4 or GPR119 with a selective agonist was evaluated alone or 
in combination with one another (over a 20 min period).  Initially, agonism of FFA1 
(TAK-875, 1 µM, ap) and FFA4 (Met-36, 100 nM, ap) was examined.  Subsequently, 
FFA1 and GPR119 agonism (Cpd.16, 1 µM, ap) was assessed followed by agonism 
of FFA4 and GPR119 in a separate mucosal preparation.  Finally, PYY was added at 
the end of the experiment.  
 
2.11 L cell GPR119 cross-desensitisation studies 
Descending colon mucosal preparations were pretreated with a high concentration of 
the GPR119 agonist, PSN632408 (30 µM, ap) or vehicle (95 % ethanol, ap) for 2 min, 
prior to raising the Isc with VIP.   Following the pretreatment, the preparations were 
apically treated with the GPR119 agonist, PSN632408 (30 µM) or Cpd.42 (100 nM), 
or the FFA1 agonist, TAK-875 (200 nM) or the FFA4 agonist, Met-36 (100 nM).  
FFA1, FFA4 and GPR119 agonism was assessed for desensitisation, in the presence 
of 30 µM PSN632408.  Responses to each selective agonist were monitored for 20 
mins prior to the application of PYY.   
 
2.12 Establishing the potency and pharmacology of pinolenic acid 
First, to investigate the pharmacology of the commercially available dual agonist, 
pinolenic acid, a concentration-response curve was constructed to establish its EC50 
value.  Descending colon mucosal preparations were pretreated with VIP, followed by 
varying concentrations of pinolenic acid (100 nM – 10 µM, ap).  These responses were 
monitored for 20 min.  Finally, exogenous PYY was added as the internal control.    
Next, having established the EC50, the pharmacology of the pinolenic acid response 
was investigated.  Descending colon mucosal preparations were pretreated with TTX 
(100 nM, bl), or ANT825 (10 µM, ap), or a combination of both FFA1 and FFA4 
antagonists (ANT825 (10 µM, ap)+AH-7614 (10 µM, ap)), or the combination of the 
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competitive Y1 and Y2 antagonists (BIBO3304 (300 nM, bl) + BIIE2046 (1 µM, bl)) 
or their respective vehicle controls (dH2O, or 0.1 % DMSO, or 0.013 % DMSO) for 
15 mins, prior to raising the Isc with VIP.  The pinolenic acid (1 µM, ap) response was 
monitored in the presence and absence of each pretreatment for 20 min, followed by 
the addition of PYY.  
 
2.13 Triple agonism of L cell FFA1, FFA4 and GPR119 receptors in the descending 
colon 
L cell triple receptor agonism was investigated utilising the dual FFA1 and FFA4 
agonist, pinolenic acid (1 µM, ap) and a commercially available GPR119 agonist 
(PSN632408, 10 µM, ap) or the selective AZ GPR119 agonist (Cpd.16, 1 µM, ap), in 
descending colon mucosal preparations.  Initially, the Isc was raised with VIP and the 
absolute Isc level was recorded at the point of agonist addition.  Triple agonism was 
monitored for 20 mins prior to the addition of exogenous PYY.  
 
2.14 Measurement of faecal pellet propulsion in vitro 
The colon (from the caeco-colonic junction to the rectum) was excised, photographed 
(t = 0 min) and bathed in KH at 37˚C with either vehicle (0.1% DMSO) or agonist 
(300 nM TUG424, TUG891, TAK-875 or Met-36).  After 20 min (t = 20 min) each 
colon length was re-photographed, and the distance travelled by the remaining pellets 
was measured from the rectum, as described previously (Tough et al., 2011).  The 
effects of chosen agonists on colonic transit were compared in the presence and 
absence of the FFA1 antagonist, GW1100 (10 µM).  In these experiments, the colon 
was bathed in vehicle (0.1 % DMSO) or antagonist, photographed at 20 min, and then 
bathed in KH containing the agonist of choice for another 20 min.  The colon was re-
photographed at t = 40 min.  The pellet movement was measured as the mean distance 






2.15 Measurement of colonic bead excretion in vivo 
Mice were acclimatised to handling 3 days prior to experimentation and were fasted 
16 h prior to the procedure (at ~ 5.30 pm), although water was provided ad libitum.  
Plasma glucose was tested before and after fasting by tail prick, utilising an AVIVA 
glucose monitoring kit.  Distal colonic propulsion was measured according to the 
methods described by Forbes et al. (2012).  One hour after administration of vehicle 
or drug (FFA1 agonist, TAK-875 (27 mg/kg); FFA4 agonist, Met-36 (6 mg/kg, 50 
mg/kg), FFA1 antagonist, ANT825 (29 mg/kg)) or the positive control, loperamide 
hydrochloride (HCl, 10 mg/kg (Myagmarjalbuu et al., 2013)) by oral gavage (po) or 
i.p., mice were placed under 4-5 % isoflurane anaesthesia (Isoflurane-VET, Merial 
Animal Health Ltd, Harlow, UK) and a 2 mm bead was inserted 2 cm intrarectally into 
the distal colon using blunt tubing (Portex, 1.7 × 0.4 mm).  The mice were 
subsequently placed into a grid bottom cage, monitored and the time to bead expulsion 
was measured.  Once the bead was excreted, the mouse was killed by cervical 
dislocation.  All drugs were suspended in their respective vehicles and sonicated for 
30 min.   
To assess the total plasma concentration of TAK-875 (27 mg/kg, po) and Met-36 (50 
mg/kg, po) was consistent with AZ in-house data, a single blood sample was taken 
immediately after cervical dislocation via cardiac puncture, which was approximately 
70 min after each agonist was administered.  Blood samples were stored in Li-heparin-
coated collection tubes provided by AZ (M. Persson).  These blood samples were 
centrifuged (1200, rpm for 20 min, personal communication, M. Persson) to obtain 50 
µl of plasma and thereafter stored at -20˚ C, until they were shipped to AZ (Mölndal) 
for further analysis.   
 
2.16 Measurement of upper GI transit in vivo 
Mice were acclimatised to handling 3 days prior to experimentation and were fasted 
for 16 h prior to testing (at ~ 5.30 pm).  TAK-875 (27 mg/kg), Met-36 (50 mg/kg), 
ANT825 (29 mg/kg), their respective vehicles or the positive control, loperamide HCl 
(10 mg/kg) were administrated via i.p. 60 min prior to the procedure.    A charcoal 
meal (10 % plant charcoal in 5 % gum acacia (Tough et al. 2011)) was given by 
intragastric gavage. 30 min later the animal was killed by cervical dislocation and the 
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small intestine was isolated from the pyloric to ileocecal junctions.   Upper GI transit 
(UGIT), encompassing gastric emptying and small intestinal motility, was measured 
as a percentage of the distance travelled by the charcoal relative to the total length of 
the small intestine, as optimised previously (Forbes et al. 2012).  
 
2.17 Statistical analysis 
Pooled responses (as µA.cm-2) are expressed as mean ± 1SEM from the number of 
observations described, using GraphPad Prism version 7.0 (GraphPad Prism Inc., La 
Jolla, CA, USA).  An initial priori power analysis calculation was carried out (unpaired 
two-tailed t-test, α = 0.05 and Power = 0.80 (80%)) using G*Power version 3.0.10.  
The power analysis indicated a power of n=5-6 was adequate for in vitro mucosal 
studies.  Single comparisons between groups of data were analysed by unpaired, two-
tailed Student's t-tests.  Multiple comparisons were analysed by one-way ANOVA 
with post hoc Dunnett’s test (in the presence of vehicle control) or Bonferroni’s post 
hoc test.   P ≤ 0.05 was considered statistically significant.  A mixture of male and 
female mice was used in this study, as no differences in FFA1, FFA4 or GPR119 
responses were observed between sexes.  The application of agonist/antagonist 
treatments to each mucosal preparation was randomised using the Latin square design 
technique.  This guaranteed the same GI mucosal preparation did not receive the same 
treatment in each experimental repeat, over the duration of 4-5 experiments.  In the in 
vivo studies, the vehicle or drug treatments were alternated in each cohort of mice to 
ensure each consecutive mouse received a different agonist/antagonist or vehicle.  Any 
discrepancies between n number cohorts were due to the loss of a single mucosal 
preparation from a single animal in vitro or removed when the result was two standard 
deviations from the mean in vitro and in vivo.  
 
2.18 Materials  
FFA1 agonists (JTT and TAK-875), FFA4 agonists (AZ423 and Met-36), GPR119 
agonists (Cpd.42 and Cpd.16) and the FFA1 antagonist (ANT825) were obtained from 
AstraZeneca, Gothenburg, Sweden.  Stock solutions of drugs were dissolved in neat 
DMSO (at 10-2 M or 10-3 M).  Initial 1:10 dilutions were in neat DMSO and subsequent 
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serial dilutions were in dH2O (excluding the FFA1 agonist, TAK-875 and the FFA4 
agonist, AZ423, where all serial dilutions were performed in distilled water).  The 
commercially available full GPR119 agonist, PSN632408 (tert-butyl 4-((3-(pyridin-
4-yl)-1,2,4-oxadiazol-5-yl)methoxy)piperidine-1-carboxylate) was purchased from 






GW9508 (4-[[(3-Phenoxyphenyl)methyl]amino]benzenepropanoic acid), TUG424, 
(3-(4-(o-Tolylethynyl)phenyl)propanoic acid), TUG891 (4-[(4-Fluoro-4'-methyl[1,1'-
biphenyl]-2-yl)methoxy]-benzenepropanoic acid), the FFA4 antagonist, AH-7614 (4-
Methyl-N-9H-xanthen-9-yl-benzenesulfonamide) were purchased from Tocris 
Bioscience (Bristol, UK).  GW1100 (4-[5-[(2-ethoxy-5-pyrimidinyl)methyl]-2-[[(4-
fluorophenyl)methyl]thio]-4-oxo-1(4H)-pyrimidinyl]-benzoic acid,ethyl ester) was 
bought from Cambridge Bioscience (Cambridge, UK).  VIP and PYY were purchased 
from Cambridge Bioscience (Cambridge, UK) and TTX from Abcam (Cambridge, 
UK).  VIP, PYY and TTX were dissolved in distilled water. Ex4 and Ex(9-39) were 
bought from Generon (Slough, UK) and were also diluted in distilled water.  All 
peptide stocks were stored at -20˚ C until required and underwent a single freeze-thaw 
cycle.  Phloridzin (1-[2-(β-D-glucopyranosyloxy)-4,6-dihydroxyphenyl]-3-(4-
hydroxyphenyl]-1-propanone), phloretin ((E)-1-[2,4-dihydroxy-6-[[(2R,3S,4R,6R)-
3,4,6-trihydroxyoxan-2-yl]methoxy]phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one) 
and UK 14,304 were purchased from Sigma-Aldrich (Dorset, UK) and it too was 
dissolved in distilled water. Sitagliptin was bought from LKT Laboratories 
(Minnesota, USA) and was diluted in distilled water.   Pinolenic acid was purchased 
from Cayman Chemicals (Ann Arbor, USA) and was diluted in 95 % ethanol.  The 
following in vivo vehicles were all suspended in warm saline, namely methylcellulose 
and polyvinylpyrrolidinone (PVP) from Sigma-Aldrich (Dorset, UK), sodium dodecyl 
sulphate (SDS) from VWR International (Leicestershire, UK), hydroxylpropyl 
methylcellulose (HPMC) from Alfa Aesar (Lancashire, UK), Tween-80 from Boston 
BioProducts (Ashland, USA). Loperamide HCl was purchased from LKT 






























3.1 The sidedness and efficacy of commercially available FFA1 and FFA4 agonists in 
descending colon mucosa 
First, basal resistance and Isc levels after stabilisation of the descending colon mucosal 
preparations were analysed and were within the ranges published previously (Figure 
3.1A) (Tough et al. 2011).  The activity of the non-selective FFA1 and FFA4 agonist, 
GW9508, as well as the TUG compounds (TUG424 and TUG891) added apically or 
basolaterally, induced a biphasic change in Isc.  The 1˚ responses were recorded within 
0-5 min of agonist addition and were due to vehicle, DMSO (Figure 3.1B).  
Extrapolation of the waning VIP secretory response revealed the 1˚ monophasic 
response observed in the presence of vehicle (Figure 3.1B) was similarly observed in 
the presence of agonist (Figure 3.1C).  The 2˚ reductions in Isc after each agonist 
addition, occurred within 10-15 min (Figure 3.1C).  When these reductions in Isc were 
compared, there were no significant differences between the response sizes and the 







Figure 3.1: Sidedness of FFA1 and FFA4 responses in descending colon mucosa.  
In A: basal Isc and resistance values after stabilisation of mucosal preparations (n=20).  
In B: representative trace showing monophasic nature of vehicle control, DMSO (0.1 
%) in descending colon mucosa, after VIP (30 nM) and followed by PYY (10 nM).  In 
C: representative trace showing the biphasic nature of the apical GW9508 (10 µM) 
response in descending colon mucosa, after VIP (30 nM) and followed by PYY (10 
nM).  In D: pooled data showing the primary (1˚) and secondary (2˚) responses to 
apical (ap) or basolateral (bl) additions of GW9508 (n=5), TUG424 (n=5) or TUG891 








3.2 The potency and efficacy of AZ FFA1, FFA4 and GPR119 agonists in descending 
colon mucosa 
The AZ selective FFA1 agonists, TAK-875 and JTT; FFA4 agonists, Met-36 and 
AZ423 or GPR119 agonists, Cpd.16 and Cpd.42 were added apically and induced a 
biphasic Isc response, in descending colon mucosal preparations.  The rapid first Isc 
component witnessed within the first 5 min  was attributed to the vehicle, 0.1 % DMSO 
(2.7 ± 0.5 µA.cm-2, n=12) when compared with the same component for JTT (1.7 ± 
0.9 µA.cm-2, n=5), Met-36 (3.2 ± 1.7 µA.cm-2, n=4), Cpd.16 (1.5 ± 0.7 µA.cm-2, n=7) 
and Cpd.42 (3.7 ± 1.4 µA.cm-2, n=5) or the vehicle 0.01 % DMSO (3.0 ± 1.1 µA.cm-
2, n=6) when compared with TAK-875 (2.5 ± 1.3 µA.cm-2, n=6) and AZ423 (4.6 ± 1.4 
µA.cm-2, n=6).   
Only the later reductions in Isc (2
◦ component) to varying concentrations of the TUG 
compounds, GW9508 and the AZ selective FFA1, FFA4 and GPR119 agonists are 
shown in Figure 3.2A-C.  The reductions in Isc to each FFA1, FFA4 or GPR119 agonist 
were concentration-dependent.  When comparing the FFA1 agonists, TUG424 and 
TAK-875 were similarly potent and efficacious, and their EC50 values were 57.1 nM 
(24.7 – 131.8 nM) and 67.6 nM (30.6 – 149.4 nM), respectively.  JTT was more potent 
(EC50 of 20.7 nM (12.7 – 34.0 nM)) than TAK-875 and TUG424, however they all 
exhibited similar efficacy (Figure 3.2A).  GW9508 was less potent with an EC50 value 
of 354.8 nM (191.6 – 656.8 nM) and its maximal response appeared to be slightly 
larger than the maximal responses of the TUG agonists, the selective FFA1 agonists 
(Figure 3.2A) and the FFA4 agonists (Figure 3.2B).  In this way, GW9508 appeared 
to be a dual agonist in comparison to the selective FFA1 and FFA4 agonists.   
The FFA4 selective agonists, Met-36 (EC50 of 15.4 nM (7.9 – 30.4 nM)) and AZ423 
(EC50 of 17.3 nM (3.6 – 83.8 nM)) were similarly potent and efficacious (Figure 3.2B).  
The commercially available FFA4 agonist, TUG891 (EC50 of 62.5 nM (24.1 – 162.3 
nM)) was similarly potent to the FFA1 agonist, TUG424 and exhibited similar efficacy 
to Met-36 and AZ423 (Figure 3.2B).   
The GPR119 agonists, Cpd.16 and Cpd.42 were similarly potent and efficacious and 
their EC50 values were 23.4 nM (10.2 – 53.4 nM) and 49.3 nM (6.4 – 382.6 nM) 
(Figure 3.2C).  The anti-secretory responses of Cpd.16 and Cpd.42 were compared 
with the commercially available and proven full GPR119 agonist, PSN632408.  In this 
118 
 
study, PSN632408 decreased the Isc and provided an EC50 value of 4.8 µM (2.2 – 10.6 
µM).  The PSN632408 maximal response was more efficacious than the maximal 
response to Cpd.16 (P ≤ 0.003) and Cpd.42 (P = 0.093), but displayed a lower potency 
compared to both AZ GPR119 agonists.  The Cpd.16 and Cpd.42 responses appeared 
partial when compared with the PSN632408 response (Figure 3.2C).   
The sidedness of FFA1, FFA4 and GPR119 agonism was assessed utilising EC80 
concentrations of the selected AZ FFA1 agonist, TAK-875; the FFA4 agonist, Met-36 
and the GPR119 agonist, Cpd.42 (Figure 3.2 continued).  There were no significant 
differences between ap and bl FFA1 (D), FFA4 (E) or GPR119 (F) response sizes or 
their kinetics (Figure 3.2 continued, D-F).  Furthermore, the absolute Isc levels before 
each agonist was applied were no different between mucosal preparations receiving 






Figure 3.2: FFA1, FFA4 and GPR119 responses in descending colon mucosa.  
Concentration-response curves for the 2˚ apical effects of FFA1 agonists: TUG424 
(n=5-6), TAK-875 (n=5-8) and JTT (n=5), compared with GW9508 (n=5) in A; for 
FFA4 agonists:  TUG891 (n=5), AZ423 (n=5) and Met-36 (n=5) in B, and for GPR119 
agonists, Cpd.16 (n=5-8), Cpd.42 (n=5-7) and PSN632408 (n=6-7, (Cox et al., 2010)) 






Figure 3.2 continued: Apical versus basolateral application of a FFA1, FFA4 and 
GPR119 agonist.  In D: time courses of the anti-secretory response to the apical (ap) 
and basolateral (bl) applied FFA1 agonist, TAK-875 (200 nM, n=3); in E: the FFA4 
agonist, Met-36 (100 nM n=3) and the GPR119 agonist, Cpd.42 in F (100 nM, n=3) 
after VIP pretreatment.  The insets in D-F display absolute Isc values at the point of 
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agonist administration.  Symbols represent the number of observations and the 
coloured horizontal line displays the mean ± 1SEM. Time course points represent the 
mean ± 1SEM.   
 
3.3 Regional variation of FFA1, FFA4 and GPR119 anti-secretory responses on basal 
Isc and after VIP  
Having established the EC50 values of the selective compounds, an EC80 concentration 
of the FFA1 agonist (TAK-875), the FFA4 agonist (Met-36) and the GPR119 agonist 
(Cpd.42) was selected to investigate the region GI variation of FFA1, FFA4 and 
GPR119 agonism.  Agonism was assessed in the mid-ileum, the terminal ileum, 
ascending colon and descending colon.  The change in Isc was examined on basal Isc 
and compared with the change in Isc after VIP pretreatment. 
 
3.3.1 FFA1, FFA4 and GPR119 agonism on basal Isc 
On basal Isc, the TAK-875 anti-secretory response appeared larger in the ascending 
and descending colon compared with the terminal ileum, however this was not 
significant.  The TAK-875 response in the descending colon was significantly larger 
than its respective DMSO control (Figure 3.4A). 
On basal Isc, the anti-secretory response of the FFA4 agonist, Met-36 was significantly 
larger in the ascending colon, compared with FFA4 agonism in the descending colon 
and terminal ileum.  Additionally, FFA4 anti-secretory responses in the ascending and 
descending colon were significantly larger than their respective DMSO controls 
(Figure 3.4B).   
The GPR119 anti-secretory responses on basal Isc (Figure 3.4C) increased along the 
GI tract, with the descending colon providing the largest GPR119 response.  The 
descending colon GPR119 anti-secretory response was significantly larger when 
compared with the response in the terminal ileum.  Moreover, in the descending colon, 






3.3.2 FFA1, FFA4, GPR119 agonism after VIP 
In mucosal preparations pretreated with VIP, lower concentrations of TAK-875, Met-
36 and Cpd.42 (Figure 3.3D) induced anti-secretory responses that were more readily 
observed.  TAK-875 responses were equally efficacious in the ascending colon, 
descending colon and terminal ileum.  This pattern resembled TAK-875 agonism on 
basal Isc.  Furthermore, the response to TAK-875 in the mid-ileum was similarly 
efficacious to the responses observed in the ascending and descending colon.  When 
comparing TAK-875 agonism after VIP with agonism on basal Isc, evidently the 
responses after VIP were significantly larger in the terminal ileum and ascending 
colon.  
In the presence of VIP, the area-specific responses of the FFA4 agonist, Met-36 were 
greatest in the ascending colon and slightly smaller in the descending colon (not 
significant), resembling a similar pattern to that observed on basal Isc.  The reduction 
in Isc in the terminal ileum was similarly efficacious to the response observed in the 
ascending colon and significantly greater than that observed under basal conditions.  
Finally, the anti-secretory responses observed in the mid-ileum was similar to those 
seen in the descending colon (Figure 3.3D).  There were no significant differences 
between the FFA1 and FFA4 responses in the presence of VIP, in each of the regions 
tested. 
In the GI regions tested, the GPR119 Cpd.42 anti-secretory responses after VIP, 
resembled the same pattern as observed on basal Isc.  Furthermore, the descending 
colon mucosal Cpd.42 response was significantly larger than the response observed 
under basal conditions.  In the presence of VIP, it was clear that the GPR119 responses 
observed in the descending colon were significantly larger than the responses observed 
in all other regions tested.  This confirmed that GPR119 agonism (Cpd.42) 
incrementally increased along a gradient from the intestine to the colon, with the 
largest anti-secretory response observed in the colon, under basal conditions and after 
VIP.  
In summary, FFA1, FFA4 and GPR119 anti-secretory responses were more readily 
observed after VIP compared with responses observed on basal Isc, in various regions 
of the GI tract.  The descending colon was selected as the optimal region for 
subsequent studies, as this area of the GI tract is highly enriched with enteroendocrine 
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PYY-containing L cells, which express the lipid metabolite receptors, FFA1 (Edfalk 
et al., 2008), FFA4 (Hirasawa et al., 2005) and GPR119 (Chu et al., 2008).   Thus, the 
descending colon provided the greatest possibility of revealing specific L cell-
mediated FFA1, FFA4 and GPR119 signalling mechanisms.  
 
Figure 3.3: Regional variation of FFA1, FFA4 and GPR119 agonism on basal Isc 
(A-C) and after VIP pretreatment (D).  The responses to the FFA1 agonist, TAK-
875 (1 µM, ap, n=5) (A), the FFA4 agonist, Met-36 (300 nM, n=5) (B) and the 
GPR119 agonist, Cpd.42 (300 nM, n=4-5) (C) on basal Isc in the terminal ileum (TI), 
ascending colon (AC) and descending colon (DC), compared to 0.1 % DMSO treated 
controls.  In D: the anti-secretory responses of the FFA1 agonist, TAK-875 (200 nM, 
ap), the FFA4 agonist, Met-36 (100 nM, ap) and the GPR119 agonist, Cpd.42 (100 
nM, ap) after VIP pretreatment in the mid-ileum (MI), TI, AC and DC (n=4-7).  
Statistical differences from vehicle controls in each GI region on basal Isc are 
represented as follows; ** P ≤ 0.01 and ***P ≤ 0.001 (Student’s t-test).  Differences 
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between anti-secretory responses on basal Isc or after VIP between GI regions (MI, TI, 
AC and DC) are shown as follows; + P ≤ 0.05, ++ P ≤ 0.01 and +++ P ≤ 0.001 (one-way 
ANOVA with Bonferroni’s test).  Differences between VIP pretreated agonist-induced 
anti-secretory responses (in D) and agonism under basal conditions (A-C) are shown 
as follows; 
•
P ≤ 0.05, •• P ≤ 0.01 and ••• P ≤ 0.001 (Student’s t-test).  Bars represent 
the mean ± 1SEM.  
 
3.4 FFA1, FFA4 and GPR119 anti-secretory responses were tetrodotoxin-insensitive 
To determine whether the FFA1, FFA4 and GPR119 responses were neuronally-
mediated, descending colon mucosal preparations were pretreated with the voltage-
gated sodium channel neurotoxin, TTX.  On basal Isc, TTX significantly decreased Isc 
in comparison to the vehicle (dH2O), revealing blockade of endogenous enteric 
neuronal transmission (Figure 3.4A).  The FFA1 (TAK-875), FFA4 (Met-36) and 
GPR119 (Cpd.42) anti-secretory responses were unaffected in the presence of TTX, 
compared to dH2O-treated controls (Figure 3.4B).  This indicated that the FFA1, FFA4 
and GPR119 responses were most likely epithelial in origin and not neuronally-
mediated.  Likewise, the VIP secretory responses (Figure 3.4C) and the exogenous 





 Figure 3.4: FFA1, FFA4 and GPR119 responses are TTX-insensitive.  In A: basal 
changes in Isc after administration of TTX (100 nM, bl) compared with vehicle control 
(Veh: dH2O).  In B: TAK-875 (200 nM, n=5), Met-36 (100 nM, n=5) and Cpd.42 (100 
nM, n=10) responses after VIP pretreatment in the absence and presence of TTX 
(n=5).  The vehicle controls, VIP (30 nM) and exogenous PYY (10 nM) are seen in C 
and D, respectively.  The statistical difference between the pretreatments on basal Isc 





3.5 GLP-1 responses were region-specific in the colon and larger in the ascending 
colon 
The GLP-1 agonist, Ex4, previously induced GLP-1-mediated secretory responses in 
the ascending colon.  These responses were larger than the Ex4 response observed in 
the descending colon and were also Ex(9-39)-sensitive (Joshi et al., 2013).  The 
variability in these region-specific responses was further investigated along the length 
of the mouse colon, by dividing the colon into eighths ( ̴ 1 cm each).  Each colon 
routinely provided 3 ascending colon mucosal preparations (AC1 – AC3), 2 transverse 
preparations: the ascending transverse colon (ATC), the transverse-descending colon 
(TDC) and 3 descending colon preparations (DC3 – DC1) (Figure 3.5A).  Next, the 
response to Ex4 on basal Isc was examined in the absence and presence of the GLP-1 
antagonist, Ex(9-39), in the newly divided regions of the colon.  In the absence of 
Ex(9-39), Ex4 provided an increasing secretory response gradient, from the 
descending region of the colon (DC1) towards the ascending region (AC1).  In the 
descending colon regions, Ex4 responses were small and anti-secretory.  Further along 
in the transverse colon, the Ex4 responses transitioned from an anti-secretory response 
into a secretory response.  These secretory responses in the transverse colon appeared 
larger than the responses observed in the descending colonic areas, but this was not 
significant.  The largest Ex4 response was observed in AC1 – AC2, followed by AC3-
ATC.  In all regions tested, the Ex4 response was abolished in the presence of Ex(9-
39) and was therefore GLP-1R-mediated (Figure 3.5B). Thus, Ex4-induced GLP-1 
responses in the mouse colon were region-specific, and the ascending colon (AC1 – 




Figure 3.5: Region-specific GLP-1 responses in the mouse colon.  In A: a 
photograph of the caeco-colorectal mucosal preparation (taken by IR Tough).  Each 
colon was divided into eight mucosal preparations.  The ascending colon provided 
AC1-AC3, the transverse was divided into the ascending-transverse colon (ATC) and 
the transverse-descending colon (TDC) and finally the descending colon provided 
three sections, DC3-DC1.  In B: Ex4 (100 nM, bl) responses on basal Isc in the absence 
(Control: dH2O) and presence of Ex(9-39) (1 µM) along the length of the colon (n=5).  
Significant differences between Ex4 in the absence and presence of Ex(9-39) are 
shown as follows; **P ≤ 0.01 and *** P ≤ 0.001 (Student’s t-test).  Bars represent the 







3.6 PSN632408 responses were insensitive to the DPPIV-inhibitor, sitagliptin 
Earlier in this study, the GPR119 full agonist, PSN632408 induced a monophasic anti-
secretory response in the descending colon (Figure 3.2C). However, no GLP-1 
component was observed. Having established that the AC1-AC2 region provided the 
largest Ex4 GLP-1 response, the PSN632408 anti-secretory response was assessed in 
this region.  This provided the optimal GI region to reveal a GLP-1 component to 
GPR119 agonism.  The presence of the DPPIV inhibitor, sitagliptin ensured any GLP-
1 response could potentially be stabilised and therefore elevated.  For comparison, 
mucosa from the ascending colon (AC1 – AC2) was compared with descending colon 
mucosa (DC2- DC1).  These two areas were incubated with an optimal concentration 
of sitagliptin or its respective vehicle control (dH2O).   
 
In the absence of sitagliptin, PSN632408 induced similarly efficacious monophasic 
reductions in Isc in the ascending and descending regions of the colon.  In the presence 
of sitagliptin, the PSN632408 responses were unaffected and remained monophasic in 
both regions of the colon, when compared with their respective vehicle controls 
(Figure 3.6A).  In the absence of sitagliptin, Ex4 responses after PSN632408 were 
significantly larger in the ascending region when compared with the descending region 
(Figure 3.6B), which was consistent with the findings in the earlier GLP-1 region-
specific study (Figure 3.5B).  In the presence of sitagliptin, the Ex4 response in the 
ascending region exhibited an apparent effect, however this was not significant            
(P = 0.2) (Figure 3.6B).  Moreover, the Ex4 response in the ascending colon was 
significantly larger than the Ex4 response in the descending region, in the presence of 
the DPPIV inhibitor.  Sitagliptin had no effect on Ex4 responses in the descending 
colon.  Exogenous PYY responses after the Ex4 additions were unaffected by the 





Figure 3.6: PSN632408 responses were insensitive to the DPPIV-inhibitor, 
sitagliptin.  In A: the responses of the GPR119 full agonist, PSN632408 (10 µM, ap) 
after VIP pretreatment in the absence (+ veh: dH2O) and presence of the DPPIV-
inhibitor, sitagliptin (1 µM, bl) in the ascending colon (AC1-AC2) (n=3-4) and 
descending colon (DC1-DC2) (n=5-6).  In B: regional Ex4 (100 nM, bl) responses 
after PSN632408 in the presence or absence of sitagliptin.  In C: exogenous PYY (10 
nM, bl) responses after Ex4 in the presence of sitagliptin or vehicle control.  Statistical 
differences between Ex4 responses in the AC region and those in the DC region, in 
the absence and presence of sitagliptin are shown as follows, * P ≤ 0.05 (Student’s t-
test).  Bars represent the mean ± 1SEM. 
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3.7 GW1100 and ANT825 each inhibited agonist-induced FFA1 responses in the 
descending colon 
The FFA1 antagonists, GW1100 and ANT825 alone revealed a similar degree of 
FFA1 tonic activity under basal conditions in the descending colon (Figure 3.7A).  The 
FFA1 tonic activity of ANT825 was examined under basal conditions in the 
duodenum, mid-ileum, terminal ileum and ascending colon, revealing regional 
variation of FFA1 tone.  The level of FFA1 tonic activity appeared uniform in all GI 
regions tested.  Moreover, the tonic activity observed in the duodenum, mid-ileum, 
terminal ileum and ascending colon was similar to that seen in the descending colon 
(Figure 3.7B).  ANT825 inhibited JTT (300 nM, ap) responses competitively, with an 
IC50 of 219 nM (Figure 3.7C).  Optimal blocking concentrations of each FFA1 
antagonist, GW1100 or ANT825, revealed the selectivity of the commercially 
available agonists, TUG424 and GW9508 for the FFA1 receptor.  The GW9508 
response was partially reduced in the presence of ANT825 or GW1100.  Additionally, 
TUG891 responses were not affected by either FFA1 antagonists (Figure 3.7D).  FFA1 
agonism (utilising the AZ selective FFA1 agonists, TAK-875 and JTT) was also 
significantly inhibited by ANT825, showing FFA1 selectivity, whereas FFA4 (Met-





Figure 3.7: Tonic FFA1 activity and inhibition of FFA1 responses by GW1100 or 
ANT825.  In A: changes in Isc to vehicle (DMSO) or the FFA1 antagonists, GW1100 
or ANT825 alone on basal Isc in descending colon.  In B: regional changes in Isc to 
ANT825 (10 µM) in the duodenum (duo, n=5), MI (n=4), TI (n=5) and AC (n=5) 
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under basal conditions.  In C: competitive inhibition of the FFA1 agonist, JTT 
responses (300 nM) after VIP, by pretreatment with the FFA1 antagonist, ANT825 in 
the descending colon.  Each point is the mean ±1SEM (n=5-6).  In D: pooled data 
shows the selective inhibition of apical TUG424 (100 nM, n=5-6) and GW9508 (1 
µM, n=5) responses, but not TUG891 (100 nM, n=5) responses following apical 
GW1100 or ANT825 treatment compared with their respective vehicle controls 
(DMSO).  In E: selective inhibition of the FFA1 agonists, TAK-875 (200 nM, n=5) 
and JTT (300 nM, n=5) responses but not the FFA4 agonist, AZ423 (100 nM, n=5) 
and Met-36 (100 nM, n=5) responses or GPR119, Cpd.42 (100 nM, n=4) responses 
following apical ANT825 treatment (10 µM, n=5).  Bars represent the mean ± 1SEM. 
Statistical differences from respective vehicle controls are shown as follows; *** P ≤ 
0.001 (Student's t-test) and ++P ≤ 0.01 and +++P ≤ 0.001 (one-way AVOVA with 
Dunnett’s post hoc test).   
 
3.8 AH-7614 inhibited agonist-induced FFA4 responses, not FFA1 responses in the 
descending colon   
First, the FFA4 antagonist, AH-7614 inhibited Met-36 responses (Figure 3.8A) and 
provided an IC50 of 42.2 nM.  Using a supramaximal blocking concentration of AH-
7614, in combination with a previously optimised concentration of the FFA1 
antagonist, ANT825, the selectivity of the dual FFA1 and FFA4 commercially 
available agonist, GW9508 was assessed.  In the presence of both antagonists, the 
GW9508 response was significantly inhibited (Figure 3.8B). Additionally, this 
response was significantly different from the GW9508 response in the presence of 
ANT825 alone in Figure 3.7D (**P ≤ 0.01, Student's t-test).  This confirmed that 
GW9508 exerts dual FFA1 and FFA4 agonism.  Furthermore, AH-7614 had no effect 
on the FFA1 TAK-875 response (Figure 3.8B).    Under basal conditions, the FFA4 
antagonist, AH-7614 did not affect the basal Isc (data not shown).  Furthermore, the 
previously observed FFA1 tone revealed in the presence of the FFA1 antagonist, 
ANT825 (Figure 3.7A) was eliminated when this antagonist was applied in 
combination with the FFA4 antagonist under basal conditions (AH-7614+ANT825; -
1.23 ± 0.93 µA.cm-2).  This latter response was significantly different (**P ≤ 0.01, 
Student's t-test) from the previously observed FFA1 tone (Figure 3.7A).   
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The basal Isc changes to AH-7614, ANT825 or the combined antagonists, were 
assessed in the presence of pharmacological Y1 and Y2 blockade or vehicle (DMSO).  
In the presence of DMSO, AH-7614 had no effect on basal Isc, as described previously.  
However, in the presence of the Y1 and Y2 antagonists, AH-7614 revealed an anti-
secretory response and this was significantly different from the corresponding control 
(Figure 3.8C).  ANT825 revealed FFA1 tonic activity as observed earlier (Figure 
3.7A), and this response was inhibited in the presence of the combined Y1 and Y2 
inhibitors.  Thus, FFA1 tone was PYY Y1/Y2-mediated (Figure 3.8C).  In the presence 
of vehicle, the combined FFA1 and FFA4 antagonists decreased the Isc, and a 
significantly larger anti-secretory response was observed in the presence of the 
competitive Y1/Y2 antagonists (Figure 3.8C).  Exogenous PYY responses were 
significantly inhibited in the presence of Y1 and Y2 receptor blockade, in comparison 







Figure 3.8: Inhibition of FFA4 responses by the FFA4 antagonist, AH-7614 in 
descending colon.  In A: competitive inhibition of the FFA4 agonist, Met-36 
responses (100 nM, after VIP) by pretreatment with the varying concentrations of the 
FFA4 antagonist, AH-7614.  Each point is the mean ± 1SEM (n=3-4).   In B: pooled 
data shows the selective inhibition of apical GW9508 (1 µM, n=5) but not TAK-875 
responses (200 nM, n=5), following the apical FFA4 antagonist AH-7614 (10 µM) ± 
FFA1 antagonist ANT825 (10 µM), compared with respective vehicle controls (0.1 % 
DMSO and 0.2 % DMSO).  In C: the effect of apical AH-7614 (10 µM, n=5), ANT825 
(10 µM, n=5) and the combination of both antagonists (Both, n=5) on basal Isc, in the 
presence of Y1 (BIBO3304; BIBO (300 nM)) and Y2 receptor blockade (BIIE2046; 
BIIE (1 µM)) or vehicle control (0.013 % DMSO).  Bars/points represent the mean ± 
1SEM. The statistical differences from respective vehicle controls are shown as 
follows; * P ≤ 0.05 and *** P ≤ 0.001 (Student's t-test). 
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3.9 FFA1, FFA4 and GPR119 colonic anti-secretory responses were Y1-BIBO3304 
sensitive but not Y2-BIIE0246 sensitive 
Endogenous PYY mediation of the FFA1 (JTT and TAK-875), FFA4 (AZ423 and 
Met-36) and GPR119 (Cpd.42) agonist responses were determined by 
pharmacological blockade of Y1 or Y2 receptors, utilising the Y1 antagonist, 
BIBO3304; the Y2 antagonist, BIIE0246 or a combination of both Y antagonists.  Each 
antagonist revealed endogenous Y1 and Y2 tonic activity under basal conditions 
(Figure 3.9A), which was similar to that observed in the mouse colon previously 
(Hyland et al., 2003; Hyland and Cox, 2005; Tough et al., 2011).  FFA1 responses to 
JTT (Figure 3.9B) and TAK-875 (Figure 3.9C) were abolished by the Y1 antagonist, 
indicating PYY-Y1 signalling predominantly mediates FFA1 responses.  Subsequent 
exogenous PYY responses were also abolished by the Y1, but not by the Y2 antagonist 
alone, while the combination of the antagonists abolished PYY activity (data not 
shown).  This confirmed exogenous PYY anti-secretory responses were also 
predominantly PYY Y1-mediated.  The responses to the FFA4 agonists, AZ423 
(Figure 3.9D) and Met-36 (Figure 3.9E), and the GPR119 agonist, Cpd.42 (Figure 
3.9F) were also abolished by the Y1 but not the Y2 antagonist.  Thus FFA1, FFA4 and 





Figure 3.9: Y1- but not Y2-receptor sensitivity of FFA1, FFA4 and GPR119 
agonism in the descending colon.  The effects of the Y1 (BIBO3304, BIBO, 300 nM) 
± the Y2 (BIIE0246, BIIE, 1 µM) antagonist and corresponding DMSO controls (+.003 
%, +.01 %, +.013 %) on baseline Isc levels are shown in A.  The effect of the FFA1 
agonists, JTT (300 nM, n=5-6) and TAK-875 (200 nM, n=5-6) after VIP in the absence 
or presence of Y antagonists are shown in B and C, respectively.  The activity of the 
FFA4 agonists, AZ423 (100 nM, n=5) and Met-36 (100 nM, n=5-6) after VIP is shown 
in D and E respectively and the GPR119 agonist, Cpd.42 responses (100 nM, n=3-5) 
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is shown in F.  Bars represent the mean ± 1SEM.  Statistical differences between 
vehicle controls (0.003 %, 0.01 % and 0.013 % DMSO) and respective antagonists 
BIBO, BIIE or both are shown as follows; *** P ≤ 0.001 (Student's t test).   
 
3.10 Absolute Isc levels at the point of TAK-875 or JTT addition were no different in 
the presence of vehicle or BIIE2046-treated preparations  
Cox et al. (1988) demonstrated that the decrease in Isc was dependent and influenced 
by the preceding level of secretory Isc (Cox et al., 1988).  As the FFA1 (TAK-875 and 
JTT) responses in the presence of the Y2 antagonist (Figure 3.9B-C) were slightly 
reduced, this was suggestive of a minor role for Y2 receptors, as seen previously 
(Tough et al. 2011).  Hence, the absolute Isc levels at the point of agonist addition were 
analysed to determine whether the subsequent agonist response was dependent on the 
residual Isc.  At the exact point of adding the FFA1 agonist (TAK-875 (Figure 3.10A) 
or JTT (Figure 3.10B)), there were no differences between descending colon mucosal 
preparations incubated with vehicle or those treated with the Y2 antagonist.  Taken 









Figure 3.10: Absolute Isc levels at the point of TAK-875 or JTT addition.  The 
scatter plot shows the absolute Isc values at the exact point of adding the FFA1 
agonist(s), TAK-875 (A) or JTT (B), in the presence of the competitive Y1 antagonist, 
BIBO3304 (300 nM), or the Y2 antagonist, BIIE2046 (1 µM) or both Y antagonists.  
Symbols represents the number of observations and the black horizontal line displays 
the mean ± 1SEM.  
 
3.11 FFA1, FFA4 and GPR119 responses were glucose-sensitive in the descending 
colon mucosa 
In order to establish the glucose-sensitivity of FFA signalling in descending colon 
mucosal preparations, the responses to the FFA1, FFA4 and GPR119 agonists were 
compared in the presence or absence of apical glucose (11.1 mM).  Mannitol 
replacement of apical glucose abolished the FFA1 responses (Figure 3.11A-B) and 
inhibited FFA4 and GPR119 activity (Figure 3.11C-E) compared to vehicle.  The 
internal control, phloridzin (added ap) decreased the Isc, but as expected only in the 
presence of glucose (because apical SGLT1 requires glucose to function).  Thus, 
FFA1, FFA4 and GPR119 receptors were activated in a glucose-sensitive manner.  In 
contrast, the PYY anti-secretory responses, after the various agonists, were glucose-
insensitive (Figure 3.11A-E).  The exogenous PYY response after the GPR119 
agonist, Cpd.42, in the presence of mannitol was significantly larger compared with 
the PYY response in the presence of glucose.  The absolute Isc level at the point of 
exogenous PYY addition was greater in these mannitol-bathed mucosal preparations 
as Cpd.42 was unable to lower the Isc, and this was attributed to the lack of glucose.  
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In this way, the greater Isc in these preparations, provided a larger residual Isc for 
exogenous PYY to inhibit (Figure 3.11E). 
 
Figure 3.11: Glucose-sensitivity of FFA1, FFA4 and GPR119 agonism after VIP 
pretreatment in the descending colon.  Glucose-sensitivity of apical FFA1 agonists, 
JTT (300 nM, n=5) in A, TAK-875 (200 nM, n=5) in B, apical FFA4 agonists, AZ423 
(100 nM, n=5) in C and Met-36 (100 nM, n=5) in D and the apical GPR119 agonist 
Cpd.42 (100 nM, n=4) in E, in the presence and absence of 11.1 mM glucose.  Control 
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mucosal preparations were bathed in glucose both sides whereas, mannitol (+ mann, 
11.1 mM) replaced glucose apically only.  Phloridzin (Phlor, 50µM, ap only) and PYY 
(10 nM) responses are also shown.  Bars represent the mean - 1SEM. Statistical 
differences between agonist or phloridzin responses in the presence or absence of 
glucose, are shown as follows; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (Student's t-
test). 
 
3.12 Blockade of SGLT1 and GLUT2 significantly decreased FFA1, FFA4 and 
GPR119 responses  
To confirm the glucose-sensitivity of FFA1, FFA4 and GPR119 responses in 
descending colon mucosal preparations, mucosae were bathed in glucose on both sides 
of the reservoir and selective agonism was assessed in the presence and absence of the 
SGLT1 inhibitor, phloridzin and the GLUT2 inhibitor, phloretin.  Firstly, under basal 
conditions the combination of the SGLT1 inhibitor, phloridzin and the GLUT2 
inhibitor, phloretin caused a biphasic change in Isc.  The first initial decrease in Isc was 
observed within the first 1-2 min, and the subsequent increase in Isc was recorded 
within 10 min, indicative of SGLT1 and GLUT2 activity, respectively.  The second 
component of the biphasic response was significantly different to the vehicle control 
(dh2O) (Figure 3.12A).  Next, the responses to the FFA1 agonist, TAK-875; the FFA4 
agonist, Met-36 and the GPR119 agonist, Cpd.42 were assessed in the presence of 
both the SGLT1 and GLUT2 inhibitors.  All three agonist responses were significantly 
attenuated in the presence of the inhibitors, in comparison to their respective vehicle 
controls (Figure 3.12B).  Exogenous PYY responses after agonist addition were 





Figure 3.12: SGLT1 and GLUT2 inhibition significantly decreases FFA1, FFA4 
and GPR119 anti-secretory responses.  In A: the combination of the SGLT1 
inhibitor, phloridzin (50 µM, ap) and the GLUT2 inhibitor, phloretin (0.1 mM, ap + 
bl) (n=5) or vehicle control, dh2O (n=5) under basal conditions.  The first initial 
decrease in Isc upon application of Phloridzin + Phloretin was observed within the first 
1-2 min, and the subsequent increase in Isc was recorded within 10 min.  In B: anti-
secretory responses of TAK-875 (200 nM, ap), Met-36 (100 nM, ap) and Cpd.42 (100 
nM, ap) after VIP, in the absence and presence of the inhibitors compared with 
respective vehicle controls (n=5).  In C: PYY (10 nM, bl) responses after agonist 
administration in the presence and absence of the inhibitors (n=5).  Statistical 
significant differences between responses in the presence of the SGLT1 + GLUT2 
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inhibitors and vehicle-treated controls are shown as follows *** P ≤ 0.001 (Student’s 
t-test).  The difference between the pretreatments on basal Isc is shown as follows; 
+++ 
P ≤ 0.001 (one-way ANOVA with Dunnett’s post hoc test).  Bars represent the mean 
± 1SEM. 
 
3.13 Co-agonism of FFA1, FFA4 or GPR119 was additive in the descending colon  
To study L cell receptor co-agonism of FFA1, FFA4 or GPR119 in descending colon 
mucosal preparations, an EC80 concentration of each selective agonist was chosen.  A 
single agonist was added to the apical reservoir and its response was monitored for 20 
min and evaluated alone, or in combination with a second selective agonist.  To study 
co-agonism, a combination of two selective agonists (added at the same time-point) 
were added apically, to a single colonic mucosal preparation.  The time-courses of co-
agonism versus single agonism were assessed for potential synergy.   
 
 3.13.1 FFA1 and FFA4 co-agonism 
The time-course of TAK-875 (Figure 3.13A) shows that this agonist decreased the Isc 
and its maximal response was recorded within 6 min, followed by a slow return of the 
Isc to baseline.  The time-course of Met-36 (Figure 3.13A) demonstrated that this FFA4 
agonist induced an anti-secretory response that reached its maxima within 4 min, 2 
min faster than the FFA1 agonist, TAK-875.  The time-course of the combined 
agonists (TAK-875 + Met-36) indicated that together their responses were additive, 
and reached a maximal response at a slower pace of 6-8 min.  The maximal response 
of the combined agonists (-13.9 ± 2.4 µA.cm-2) was significantly different from the 
maximal TAK-875 response (-6.2 ± 0.7 µA.cm-2, ** P ≤ 0.01) and Met-36 response   
(-6.1 ± 0.9 µA.cm-2, * P ≤ 0.05), clearly showing co-agonism of FFA1 and FFA4 
responses was additive.  The time-course of the TAK-875 response was significantly 
different from the combined response at 5, 6 and 8 min.  In contrast, the time-course 
of the Met-36 response was significantly different from the combined response at 5, 
6, 8, and 10 min.  The inset displays the absolute Isc values at the point of agonist 
addition, indicating the absolute Isc levels were no different between the three cohorts 
(Figure 3.13A inset).   
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 3.13.2 GPR119 and FFA1 co-agonism 
The GPR119 Cpd.16 anti-secretory response in earlier experiments appeared partial, 
compared to the PSN632408 response (Figure 3.2C).  Here, Cpd.16 decreased the Isc 
and its maximal response was observed within 6 min. The time-course of the combined 
agonists (Cpd.16 + TAK-875) showed that co-agonism was additive and the maximal 
response was observed within 8-10 min (Figure 3.13B).  This duration was 2-4 min 
longer than the maximal response observed for FFA1 and FFA4 co-agonism.  The 
maxima of the combined agonist response (-12.2 ± 1.9 µA.cm-2) was significantly 
different from the maximal TAK-875 response (-6.2 ± 0.5 µA.cm-2, ** P ≤ 0.01), but 
not the maximal Cpd.16 response (-7.5 ± 0.5 µA.cm-2).  The time-course of the TAK-
875 response was significantly different from the combined response at 10, 12, 15 and 
20 min.  In contrast, the time-course of the Cpd.16 response was significantly different 
from the combined response at 8, 10, 12, 15 and 20 min.  Overall, the combined TAK-
875 + Cpd.16 response appeared additive.  The inset shows that there were no 
differences between the absolute Isc levels at the point of addition of TAK-875, Cpd.16 
or the combined agonists (Figure 3.13B inset).   
 
 3.13.3 GPR119 and FFA4 co-agonism 
The combined response to the FFA4 agonist and the GPR119 agonist, Cpd.16 was 
additive, and reached maximum within 7 min (Figure 3.13C), a duration similar to that 
of FFA1 and FFA4 co-agonism.  The maximal combined response of Cpd.16 and Met-
36 (-18.8 ± 2.5 µA.cm-2) was significantly different from the maximal response of 
Cpd.16 GPR119 agonism (-7.3 ± 0.8 µA.cm-2, *** P ≤ 0.001) and Met-36 FFA4 
agonism (-8.8 ± 1.2 µA.cm-2, ** P ≤ 0.01), indicating that together the Cpd.16 and 
Met-36 responses were additive.  The time-course of the Met-36 response was 
significantly different from the combined response at 6, 8, 10, 12 and 15 min.  In 
contrast, the time-course of the Cpd.16 response was significantly different from the 
combined response at 5, 6, 8, 10, 12 and 15 min.  The inset shows there were no 
differences between absolute Isc levels at the point of addition of Met-36, Cpd.16 or 






Figure 3.13: Co-agonism of FFA1, FFA4 or GPR119 after VIP pretreatment is 
additive.  In A: time courses of the anti-secretory response to the FFA1 agonist, TAK-
875 (1 µM, n=9); the FFA4 agonist, Met-36 (100 nM n=9) and the combination of 
TAK-875 + Met-36 (Both) (n=5).  The insets in A-C display absolute Isc values at the 
point of agonist administration.  Symbols represent the number of observations and 
the black horizontal line displays the mean ± 1SEM.  In B: time courses of anti-
secretory response to the FFA1 agonist, TAK-875 (n=9); the GPR119 agonist, Cpd.16 
(1 µM, n=9-10) and the combination of TAK-875 + Cpd.16 (Both) (n=5).  In C: time 
courses of the anti-secretory response to the FFA4 agonist, Met-36; the GPR119 
agonist, Cpd.16 and the combination of Met-36 + Cpd.16 (Both) (n=5).  Notably, the 
time-course of individual agonist responses (TAK-875, Met-36 and Cpd.16) were 
duplicated in A-C to show the comparison between it, the second agonist response and 
their combined response. Significant differences between individual agonist responses 
and the combined agonists response were analysed using a one-way ANOVA, with 
Bonferroni’s post hoc test. Statistical differences between each individual agonist 
response (at specific time-points) and the combined agonist response are shown as 
follows; * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.  Points represent the mean ± 1SEM.  
 
3.14 Pre-stimulation of descending colon with the GPR119 agonist, PSN632408 
inhibited subsequent GPR119 agonism but not subsequent FFA1 or FFA4 agonism  
Descending colon mucosal preparations were incubated for 2 min with a high 
concentration of the commercially available GPR119 agonist, PSN632408 or its 
vehicle control, 95 % ethanol.  Following the incubation period, the anti-secretory 
responses to the FFA1 agonist, TAK-875; the FFA4 agonist, Met-36 and the GPR119 
agonists, PSN632408 or Cpd.42 were assessed in the presence or absence of 
PSN632408 pretreatment.  In the presence of vehicle, each FFA1, FFA4 or GPR119 
agonist decreased the Isc.  In the presence of PSN632408, the TAK-875 and Met-36 
anti-secretory responses were no different to their corresponding controls, whereas the 
PSN632408 and Cpd.42 responses were significantly inhibited (Figure 3.14A).  In the 
presence of PSN632408 pretreatment, exogenous PYY responses were not affected 
(Figure 3.14B).  In summary, pre-stimulation of GPR119 reduces the response to 























Figure 3.14: Apical pre-stimulation with a GPR119 agonist inhibits subsequent 
GPR119 agonism.  In A: the anti-secretory responses of TAK-875 (200 nM, n=5), 
Met-36 (100 nM, n=4-5), PSN632408 (30 µM, n=5) and Cpd.42 (100 nM, n=5-6) after 
VIP pretreatment in the absence (95 % ethanol) and presence of PSN632408 (30 µM).  
In B: PYY (10 nM, bl) responses after agonist addition in the absence and presence of 
the pretreatments.  The statistical difference between agonist responses in the presence 
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of PSN632408-pretreated or vehicle-treated controls (in A) are shown as follows, 
***P ≤ 0.001 (Student’s t-test).  Bars represent the mean - 1SEM.  
 
3.15 Pinolenic acid was a dual FFA1 and FFA4 agonist and its response was PYY 
Y1/Y2-mediated in descending colon mucosa 
The dietary metabolite, pinolenic acid has been reported as a dual FFA1 and FFA4 
agonist.  Here, pinolenic acid induced monophasic reductions in Isc, which were 
concentration-dependent, and provided an EC50 value of 298.2 nM (Figure 3.15A).  
Additionally, pinolenic acid was equipotent and as efficacious as the commercially 
available dual FFA1 and FFA4 agonist, GW9508 (seen previously in Figure 3.2A).  
To establish the pharmacology of pinolenic acid in the descending colon, the mucosa 
was pretreated with the neuronal inhibitor, TTX; the FFA1 antagonist, ANT825; a 
combination of the FFA4 antagonist (AH-7614) + FFA1 antagonist (ANT825) or a 
combination of the Y1 and Y2 antagonists, BIBO3304 + BIIE2046, respectively.  As 
shown earlier, under basal conditions TTX significantly decreased Isc, displaying loss 
of endogenous neuronal activity, ANT825 significantly increased Isc revealing FFA1-
tonic activity, the combination of the FFA1 and FFA4 antagonists slightly decreased 
basal Isc but this was not significant, and the combination of Y1 and Y2 antagonists 
increased Isc displaying Y1 and Y2 tone (Figure 3.15B).  In the presence of these 
various pretreatments, the pinolenic acid anti-secretory response was TTX-insensitive, 
partially inhibited by ANT825 (as seen previously with GW9508), significantly 
inhibited in the presence of both FFA1 and FFA4 antagonists, and its activity was 
abolished by the Y1+Y2 antagonists (Figure 3.15C).  Furthermore, the pinolenic 
response in the presence of both FFA1 and FFA4 antagonists was significantly 
different from the response in the presence of the FFA1 antagonist, ANT825 alone 
(Figure 3.15C). This indicated that pinolenic acid selectively activated FFA1 and 
FFA4 receptors in the descending colon, and its response was epithelial in origin and 
Y1/Y2-mediated.  As expected, exogenous PYY responses after Y1 and Y2 blockade 
were abolished compared to the vehicle control, whereas PYY responses in the 




Figure 3.15: The anti-secretory response to pinolenic acid is FFA1 and FFA4 
selective and PYY Y1/Y2-mediated.  In A: concentration-response curve of varying 
concentrations of pinolenic acid (n=4-5).  Points represent mean ± 1SEM.  In B: basal 
changes in Isc to TTX (100 nM, n=5), ANT825 (10 µM, n=5), AH-7614 (10 µM) + 
ANT825 (10 µM, n=5) and Y1 and Y2 antagonists (BIBO3304 + BIIE2046, n=5) 
compared with dH2O (n=5), 0.1 % DMSO (n=5), 0.2 % DMSO (n=5) and 0.013 % 
DMSO (n=5), respectively.  In C: pinolenic acid responses after VIP pretreatment in 
the absence and presence of TTX, ANT825, AH-7614+ANT825 or Y1 + Y2 
antagonists.  The responses of the internal control, exogenous PYY are shown in D.  
Bars represent the mean ± 1SEM. Statistical differences are shown as follows; *P ≤ 




3.16 Triple agonism of FFA1, FFA4 and GPR119, utilising the dual FFA1 and FFA4 
agonist, pinolenic acid and selective GPR119 agonists  
Having established co-agonism of FFA1, FFA4 or GPR119 in the descending colon 
mucosa was additive, the response to coincident triple receptor activation was next 
investigated, in an attempt to replicate the physiological activation of all three L cell 
receptors postprandially, in vitro.  The responses to the dual FFA1 and FFA4 agonist, 
pinolenic acid, in combination with the full GPR119 agonist, PSN632408 or the 
selective GPR119 agonist, Cpd.16 were monitored for 20 min.   
On its own, pinolenic acid slowly decreased Isc and reached a maximal response within 
8-10 min (Figure 3.16A).  As expected, this duration was within the same time-frame 
reached by the maximal response to FFA1 (TAK-875) and FFA4 (Met-36) co-
agonism, observed in the earlier study (seen previously in Figure 3.13A).  The full 
GPR119 agonist, PSN632408, significantly decreased Isc and its maximal response 
was observed within 8-10 min.  Together, the combination of pinolenic acid and 
PSN632408 reduced the peak GPR119 PSN632408 response, however this was not 
significant when comparing the maxima.  The combined response was reached within 
6-8 min, 2 min faster than the individual agonist responses. Once the maximum of the 
combined response was reached, the Isc rapidly returned to baseline.  The time-course 
of the PSN632408 response was significantly different from the combined response at 
12 and 15 min (Figure 3.16A).   
The selective GPR119 agonist, Cpd.16 reached a maximal response within 5 mins, 
after which the Isc rapidly returned to baseline Isc.  The time course of the response to 
the combination of Cpd.16 and pinolenic acid was not additive nor inhibitory, however 
showed similar kinetics to the time-course of the pinolenic acid response.  
Additionally, the combined response Isc levels rapidly returned to baseline after it 
reached its maximum (Figure 3.16B).  The absolute Isc levels at the point of agonist 
addition were no different from one another in each cohort (Figure 3.16A-B insets).  
Exogenous PYY responses were no different in the presence of the various 
combinations of agonists (Figure 3.16C).  However, the exogenous PYY response 
after PSN632408 appeared smaller (not significantly) in comparison to all other 
exogenous PYY responses (Figure 3.16C).  This was attributed to a significantly lower 
absolute Isc level before PYY application (after the PSN632408 response), in 
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comparison to the absolute Isc levels after the Cpd.16 response and the Cpd.16 + 


























Figure 3.16: Triple agonism of FFA1, FFA4 and GPR119 after VIP pretreatment, 
utilising the dual FFA1 and FFA4 agonist, pinolenic acid and selective GPR119 
agonists.  In A: time courses of the anti-secretory responses induced by the dual 
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agonist, pinolenic acid (1 µM, n=5), the GPR119 full agonist, PSN632408 (10 µM, 
n=5) and the combination of both pinolenic acid and PSN632408 (Both, n=5).  In B: 
time courses of the anti-secretory responses of pinolenic acid, Cpd.16 (1 µM, n=5) and 
the combination of pinolenic acid and Cpd.16 (Both, n=5).  Notably, the pinolenic acid 
response time-course was duplicated in A and B to show the comparison between it, 
two independent GPR119 agonist responses and their combined responses with 
pinolenic acid, respectively.   In C: PYY (10 nM, bl, n=5) control responses after 
agonist addition. Single points and bars represent the mean ± 1SEM. The insets in A - 
C display absolute Isc values at the point of agonist addition. Symbols represent the 
number of observations and the black horizontal line displays the mean ± SEM.  
Statistical differences between each individual agonist response (at specific time-
points) and the combined agonist response are shown as follows; * P ≤ 0.05 (one-way 
ANOVA, with Bonferroni’s post hoc test).  The statistical differences between 
absolute Isc cohorts before PYY addition (C) were analysed with a one-way ANOVA 
with a Bonferroni’s post hoc test and shown as follows, + P ≤ 0.05. 
 
3.17 Caeco-colonic transit was inhibited by FFA1 and FFA4 agonists  
Since FFA1 and FFA4 mucosal responses in the colon were mediated by PYY and 
this endogenous peptide was known to slow colonic transit (Savage et al., 1987; Lin 
et al., 1996; Maljaars et al., 2008; Tough et al., 2011), the ability of the FFA1 and 
FFA4 agonists were assessed to reduce colonic transit at single optimal concentrations 
(Figure 3.17A).  In isolated colons, TUG424, TUG891, TAK-875 and Met-36 
significantly decreased transit in comparison to vehicle-treated controls.  
Since GW1100 inhibited FFA1 responses in colonic mucosa, the ability of GW1100 
alone to increase basal faecal transit and reverse the effect of the FFA1 agonist on 
colonic transit was examined, in vitro.   Figure 3.17B shows that GW1100 alone 
significantly increased basal colonic transit, again indicating endogenous FFA1 
inhibitory tone.  After 20 min pretreatment with the FFA1 antagonist, GW1100, the 
effect of TUG424 and TUG891 was assessed in the presence and absence of GW1100.  
In the presence of GW1100, the inhibitory effect on colonic transit of TUG424 was 
reversed, but GW1100 had no effect on TUG891 (FFA4) activity, showing FFA1 
selectivity (Figure 3.17B).  The positive control, loperamide HCl significantly 
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decreased faecal pellet propulsion in comparison to vehicle-treated controls (Figure 
3.17C).  
 
Figure 3.17: Colonic transit is slowed by FFA1 and FFA4 agonists in isolated 
colons in vitro.  Colonic transit was slowed by TUG424 (300 nM, n=6), TAK-875 
(300 nM, n=6), TUG891 (300 nM, n=6) and Met-36 (Met-36, 300 nM, n=6) in A at    
t =20 min.  In B: the effects of FFA1 antagonist GW1100 (10 μM) and DMSO (0.1 
%) are compared on basal faecal transit at t=20 min and on subsequent inhibition of 
transit following 20 min treatment with TUG424 (300 nM) or TUG891 (300 nM) at 
t=40 min (n=5, IR Tough data).  In C: the positive control Loperamide HCl (10 µM, 
n=5) slowed colonic transit in vitro compared with DMSO (0.1 %, n=6).  Each bar 
represents the mean + 1SEM.  Statistically significant differences from controls were; 
* P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 (Student's t test) and + P ≤ 0.05 and ++ P ≤ 0.01 
(one-way ANOVA with Dunnett’s post hoc test). 
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3.18 Selecting a dose for TAK-875, ANT825 and Met-36 for in vivo experimentation 
To establish a starting dose for each chosen compound (FFA1 agonist, TAK-875; the 
FFA1 antagonist, ANT825 and the FFA4 agonist, Met-36) selected to take forward 
into the in vivo GI motility studies, the following AZ in-house data provided insight 
(Figure 3.18A-F).   Using this data, an optimum starting dose (and a higher dose if 
required) was chosen.  The AZ in-house studies were performed in C57BL/6J mice 
(males and females), and therefore the results were comparable with the C57BL/6J 
mice used in this thesis.  Mice received an intravenous (IV) or oral administration of 
each compound (various doses) and were monitored for 14-30 h.  Blood samples were 
taken intermittently and analysed, measuring the total plasma concentration and the 
free plasma concentration of each compound.  The administration (both routes) of each 
compound, TAK-875, Met-36 and ANT825, provided a maximal exposure (Cmax) 
roughly around 1 h after administration.  Therefore, in this thesis, the chosen 
compounds were administered (po or i.p.) 1 h prior to experimentation.   
 
3.18.1 FFA1 agonist: TAK-875 
The FFA1 agonist, TAK-875 produced by Takeda, has been used widely in the 
literature.  In these studies, doses ranged from 3 mg/kg to 30 mg/kg (Tsujihata et al., 
2011; Ito et al., 2013; Ito et al., 2016).  In the in vitro studies in this thesis, TAK-875 
provided an EC50 of 0.0676 µM (Figure 3.2A).  Therefore, a dose was selected that 
provided a free plasma concentration around 0.1 µM of TAK-875 (around the EC80 
concentration) (Figure 3.18A-B).  Hence, with the support of AZ’s drug metabolism 
and pharmacokinetics (DMPK) department, the starting po/i.p. dose for TAK-875 was 
27 mg/kg.  
 
 3.18.2 FFA1 antagonist: ANT825 
In this thesis, the FFA1 selective antagonist, ANT825 provided an IC50 value of 0.219 
µM (seen previously in Figure 3.7C).  Using AZ’s in-house data, a dose of 29 mg/kg 
was selected for the initial po/i.p. dose of ANT825, as it provided a free-plasma 
concentration of 0.35 µM (an IC80 concentration of ANT825) (Figure 3.18C-D).  
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 3.18.3 FFA4 agonist: Met-36 
The FFA4 agonist, Met-36 provided an EC50 in this thesis of 0.015 µM (seen 
previously in Figure 3.2B).  The in vivo motility studies required a free plasma 
concentration exposure of 0.024 µM of Met-36 (around the EC80 concentration).  
Hence, a starting po/i.p. dose of 6 mg/kg was selected however, this was later 






Figure 3.18: Time profiles of the total and free plasma concentrations of TAK-
875, ANT825 and Met-36 in C57BL/6J mice.  Total plasma concentration (µM) of 
the FFA1 agonist, TAK-875 (1.4 mg/kg, 8 mg/kg, 27 mg/kg (po) and 4 mg/kg 
intravenously (IV)) in A; the FFA1 antagonist, ANT825 (2 mg/kg, 29 mg/kg (po) and 
0.7 mg/kg (IV)) in C and the FFA4 agonist, Met-36 (6 mg/kg, 72 mg/kg, 246 mg/kg 
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(po) and 10 mg/kg (IV)) in E, versus their free plasma concentrations (µM) in plasma 
(B, D, F respectively).  Each point represents the time of blood sampling and the 
corresponding measurement of the total or free plasma concentration of agonist or 
antagonist.  
 
3.19 Plasma glucose significantly decreased after a 16 h fast in mice 
Before in vivo experimentation, mice were fasted for 16 h overnight.  As FFA1, FFA4 
and GPR119 agonist responses were glucose-sensitive in vitro, the blood glucose 
concentrations of a cohort of mice, were evaluated before and after a 16 h fast 
overnight.  A blood sample was obtained from the tail vein, from each mouse, before 
and after fasting.  The overall mean blood glucose concentration after fasting was 
significantly lower than the blood glucose concentration assessed before fasting 
(Figure 3.19).  In summary, prior to in vivo experimentation, the C57BL/6J mice were 










Figure 3.19: Plasma glucose concentrations pre- and post- 16 h fasting in 
C57BL/6J mice. Plasma glucose (mmol/l) concentrations before and after a 16 h 
overnight fast, prior to in vivo experimentation (n=7).  The statistical difference 
between pre- and post-fasting is shown as ***P ≤ 0.001 (Student’s t-test). Bars 
represent mean + 1SEM.  
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3.20 TAK-875 and Met-36 responses were no different in 5.0 mM or 25.0 mM glucose 
in vitro  
Having established that mice were hypoglycaemic after an overnight fast, the TAK-
875 and Met-36 responses were assessed in descending colon mucosal preparations in 
vitro, bathed in KH containing 5.0 mM or 25.0 mM glucose on both sides of the 
reservoir (ap+bl).  These glucose concentrations represented a hypoglycaemic (5.0 
mM) and hyperglycaemic (25.0 mM) environment.  Both TAK-875 and Met-36 
responses were no different when the concentration of glucose in the KH was altered 
(Figure 3.20A).  Phloridzin and PYY responses after agonist addition were also 
unaffected when the glucose concentration in the KH was altered (Figure 3.20B-C).  
In summary, although the mice used in this thesis were hypoglycaemic after fasting 
(before in vivo experimentation), FFA1 and FFA4 agonism was not affected when the 
glucose concentration in the KH was reduced (5.0 mM) to represent a hypoglycaemic 
environment in vitro.  Additionally, FFA1 (TAK-875) or FFA4 (Met-36) responses in 
the presence of 5.0 mM or 25 mM glucose (in KH) were no different when compared 





Figure 3.20: FFA1 and FFA4 responses were no different when the glucose 
concentration in the KH was altered to 5 mM or 25 mM. In A: Apical TAK-875 
(200 nM, n=5) and Met-36 (100 nM, n=5) anti-secretory responses in descending 
colon mucosa, bathed in KH with a glucose concentration of  5.0 mM or 25.0 mM (ap 
+ bl).  Exogenous phloridzin (B) and PYY (C) responses (n=5) after agonist 
administration were unaffected in the presence of various concentrations of glucose. 









3.21 Colonic bead propulsion was slowed by Met-36, not TAK-875 or ANT825 in vivo 
As the FFA1 and FFA4 agonists (TAK-875 and Met-36, respectively) slowed transit 
in isolated colons in vitro, the ability of these agonists and loperamide HCl (positive 
control) to slow colonic transit was assessed in vivo, comparing po and i.p. 
administration.  Whether ANT825 had the potential to reveal FFA1 tone was also 
investigated in vivo.   
Oral administration of the positive control, loperamide HCl significantly slowed 
transit compared to its vehicle control.  Two doses of Met-36 were evaluated orally; 
the lower dose had no effect on colonic transit, whereas the higher dose significantly 
slowed transit.  Furthermore, oral gavage of TAK-875 and ANT825 had no effect on 
colonic transit (Figure 3.21A).  Notably, the measured total plasma concentrations (as 
described in Methods & Materials) of TAK-875 (27 mg/kg, po) and Met-36 (50 mg/kg, 
po) were similar to that observed in AZ in-house in vivo studies (data not shown).  
Administration of loperamide HCl or Met-36 via i.p., significantly slowed colonic 
transit.  Conversely, TAK-875 and ANT825 had no effect (Figure 3.21B).  Notably, 
loperamide HCl (i.p.) slowed colonic transit significantly compared to all other 
compounds tested (Met-36, TAK-875, ANT825).  As i.p. administration of loperamide 
HCl slowed transit more efficiently in comparison to oral gavage, this route of 




























Figure 3.21: The effect of oral gavage versus i.p. administration of FFA ligands 
and loperamide HCl on colonic bead expulsion in vivo.  The effect on colonic bead 
expulsion (expressed as time until bead expelled (min)) after oral gavage or i.p. 
administration of loperamide HCl (10 mg/kg, red bar, n=11) compared with its vehicle 
control, 0.5 % methylcellulose (blue bar, n=11); the FFA4 agonist, Met-36 at two 
doses: 6 mg/kg (yellow bar with black horizontal stripes, n=6) and 50 mg/kg (yellow 
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bar with black diagonal stripes, n=10)  compared with their vehicle control, 0.5 % 
hydroxylpropyl methylcellulose (HPMC) + 0.1 % Tween-80 (yellow bar, n=10); the 
FFA1 agonist, TAK-875 (27 mg/kg, blue bar with white diagonal stripes, n=11) 
compared with its vehicle control (0.5 % methylcellulose, blue bar) and finally the 
FFA1 antagonist, ANT825 (29 mg/kg, orange bar with white diagonal stripes, n=7) 
compared with its vehicle (0.25 % polyvinylpyrrolidone (PVP) + 0.05 % sodium 
dodecyl sulphate (SDS), orange bar, n=7). Bars represent the mean + 1SEM.  
Statistically differences from controls were; * P ≤ 0.05 and *** P ≤ 0.001 (Student's 
t-test).  Differences between the oral doses of Met-36 (po) from its control and 
additionally between loperamide HCl (i.p.) and the FFA drugs were; + P ≤ 0.05 and 
+++ P ≤ 0.001  (one-way ANOVA with Dunnett’s post hoc test). 
 
3.22 Upper GI transit was increased by Met-36 in vivo 
The effect (i.p.) of the chosen FFA agonists and loperamide HCl was investigated on 
UGIT, at the same doses utilised in the colonic motility in vivo study (section 3.21).  
Furthermore, as ANT825 revealed FFA1 tone in vitro, the effect of this antagonist was 
assessed in vivo.  Mice were given a charcoal meal (as described in the Methods & 
Materials).  The positive control, loperamide HCl significantly slowed UGIT as 
expected, compared to its vehicle control (Figure 3.22).  Furthermore, loperamide HCl 
slowed UGIT significantly compared to all other compounds tested (Met-36, TAK-
875, ANT825).  Met-36 significantly increased upper intestinal transit, whereas TAK-















Figure 3.22: The effect of FFA ligands and loperamide HCl (i.p.) on UGIT in vivo.  
The intestinal transit of a charcoal meal (expressed as a percentage of the small 
intestine length) after the positive control, loperamide HCl (10 mg/kg, red bar, n=6) 
compared with its vehicle control, 0.5 % methylcellulose (blue bar, n=6); the FFA4 
agonist, Met-36 (50 mg/kg, yellow bar with black diagonal stripes, n=6) compared 
with its vehicle control, 0.5 % HPMC + 0.1 % Tween-80 (yellow bar, n=6); the FFA1 
agonist, TAK-875 (27 mg/kg, blue bar with white diagonal stripes, n=5) compared 
with its vehicle control (0.5 % methylcellulose, blue bar) and the FFA1 antagonist, 
ANT825 (29 mg/kg, orange bar with white diagonal stripes, n=5) compared with its 
vehicle (0.25 % PVP + 0.05 % SDS, orange bar, n=5).  Bars represent the mean + 
1SEM.  Statistically differences from controls were; * P ≤ 0.05 and *** P ≤ 0.001 
(Student’s t-test).  Differences between loperamide HCl and FFA drugs were; +++ P ≤ 












































4.1 Bi-directional signalling of FFA1, FFA4 and GPR119 receptors 
At the start of this PhD, the pharmacology of the FFA1, FFA4 and GPR119 receptors 
in native tissue was unclear, and very few functional studies had been performed 
interrogating their intestinal mechanisms.  The first aim of this study was to determine 
the sidedness, potencies and efficacies of the novel selective agonists received from 
AZ (FFA1 agonists: JTT, TAK-875; FFA4 agonists: AZ423, Met-36 and GPR119 
agonists: Cpd.16, Cpd.42) and compare them with commercially available agonists 
(FFA1 agonist: TUG424; FFA4 agonist: TUG891; FFA1 and FFA4 dual agonist: 
GW9508 and the GPR119 agonist: PSN632408).  This study showed that FFA1, FFA4 
and GPR119 agonism was independent of the surface of administration and the time-
dependence of Isc changes was similar upon luminal and serosal application.  This 
suggested FFA1, FFA4 and GPR119 receptors were expressed on both the apical and 
basolateral epithelial surfaces, resulting in bi-directional signalling.  Notably, all 
FFA1, FFA4 and GPR119 agonists (and antagonists) utilised in the present study were 
lipid-soluble, requiring DMSO as a vehicle.  Thus, agonists added on the apical surface 
could activate receptors on the basolateral L cell domain and vice versa.  However, no 
latency in Isc was observed when comparing the apical versus basolateral time-courses 
of FFA1, FFA4 or GPR119 agonism.   Thus, this increased the likelihood of FFA1, 
FFA4 and GPR119 receptor expression on both L cell surfaces, allowing bi-directional 
signalling to occur (Figure 4.1).  Recently, Christensen et al. (2015) showed 
preferential but not exclusive vascular (basolateral) FFA1 evoked GLP-1 secretion, 
using endogenous and synthetic agonists in rat proximal small intestine.  Luminal 
perfusion of the FFA1 agonist, AM-5262 (10 µM, 20 min) significantly increased 
portal vein total GLP-1 levels, at a concentration 10-fold higher than the concentration 
of AM-5262 (1 µM) perfused vascularly (Christensen et al., 2015).  Despite the greater 
luminal concentration of AM-5262 (10 µM), it was still within the normal 
physiological luminal lipid range (mM).  This revealed FFA1 receptors may also be 
expressed on the L cell apical domain in rat small intestine.  A recent preliminary study 
has suggested exclusive vascular GPR119 agonism stimulated GLP-1 secretion in 
mouse and rat perfused small intestine, at a physiologically relevant concentration (1 
µM) (Svendsen and Holst, 2016).  However, no further findings have been published.   
Taken together, these studies suggested that the FFA1 and GPR119 receptors were 
preferentially expressed on the basolateral L cell domain in the small intestine.  At 
odds with these studies, recently the novel first-in-class GPR119 water soluble 
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agonist, AR440006 (as well as OEA and 2-OG) elicited equi-effective apical and 
basolateral anti-secretory responses in mouse and human mucosa.  Furthermore, liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) analysis displayed only 
trace amounts of AR440006 (~2 nM) permeated the epithelial tight junctions, 10 mins 
after agonist addition (time of maximal agonism) (Tough et al., 2018b).  This 
suggested GPR119 is expressed on apical and basolateral L cell domains in mouse and 
human colon, allowing bi-directional sensing, and this was consistent with the 
observed findings in this thesis.  Differences between the findings in this thesis and 
the Christensen et al. (2015) study may be attributed to possible species differences in 
FFA1 and GPR119 signalling between rat intestine and mouse colon, respectively.  
Indeed, species variation exists between rat and mouse L cell MC4 receptor 
enteroendocrine signalling (Panaro et al., 2014).  Panaro et al. (2014) revealed the rat 
was not a suitable animal model to investigate L cell MC4 receptor signalling as rat 
intestinal/colonic mucosa was unresponsive to the melanocortin, α-MSH (1 µM).  α-
MSH (10 nM or 1 µM) was also unable to elicit GLP-1 secretion in rat perfused small 
intestine.  Conversely, α-MSH (1 µM) applied basolaterally in mouse descending 
colon mucosa (and human mucosa) caused an inhibition of epithelial ion transport and 
this functional effect was abolished in MC4
-/- mice (Panaro et al., 2014).  Species 
variation also exists between rat and mouse (and human) Y1/Y2 receptor signalling.  
The complexity increases as rat Y1/Y2 receptor signalling also differs between GI 
regions, specifically the jejunum and colon (Cox and Cuthbert, 1990; Tough and Cox, 
1996).  In the rat jejunum, Y receptor signalling is preferentially Y2-mediated, post-
junctional and lacks Y1-signalling.  Conversely, in rat colonic mucosa there is a 
mixture of Y1 and Y2 signalling.  Here, Y1 receptors are neuronally expressed and Y2 
receptors are located post-junctionally (Tough and Cox, 1996).  Similarly, in mouse 
and human colon there is a mixture of Y1 and Y2 signalling, however Y1 receptors are 
predominantly found post-junctionally and expressed on epithelia whereas, Y2 
receptors are prejunctional (Cox et al., 2002; Hyland et al., 2003).  Thus, Y-receptor 
signalling differences exist not only between the rat intestine and colon but also 
between rat and mouse colon.  These key functional differences indicate Y1/Y2 
receptor signalling in the mouse, not in the rat, more closely resemble human Y 
receptor signalling.  Thus, caution should be taken when comparing rat and mouse 




Luminal administered lipids or lipid metabolites i.e. FFAs have stimulated GLP-1 
release in human (Carr et al., 2008; Little et al., 2005; Beglinger et al., 2010), mouse 
(Adachi et al., 2006) and rat (Dailey et al., 2014).  Initial studies proposed FFA1 
(Edfalk et al., 2008), FFA4 (Hirasawa et al., 2005) and GPR119 (Chu et al., 2008) 
were lipid-sensing receptors located on GLP-1 containing L cells, and that these 
receptors were responsible for sensing luminal lipid metabolites, to cause GLP-1 
release.  Indeed, over the years studies have shown that orally administered lipids or 
lipid metabolites can activate FFA1 (Edfalk et al., 2008; Xiong et al., 2013; Ekberg et 
al., 2016), FFA4 (Hirasawa et al., 2005; Ekberg et al., 2016) and GPR119 (Ekberg et 
al., 2016; Moss et al., 2016), to evoke GLP-1 secretion in WT mice in vivo.  In rats, 
intraluminal application of the GPR119 endogenous agonist, OEA (10 µmol/l) but not 
intravenous administration (5 mg/kg), increased GLP-1 secretion in vivo (Lauffer et 
al., 2009).  This OEA-mediated incretin effect demonstrated functional GPR119 
agonism, and thus a possible indication of apical GPR119 receptors.  The 
translatability of this luminal GPR119 response was observed in healthy human 
subjects as intrajejunal administration of the GPR119 endogenous agonist, 2-OG 
(Hansen et al., 2011) or oral administration of a lipid meal (C8-dietary oil, containing 
2-OG) (Mandøe et al., 2015), also raised plasma total GLP-1 secretion.  Taken 
together, apical administration was selected (Figure 4.1) to interrogate receptor 
function in further studies, as the concentration-dependent reductions in Isc occurred 
within the same time frame as other agonists targeting apically located L cell GPCRs 
i.e. Cpd 1(FFA2) (Forbes et al., 2015), L-glutamine (calcium-sensing receptor) (Joshi 
et al., 2013), L-arginine (GPRC6A) (Alamshah et al., 2016) and the water-soluble 




Figure 4.1: Proposed model of FFA1, FFA4 and GPR119 receptor sidedness in 
enteroendocrine L cells.  FFA1, FFA4 and GPR119 receptors are present on both the 
apical (ap) and basolateral (bl) L cell epithelial domains, allowing bi-directional 
signalling in mouse descending colon mucosa.  
 
4.2 The improved potency and selectivity of FFA1, FFA4 and GPR119 AZ agonists 
4.2.1 Selective FFA1 agonists versus commercially available FFA1 agonists 
The AZ FFA1 agonists, TAK-875 and JTT were equipotent and similarly efficacious 
in mouse native colonic mucosa.  The potency of TAK-875 was similar to the EC50 of 
this compound (31 nM), in CHO cells expressing mouse FFA1 (AZ in-house data, 
Table 1.5).  In another study, TAK-875 was more potent than FFA1 selective 
endogenous FFAs in a Ca2+ mobilisation assay, in CHO cells expressing mouse FFA1 
(Yabuki et al., 2013).  However, TAK-875 was not as efficacious as γ-linolenic acid, 
and therefore Yabuki et al. (2013) termed TAK-875 a partial FFA1 agonist.  In this 
PhD thesis, TAK-875 (as well as JTT, TUG424, TUG891, AZ423 and Met-36) had a 
lower maximal response compared to the dual FFA1/FFA4 agonist, GW9508. 
However, due to the unavailability of known full selective FFA1 or FFA4 reference 
agonists, this PhD thesis had no evidence to suggest that these FFA1 agonists (TAK-
875, JTT, TUG424) or FFA4 agonists (AZ423, Met-36 and TUG891) were partial 
agonists.  More recently, TAK-875 exhibited a higher potency (EC50=12.5 nM) than 
that observed in this PhD, in COS-7 cells expressing human FFA1 in an IP turnover 
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assay (Hauge et al., 2015), and this was similar to the potency of TAK-875 (EC50=14 
nM, fluorometric imaging plate reader (FLIPR)) at the human FFA1 receptor in the 
initial discovery study (Negoro et al., 2010).  This modest difference in potencies 
between the findings in this thesis and those by Negoro et al. (2010) and Hauge et al. 
(2015), may be attributed to the transfection of the human, not mouse FFA1 receptor, 
of which its amino acid sequence differs by 17 % from the mouse FFA1 sequence 
(Table 1.3).  In this PhD study, the EC50 of the second selective FFA1 agonist, JTT 
was more potent in native tissue than that obtained by AZ (Table 1.5).  Furthermore, 
the EC50 of JTT was within the potency range of two lead compounds, compound 5 
and 6 (between 1 nM -100 nM), published in a patent application by Japan Tobacco 
(NCT01699737).  One of these compounds is thought to be JTT-851, and thus is 
consistent with the EC50 of JTT in this thesis.   
 
The AZ FFA1 agonists were more potent but exhibited lower maximal responses than 
GW9508.  GW9508 was reported to act as a dual agonist via FFA1 and FFA4, with 
100x higher affinity for FFA1 than FFA4 (Briscoe et al. 2006).  More recently, 
GW9508 has also been termed a partial agonist in comparison to two other FFA1 
agonists (AM-1638 and AMG-6226) in A9 cells (a subline of mouse L cells), 
expressing FFA1 in an IP accumulation assay (Luo et al., 2012).  Therefore, this dual 
FFA1 and FFA4 agonism with GW9508 may explain its slightly greater maximal 
response than the more selective FFA1 or FFA4 agonists used in this thesis.  The EC50 
of GW9508 obtained in this study was similar  to the EC50 revealed in HEK293 cells, 
transfected with FFA1 or FFA4, in a Ca2+ mobilisation assay (Briscoe et al., 2006), 
and was not dissimilar from the potency observed in CHO cells expressing mouse 
FFA1 (Yabuki et al., 2013).  The second commercially available FFA1 agonist, 
TUG424 showed similar kinetics as the selective FFA1 agonists, namely TAK-875 
and JTT.  In this present study, the EC50 of TUG424 was similarly potent to the EC50 
of TUG424 (32 nM) observed in a label-free dynamic mass redistribution (DMR) 
assay.  DMR is a measurement of the change in baseline refraction index upon receptor 
activation in a cell monolayer (Christiansen et al., 2008).  Christiansen et al. (2008) 
first described TUG424 as a full FFA1 agonist but like GW9508 (Luo et al., 2012) and 
TAK-875 (Yabuki et al., 2013), TUG424 has also been termed a partial agonist in 
comparison to two other FFA1 agonists (AM-1638 and AMG-6226) in an IP 




FFA1 agonists are preferentially Gαq/11-linked and recent evidence suggests that 
'Gαq/11-only' FFA1 agonists (e.g. TAK-875) stimulate the release of incretin hormones, 
GLP-1 and GIP, with reduced efficacy compared to second generation FFA1 agonists.  
These second generation FFA1 agonists couple and signal via Gαq/11 and Gαs pathways, 
to cause a more robust release of GLP-1 and GIP in murine colonic crypt cultures 
(Hauge et al., 2015; Hauge et al., 2017) and in mice in vivo (Hauge et al., 2015).  The 
FFA1 agonists used in this present PhD study appear to be preferentially Gαq/11-
coupled as mucosal responses were transient in comparison with sustained Gαs-
coupled L cell signalling e.g. GPR119 (Cox et al., 2010; Patel et al., 2014) and MC4 
agonism (Panaro et al., 2014).   
 
4.2.2 FFA4 selective agonists versus commercially available FFA4 agonists 
In this PhD study, shown for the first time in native tissue, Met-36 and AZ423 were 
highly potent FFA4 agonists, more potent than the commercial FFA4 agonist, 
TUG891.  Furthermore, all three FFA4 agonists were similarly efficacious.  Recently, 
Met-36 (Sundström et al., 2017) and AZ423 (McCoull et al., 2017) exhibited EC50 
values of 130 nM and 510 nM respectively, in CHO cells expressing mouse FFA4 in 
a DMR assay.  In this PhD study, Met-36 and AZ423 appeared more potent in native 
tissue.  In fact, the potency of AZ423 in HEK293 and CHO cells expressing mouse 
FFA4 (AZ-in house data, Table 1.5) was less potent than the potency observed in 
native tissue, demonstrating clear variation between cell-based assays and mouse 
native colonic mucosa.  The commercially available FFA4 agonist, TUG891 exhibited 
an EC50 (62.5 nM (24.1 – 162.3)) within ranges previously published in a Ca2+ 
mobilisation assay at mouse FFA4 in HEK293 cells (Hudson et al., 2013).  Notably, 
as only 3-fold TUG891 selectivity exists between mouse FFA4 and FFA1 receptors 
(Hudson et al., 2013), it is important to note that both FFA1 antagonists had no effect 
on the TUG891 response (300 nM) in this thesis.  
 
In the past, FFA4 was shown to signal via Gαq-coupled signalling pathways (Hirasawa 
et al., 2005).  Recently, further complexity has been revealed as studies have suggested 
that FFA4 couples to Gαi signalling pathways in gastric ghrelin cells (Koyama et al., 
2016), gastric somatostatin cells (Egerod et al., 2015) and pancreatic delta cells (Stone 
et al., 2014).  In this thesis, the transient mucosal responses to the FFA4 agonists 
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resembled the same kinetics as the FFA1 agonists, and thus most likely signalled via 
Gαq-linked pathways in mouse descending colon mucosa.  
 
 
4.2.3 GPR119 selective agonists versus commercially available GPR119 agonists 
The AZ GPR119 agonists, namely Cpd.16 and Cpd.42 were highly potent and 
exhibited low efficacy.  The potencies of Cpd.16 and Cpd.42 were within ranges 
previously established in cAMP assays, in HEK293 cells expressing mouse GPR119 
(Scott et al., 2012, Scott et al., 2014) (AZ in-house studies, Table 1.5).   The 
commercially available full agonist, PSN632408 was highly efficacious and exhibited 
a low potency as previously shown (Overton et al., 2006; Cox et al., 2010).  In 
comparison to the PSN632408 response, the selective GPR119 agonists appeared 
partial and displayed a maximal response similar to the GPR119 agonist developed by 
Prosidion, PSN-GPR119 (Patel et al., 2014).  The maximum response to PSN-GPR119 
was approximately 50 % lower than the maximum response to PSN632408 (Patel et 
al., 2014), as similarly observed with the AZ GPR119 agonists.  Thus, like PSN-
GPR119, the AZ agonists displayed partial GPR119 agonism.  More recently, the 
GPR119 agonist, AR231453 also exhibited similar activity as PSN-GPR119, Cpd.16 
and Cpd.42 (Tough et al., 2018b).  This phenomenon of high potency but a low 
maximal response is indicative of a lower intrinsic ability of Cpd.16 and Cpd.42 to 
activate the GPR119 receptors once bound in comparison to PSN632408.  
Furthermore, the lower maximal responses of Cpd.16 and Cpd.42 may be attributed to 
enhanced receptor desensitisation/internalisation and will be discussed further in 
section 4.2.4 (below).  In the present study, the sustained mucosal responses of 
PSN632408, Cpd.16 and Cpd.42 resembled Gαs-signalling, as seen in previous L cell 
Gαs-signalling investigations i.e. GPR119 (Cox et al., 2010; Patel et al., 2014; Tough 
et al., 2018b) and MC4 (Panaro et al., 2014).   
 
4.2.4 The selective and highly potent AZ FFA1, FFA4 and GPR119 agonists all 
displayed low maximal responses in mouse descending colon mucosa 
The AZ FFA1 agonists (TAK-875, JTT) and FFA4 agonists (Met-36 and AZ423) 
exhibited lower maximal responses compared to the dual agonist, GW9508, whereas 
the AZ GPR119 agonists (Cpd.16 and Cpd.42) displayed partial activity in comparison 
to the PSN632408 response.  Recently, Qian et al. (2014) demonstrated FFA1 agonist-
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mediated internalisation was concentration and time dependent, with 300 nM - 1 µM 
linoleic acid causing approximately 40 % FFA1 internalisation, in HEK293 cells 
expressing FFA1.  This agonist-mediated internalisation was β-arrestin 2 dependent 
(Qian et al., 2014).   Further investigations by Mancini et al. (2015) in HEK293T cells 
(expressing GFP-tagged FFA1) revealed the FFA1 agonist, TAK-875 was a potent 
activator and full agonist in the recruitment of β-arrestin 1 (EC50 = 64.1 nM) and β-
arrestin 2 (EC50 = 54.7 nM), compared to the endogenous FFA1 agonists, palmitate 
and oleate (Mancini et al., 2015).  The activity of TAK-875 appeared partial in FFA1 
Gαq-coupled/Ca
2+ signalling (Mancini et al., 2015) and Ca2+ flux assays (Yabuki et al., 
2013) in comparison to other FFAs.  Taken together, in these cell-based assays TAK-
875 appeared to possess partial activity in Gαq/Ca
2+-signalling and full agonism in β-
arrestin 1 and 2 recruitment in comparison to palmitate and oleate (Mancini et al., 
2015), clearly revealing signalling bias.   In this PhD study, the low maximal response 
of TAK-875 and the other FFA1 agonist, JTT may be attributed to potential partial 
activity of these agonists in Gαq/Ca
2+ signalling. 
 
Like the FFA1 receptor, FFA4 can also be internalised upon agonist stimulation 
(Hirasawa et al., 2005; Watson et al., 2012; Hudson et al., 2013).   Hirasawa et al. 
(2005) demonstrated that 1 h incubation of the LCFA, α-linolenic acid (10 µM) caused 
internalisation of EGFP-tagged FFA4 in HEK293 cells.   Hudson et al. (2013) went 
on further to investigate β-arrestin 2 recruitment and internalisation of GPR120S, the 
human short FFA4 isoform that closely resembles mouse FFA4.  In this study, 
GW9508 activated GPR120S and this resulted in the recruitment of β-arrestin 2 (EC50 
= 7.9 µM) in HEK293 cells.  This potency was not dissimilar to the potency of 
GW9508 observed in their calcium mobilisation assay.  Furthermore, GW9508 (100 
µM) stimulated GPR120S internalisation with a half-life of 13 min and FFA4 
endocytosis was predominantly non-recyclable.  In the same study, the selective and 
potent FFA4 agonist, TUG891 (at 10 µM) induced robust FFA4 phosphorylation and 
internalisation of FFA4 in a HEK293 cell line expressing human FFA4, which was 
clearly observed within 10 mins (Hudson et al., 2013).  The TUG891 EC50 (17.0 nM) 
obtained in the β-arrestin assay was similar to the EC50 of TUG891 in descending 
colon mucosa in this PhD study.  In another study, the LCFA, DHA (EC50 = 1 µM) 
induced FFA4 phosphorylation in a HEK293 cell line expressing human FFA4 (short 
isoform).  Furthermore, DHA (1 µM)  stimulated human FFA4 internalisation within 
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15 min (Sánchez-Reyes et al., 2014).  Recently, the FFA4 agonist, Met-36 efficiently 
recruited β-arrestin in U2OS cells expressing human FFA4, and obtained an EC50 
value of 1400 ± 700 nM (Sundström et al., 2017).  This is far less potent than the 
potency derived in this PhD study, which may suggest that 100 nM Met-36 may not 
recruit β-arrestin.  The low potency of Met-36 observed by Sundström et al. (2017) 
may be attributed to the transfection of human, not mouse FFA4.  Thus, this PhD study 
cannot rule out the possibility that Met-36 recruited β-arrestin to the FFA4 receptor, 
resulting in a low maximal response.  Taken together, FFA4 agonism prompts receptor 
phosphorylation, β-arrestin recruitment and receptor internalisation.  These 
mechanisms occur within a period of 10 -15 min and may underpin the low maximal 
response of the AZ selective FFA4 agonists utilised in this thesis.  
 
Preliminary studies by Lauffer et al. (2009) demonstrated that when the human cell 
line, hNCI-H716 was incubated with PSN632408 (10 µM) for 6 h, this caused a 
significant decrease in subsequent OEA (70 %) or PSN632408 (50 %) induced GLP-
1 secretion.  This suggested GPR119 may undergo homologous desensitisation.  For 
the first time, Hassing et al. (2016b) showed the GPR119 agonist, AR231453 was 166-
fold more potent than the endogenous GPR119 agonist, OEA in a β-arrestin 
recruitment assay, utilising U2OS A2 cells, expressing GPR119.  Furthermore, 
recently AR231453 also displayed high potency with low maximal responses in mouse 
colon mucosa (Tough et al., 2018b).  Thus, GPR119 partial agonists may recruit β-
arrestin more potently than endogenous GPR119 agonists.  In this thesis, GPR119 
desensitisation was observed when the mucosa was pretreated with a high 
concentration of the GPR119 agonist, PSN632408, followed by a second application 
of PSN632408.  However, a lack of FFA1 and FFA4 desensitisation was observed 
when the mucosa was pretreated with a high concentration of PSN632408, followed 
by the application of a FFA1 or FFA4 agonist.  This indicated the GPR119 receptor 
may undergo homologous desensitisation but not cross-desensitisation, as shown 
previously by Lauffer et al. (2009).  Notably, a limitation of this experimental design 
lies in the fact that there was no wash out period after the first PSN632408 addition.  
A lack of a response to the second addition of GPR119 agonist (PSN632408 or 
Cpd.42) may be attributed to first addition PSN632408 still occupying, activating and 
competing with the second addition of GPR119 agonist for occupancy of the GPR119 
receptors.  Therefore, a significant lower response would be observed to the second 
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GPR119 agonist as the receptors would already be occupied and activated.  Recently, 
GPR119 homologous desensitisation was also observed with various potent synthetic 
GPR119 agonists and PSN632408 (at the same concentration used in this PhD study, 
30 µM) in HEK293 cells (Zhang et al., 2014), which is consistent with the findings in 
this thesis.   
 
Taken together, activation of FFA1, FFA4 and GPR119 with highly potent selective 
agonists, appears to recruit β-arrestin to each receptor.  As β-arrestin proteins are 
essential in receptor desensitisation and internalisation (Luttrell and Lefkowitz, 2002), 
the low maximal responses displayed by the AZ agonists may be a result of bias 
signalling towards enhanced desensitisation and potential internalisation of these lipid 
receptors.  This may be the reason tachyphylaxis was observed by the GPR119 clinical 
candidate, GSK1292263 (Kang, 2013).  Repeated dosing of GSK1292263 in a Phase 
II trial was unable to reduce plasma fasting glucose or glucose AUC(0-24h) on day 13 
or 14 in T2DM subjects, compared to placebo (Nunez et al., 2014).  Therefore, this 
clinical trial was terminated due to lack of efficacy.       
 
  
4.3 Regional variation of FFA1, FFA4 and GPR119 responses were more readily 
observed after VIP application 
For the first time, the regional variation of FFA1, FFA4 and GPR119 agonism was 
assessed along the length of the GI tract on basal Isc and after VIP pretreatment, in 
native intestinal mucosa utilising the AZ selective agonists.    Agonism of FFA1, FFA4 
or GPR119 revealed a similar response profile on basal Isc and after VIP, however the 
changes in Isc after VIP were greater and more readily observed.  VIP allowed 
subsequent FFA1, FFA4 and GPR119 agonism to be more readily revealed, as the 
absolute Isc after VIP was greater in comparison to the absolute basal Isc.   
 
The endogenous neuropeptide, VIP is a high affinity agonist of epithelial VPAC 
receptors (VPAC1 and VPAC2) (Laburthe et al., 2007).  VPAC1 is highly expressed 
in the colon (proximal and distal) and the small intestine (Karacay et al., 2001; 
Jayawardena et al., 2017) whereas, VPAC2 is highly expressed in the colon (Harmar 
et al., 2004; Jayawardena et al., 2017).  Radioligand binding studies have shown VIP 
binds to basolateral not luminal epithelial membranes in rat jejunum and rabbit ileum 
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(Dharmsathaphorn et al., 1983), and therefore VIP was applied basolaterally in this 
PhD study.    As VPAC1 is the known predominant VIP receptor in the mouse intestine 
and colon, VIP responses in this thesis were presumably mediated via VPAC1 
throughout the GI tract and VPAC2 may have had a role, specifically in the colon.  
The VPAC GPCRs are Gαs-coupled, activation of which increases AC and 
accumulates cAMP, which elevates the Isc  (Vaudry et al., 2009).  In this thesis, VIP 
pretreatment was used for enabling further characterisation of FFA1, FFA4 and 
GPR119 mucosal investigations. 
 
4.3.1 FFA1 responses  
In the present study, FFA1 mucosal responses after VIP appeared uniform along the 
length of the GI tract.  This compared well with an initial study in mouse that utilised 
lacZ activity to show FFA1 expression was equally scattered along the GI tract, 
specifically in the duodenum, jejunum, ileum and colon (Edfalk et al., 2008).    FFA1 
responses after VIP in the mid-ileum were similar (modestly larger) to the responses 
observed in other regions of the GI tract.  These findings correlated with mouse FFA1 
mRNA relative expression findings, which indicated that FFA1 mRNA was greatest 
in the ileum and slightly lower in the distal regions of the GI tract (Symonds et al., 
2015).   Similarly, rat FFA1 mRNA (RT-PCR) was greatest in the ileum and equally 
expressed in duodenum, jejunum, caecum and colon (Itoh et al., 2003).  More recently, 
FFA1 mRNA was also detected in human ileal mucosa (Tsukahara et al., 2015).  Taken 
together, mouse and rat FFA1 mRNA appears to be highly expressed in the ileum, and 
this correlated with findings in this thesis, which showed FFA1 responses after VIP 
were greatest in this region too.  As the expression and agonism of FFA1 appeared 
modestly larger in the ileum compared to FFA4 and GPR119 agonism, the FFA1 
receptor may be the predominant lipid receptor in this area.   
 
4.3.2 FFA4 responses 
FFA4 mucosal responses were largest in the ascending colon and VIP pretreatment 
more readily revealed FFA4 agonism in the terminal ileum, which was modestly lower 
than agonism in the ascending colon.  The regional variation of FFA4 agonism 
revealed by VIP was identical to the relative FFA4 mRNA expression profile along 
the length of the mouse GI tract (Symonds et al., 2015).  Hirasawa et al. (2005) also 
revealed FFA4 mRNA expression (RT-PCR) was largest in the colon compared to the 
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ileum, in mouse and human (Hirasawa et al., 2005).  Furthermore, in another study the 
relative expression of FFA4 increased along the length of the GI tract, with largest 
expression observed in the proximal mouse colon, which was consistent with findings 
in this PhD study (Ito et al., 2009).  As FFA4 expression and FFA4 agonism was 
greatest in the proximal colon compared to FFA1 or GPR119 agonism, the FFA4 
receptor may be the primary lipid receptor in this region.   
 
4.3.3 GPR119 responses 
Mucosal GPR119 anti-secretory responses increased in size along the length of the GI 
tract, on basal Isc and after VIP, with the largest response observed in the descending 
colon, as displayed previously (Cox et al., 2010; Patel et al., 2014).  This was also 
consistent with initial investigations demonstrating GPR119 expression was greater in 
the mouse colon than the small intestine, utilising a 32P-labeled riboprobe containing 
an antisense mouse GPR119 sequence (Chu et al., 2008).  Furthermore, the largest 
GPR119 response in the descending colon in this thesis correlated with the highest 
expression level of GPR119 mRNA (RT-PCR) in this region (Symonds et al., 2015). 
Recently, Moss et al. (2016) demonstrated that GLP-1 secretion to the synthetic 
GPR119 agonist, AR231453 and the endogenous GPR119 agonists, namely OEA and 
2-OG from mouse primary cultures, was greatest in the colon, compared to the ileum 
and duodenum/jejunum (Moss et al., 2016).  These findings were consistent with the 
GPR119 response profile observed in this thesis.  Furthermore, Moss et al. (2016) 
revealed agonist-stimulated GLP-1 secretion was absent in colonic GPR119-/- cultures, 
indicating GLP-1 secretion was GPR119-mediated.  Taken together, the findings in 
the present study, which were consistent with previous studies, confirm GPR119 
agonism was greatest and more readily observed in the descending colon. 
 
Lipids are predominantly absorbed and sensed in the duodenum (Iqbal and Hussain, 
2009), a region where enteroendocrine L cells are relatively sparse (Sundler et al., 
1993).    In the present study, FFA1, FFA4 and GPR119 are predominantly expressed 
in the ileum, ascending colon and descending colon, respectively.  Physiologically, in 
healthy individuals’ dietary lipid metabolites are unlikely to be found in these distal 
intestinal regions (the ileum and colon).  This does not mean these three receptors are 
not involved in lipid sensing in the upper intestine.  In the proximal intestine, FFA1, 
FFA4 and GPR119 are expressed in CCK-containing I cells (Liou et al, 2011; Sykaras 
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et al., 2012) and GIP-containing K cells (Parker et al., 2009; Iwasaki et al., 2015).  
Thus, these three lipid receptors can be activated by dietary LCFAs in this region.  
Additionally, GPR119 is a well-known constitutively active receptor (Chu et al., 2007) 
and is also activated by endogenously synthesised OEA (Overton et al., 2006) and 
dietary-derived 2-OG (Hansen et al., 2011; Hassing et al., 2016a).  Therefore, all three 
receptors in I or K cells could be activated as the luminal nutrient levels rise 
postprandially, and this would cause CCK and GIP secretion (see Table 1.2 for major 
functional effects of CCK and GIP).   
 
As the greatest FFA1, FFA4 and GPR119 anti-secretory responses were observed in 
the distal small intestine and colonic regions, this suggests these lipid receptors may 
have a role in pathophysiological or drug/surgery-induced lipid malabsorption.  In 
humans, colipase-deficiency (Hildebrand et al., 1982), pancreatic lipase-deficiency 
(Adrian et al., 1986), combined colipase/pancreatic lipase-deficiency (Ghishan et al., 
1984), chronic destructive pancreatitis and coeliac disease (also known as tropical 
sprue) (Adrian et al., 1986) all result in lipid malabsorption and steatorrhea.  Colipase 
is the pancreatic enzyme that allows pancreatic lipase to anchor onto the surface of 
triglycerides in the presence of bile, to initiate triglyceride hydrolysis (Erlanson-
Albertsson, 1992; Lowe, 1997).  Lipid absorption is reduced by approximately 50-75 
% in colipase or pancreatic lipase deficiency (Hildebrand et al., 1982; Ghishan et al., 
1984), allowing significant amounts of unabsorbed triglycerides and lipid metabolites 
to reach the distal intestine and colon.  As FFA1, FFA4 and GPR119 agonism was 
greatest in these areas of the GI tract, one would expect the arrival of some LCFAs 
here (attributed to steatorrhea) to cause PYY release.  Indeed, pre- and postprandial 
plasma PYY was increased in patients with steatorrhea induced by coeliac disease or 
chronic destructive pancreatitis. Furthermore, patients with steatorrhea exhibited 
increased weight loss and prolonged orocecal transit time (Adrian et al.,1986), which 
may have been attributed to the elevation in PYY.   
 
Orlistat, a drug that inhibits the activity of pancreatic lipase by approximately 30 %, 
consequently causes steatorrhea and a 10-fold increase in faecal fat mass (Guerciolini 
et al., 2001).  Long-term Orlistat usage has been shown to elevate pre-prandial PYY 
and GLP-1 levels and prolong orocecal transit time (Olszanecka-Glinianowicz et al., 
2013).  These effects may contribute to the modest weight loss these patients observe 
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and may suppress appetite and enhance insulin secretion with chronic drug use.  
Recently, steatorrhea was observed in some patients one-year post-RYGB surgery and 
this was associated with higher postprandial plasma PYY levels and prolongation of 
the ileal brake (O’Keefe et al., 2017).  Thus, the presence of triglyceride metabolites 
in the distal intestine and colon presumably activates L cell FFA1, FFA4 and GPR119, 
which may lead to PYY release.  Released PYY contributes to the ileal and colonic 
brakes (Spiller et al., 1984; Spiller et al., 1988; Lin et al., 1996) and is a defender 
against hypersecretion (Playford et al., 1990).  Therefore, these three receptors are 
likely to be involved in the slowing of gut motility, which enhances lipid absorption 
and may prevent malnutrition in individuals experiencing steatorrhoea.  Furthermore, 
functional agonism of these receptors may provide protection against diarrhoea and 
also contribute to the modest weight loss observed in Orlistat-treated individuals 
(Olszanecka-Glinianowicz et al., 2013).    
 
The descending colon was selected as the optimal region for subsequent mucosal 
studies as this area of the GI tract is highly enriched with enteroendocrine PYY-
containing L cells, which express all three lipid receptors.  Moreover, this region also 
provided similar FFA1, FFA4 and GPR119 mucosal responses after VIP.  As Y1 
receptors are highly enriched in the PYY-negative enterocytes surrounding the L cells 
(Mannon et al., 1999), this juxtaposition of PYY-containing L cells and enterocyte Y1 
receptors allowed PYY-Y1 signalling to be interrogated.  Therefore, the descending 
colon provided the greatest possibility of revealing specific L cell-mediated FFA1, 
FFA4 and GPR119 signalling mechanisms.  
 
4.4 PYY-Y1 but not PYY-Y2 mediation of FFA1, FFA4 and GPR119 signalling in mouse 
colonic mucosa 
For the first time, FFA1 and FFA4 agonist responses in the mouse colon were shown 
to be Y1 receptor-mediated.  The mucosal responses to the selective GPR119 agonist 
were also Y1 receptor-mediated and not affected by Y2 blockade, as shown previously 
utilising the following GPR119 agonists, namely PSN632408 (Cox et al., 2010) and 
PSN-GPR119 (Patel et al., 2014).    This predominant PYY-Y1 signalling mechanism 
suggested FFA1, FFA4 and GPR119 agonism did not involve enteric neurons. 
Pretreatment of the mucosa with TTX revealed neuronal tone attributed to the 
blockade of intrinsic neurogenic secretory activity.  This was observed as a decrease 
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in Isc as shown previously (Cuthbert and Hickman, 1985; Cox et al., 1988; Cox and 
Tough, 2002; Tough et al., 2011).  Furthermore, FFA1, FFA4 and GPR119 responses 
were TTX-insensitive indicating FFA1, FFA4 and GPR119 activity was epithelial in 
origin and did not involve TTX-sensitive submucosal neurons.  The TTX-insensitivity 
of GPR119 agonism has been revealed previously when investigating mucosal 
function, utilising the following GPR119 agonists, PSN632408 and PSN-GPR119 
(Cox et al., 2010; Patel et al., 2014), and this was consistent with findings in this thesis.  
As a result, FFA1, FFA4 and GPR119 signalling in colonic mucosa was mediated by 
endogenous PYY acting on local epithelial Y1 receptors (Gαi-coupled).  This inhibited 
AC activity and epithelial cAMP production, which limited anion secretion via CFTR 
(Figure 4.2) and caused an anti-secretory response.  The epithelial Y1 mediation and 
lack of any Y2 (neuronal) involvement is consistent with the previous findings for 
other L cell-enriched receptors e.g. MC4 (Panaro et al., 2014), FFA2 (Forbes et al., 
2015) and the calcium-sensing receptor (Joshi et al., 2013).  
 
 
Figure 4.2: FFA1, FFA4 and GPR119 agonism is PYY Y1-mediated resulting in 
inhibition of anion (Cl-) secretion.  Activation of apical (and basolateral, unlabelled 
for clarity) FFA1, FFA4 and GPR119 receptors with selective agonists (shown in 
figure) activates Gαq and Gαs-signalling in the L cell to cause PYY release.  PYY binds 
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epithelial Y1 receptors (Gαi) in a paracrine manner which consequently inhibits anion 
secretion via the CFTR channel.  Thus, this lowers the Isc and is observed as an anti-
secretory response.  VIP released from secretomotor submucosal neurons (or 
application of exogenous VIP) binds epithelial VPAC receptors (coupled to Gαs), and 
this increases cAMP accumulation to cause anion (presumably Cl-) secretion via 
CFTR. 
 
4.4.1 Y1 and Y2 tonic activity  
The Y1 (BIBO3304) and Y2 (BIIE2046) competitive antagonists revealed Y1 and Y2 
tonic activity respectively, indicative of endogenous PYY-Y1 and NPY-Y2 activity.  
The degree of anti-secretory tone mediated by the Y1 and Y2 receptors was similar to 
that shown previously in mouse colon (Hyland et al., 2003; Hyland and Cox, 2005; 
Tough et al., 2011).  Tough et al. (2011) demonstrated that Y1 tone was significantly 
reduced (90 %) in PYY-/- and remained unaffected in NPY-/- colonic mucosal 
preparations.  Conversely, the Y2 tone was partially inhibited in both PYY
-/- and NPY 
-/-
 preparations.  The residual response observed in PYY
-/- mucosae was TTX-sensitive.  
Moreover, Y1 and Y2 tone was abolished in double NPY/PYY
-/- colonic mucosa.  This 
confirmed that the Y1 anti-secretory tone was epithelial in origin and PYY-mediated, 
whereas the Y2 tone was neuronal and predominantly NPY-mediated (Hyland et al., 
2003; Hyland and Cox, 2005; Tough et al., 2011).  Thus, in this PhD, endogenous 
PYY and NPY activated Y1 and Y2 receptors to cause tonic Y1 and Y2 activity, 
respectively.  Y1 receptor tone may also be an indicator of tonic L cell PYY release.  
Indeed, Crivellato et al. (2002) demonstrated murine and human GI EECs undergo a 
slow secretory mechanism of stored peptides from the cell cytoplasm secretory 
vesicles, termed piecemeal degranulation (PMD).  Utilising transmission electron-
microscopy (TEM), this study clearly illustrated that the secretory granules lost 
density, structure and their matrices were loosely packed/diminished in mouse and 
human EECs.  The peptides within these granules were completely or partially absent, 
leaving large translucent granules that did not fuse with one another or the plasma 
membrane (Crivellato et al., 2002; Crivellato et al., 2003).  This revealed an active L 
cell mechanism, which consequently caused release of stored peptide hormones.  
Activation of L cell receptors by endogenous mediators or receptor constitutive 
activity may initiate PYY release and underpin the mechanism of PMD in these cells.  
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4.5 Ex4 GLP-1 responses were largest in the ascending colon and a DPPIV inhibitor 
had the tendency to increase the stability of Ex4 in this region 
4.5.1 Ex4 GLP-1 responses were largest in the proximal colon 
In this PhD study, the mucosal responses to the GLP-1 agonist, Ex4 were graded along 
the length of the colon (Tough et al., 2018a).  The secretory response observed in the 
ascending colon declined in size towards the rectum and transitioned into an anti-
secretory response in the descending colon.  Furthermore, these mucosal responses 
were Ex(9-39)-sensitive, confirming the responses were GLP-1R-mediated, as shown 
previously (Joshi et al., 2013).  In 2013, Joshi et al. demonstrated GLP-1 sensitivity 
was greater in the proximal colon compared with the descending colon.  The proximal 
colon is the main region of fluid absorption (Barrett and Raybould, 2010).  Notably, 
4-20 % of patients on GLP-1 mimetics experience diarrhoea (Filippatos et al., 2014).  
Thus, greater GLP-1 signalling in the proximal colon may contribute to the diarrhoeal 
side effects experienced in these patients.  This regional variation of GLP-1 responses 
raises the importance of future studies to stipulate the region of colon utilised.   
 
4.5.2 The GLP-1R and CGRP mechanism 
In the ascending colon, the Ex4 GLP-1 mucosal responses were TTX-sensitive (Tough 
et al., 2018a).  Indeed, this confirmed that in the ascending colon, the GLP-1R was 
neuronally located.   In the descending colon, Ex4 anti-secretory responses were too 
small to definitively confirm TTX-sensitivity.  However, in both regions of the colon 
the Ex4 response was CGRP receptor-mediated.   Approximately, 20 % of colonic 
submucosal cholinergic neurons co-stained for CGRP, and these ChAT/CGRP 
neurons were highly abundant in the ascending colon compared to the descending 
colon (Foong et al., 2014).  Tough et al. (2018a) attributed this difference in the 
preponderance of ChAT/CGRP neurons in these colonic regions to the functional 
differences observed between the proximal and distal colon in their study.  Thus, 
released GLP-1 activated GLP-1R on intrinsic submucosal neurons containing CGRP.  
The released CGRP activated epithelial CGRP receptors (Gαs-coupled), which 
increased the production of cAMP and this opened anion channels, presumably CFTR 
and caused Cl- secretion (Figure 4.3).  Thus, in the ascending colon Ex4-induced a 
secretory response (Tough et al., 2018a).   The finding that the GLP-1R was neuronally 
located in the colon was opposed by data published by Kedees et al. (2013).  In their 
study, they showed GLP-1R localisation on mucosal epithelia in CD1 mouse ileum 
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and colon.  However, the GLP-1R antibody utilised in their study was non-specific 
(Kedees et al., 2013).  More recently, Richards et al. (2014) showed the localisation 
of the GLP-1R in different tissues utilising a transgenic glpr-cre mouse model that was 
crossed with fluorescent reporter strains.  This allowed the expression of GLP-1R to 
be observed independent of a GLP-1R antibody.  In their study, they showed GLP-1R 
expression in myenteric neurons and cell bodies in the small intestine and colon, which 
was consistent with findings revealed by Tough et al. (2018a).  19 % of colonic 
neurons contained NOS and a small percentage stained for CGRP and other markers 
(calretinin and calbindin) associated with IPANs (Richards et al., 2014).  Thus, Tough 
et al. (2018a) proposed that these CGRP-containing sensory neurons were activated 


















Figure 4.3: GLP-1/CGRP mechanism in the ascending colon.  L cell released GLP-
1 activates GLP-1R on intrinsic submucosal neurons to cause CGRP release.  The 
released CGRP activates epithelial CGRP receptors (Gαs-coupled) (blocked by CGRP 
antagonist, BIBN4096) which open CFTR to increase Cl- secretion.  Image from 




4.5.3 DPPIV inhibition had no effect on GPR119 agonism 
While GLP-1 is the most common measured L cell hormone, in this PhD study no 
significant GLP-1 component was observed during FFA1, FFA4 or GPR119 agonism 
in descending colon mucosal preparations.  Having established the largest GLP-1 
sensitivity was found in the AC1-2 region of the ascending colon (Tough et al., 2018a), 
GPR119 agonism (utilising the full GPR119 agonist, PSN632408) was assessed in the 
presence of the DPPIV inhibitor, sitagliptin in this region and compared with mucosal 
responses in the descending colon.  The DPPIV inhibitor prevents rapid degradation 
of the GLP-1 and PYY peptides (Mentlein et al., 1993a; Mentlein et al., 1993b), thus 
increasing their stability.  In both regions of the colon in the presence of sitagliptin, 
the PSN632408 mucosal anti-secretory response was monophasic, not amplified by 
increased PYY stability and sitagliptin did not reveal any GLP-1 secretory component, 
as seen previously in mouse descending colon (Cox et al., 2010).  Consistently, Cox 
et al. (2010) demonstrated that the conversion of PYY to PYY(3-36) was not significant 
in GPR119 agonism utilising PSN632408, and that the DPPIV inhibitor (Cpd.3) did 
not reveal a GLP-1 component to GPR119 agonism in mouse and human descending 
colon.  More recently, the GPR119 agonist, AR231453 also displayed monophasic 
PYY Y1-mediated responses and lacked a GLP-1 response (Tough et al., 2018b).  
Notably, in human mucosa blockade of Y1 and Y2 receptors revealed a GLP-1 
component to the PSN632408 response (Cox et al., 2010). This suggested GLP-1 and 
PYY are co-released from enteroendocrine L cells and that the GLP-1 component was 
too small to be revealed in the presence of PYY Y1 and Y2 agonism in human tissue.  
Thus, the lack of a GLP-1 secretory response to GPR119 agonism (and FFA1 or FFA4 
agonism) in this thesis, was most likely attributed to the low levels of the GLP-1R 
expressed in submucosal neuronal fibres in the mouse colon (Richards et al., 2014), in 
comparison to the high expression levels of the epithelial Y1 receptors in this region 
(Mannon et al., 1999).  This contrasting ratio of receptor expression could limit GLP-
1 signalling in the colon, as PYY-Y1 epithelial responses would be more readily 
observed.  The DPPIV inhibitor, sitagliptin had the tendency to increase the stability 
of the Ex4 mucosal response in the ascending colon, indicated by the apparent increase 
in Isc compared to the control.  The small Ex4 mucosal response observed in the 
descending colon and the lack of effect of sitagliptin here, was most likely attributed 
to fewer GLP-1R containing ChAT/CGRP neurons in this region, in comparison to 
the ascending colon (Foong et al., 2014; Richards et al., 2014).    
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The lack of a GLP-1 secretory component associated with GPR119 agonism was at 
odds with previous studies in cell-based assays (ex vivo) and in vivo studies, which 
have shown GPR119 agonism robustly stimulates GLP-1 release (Chu et al., 2008; 
Mace et al., 2012; Patel et al., 2014; Hauge et al., 2015; Ekberg et al., 2016; Hassing 
et al., 2016a; Moss et al., 2016; Hauge et al., 2017).  Furthermore, PSN-GPR119 (Patel 
et al., 2014) and OEA (Mace et al., 2012) have been shown to increase GLP-1, GIP 
and PYY secretion in the presence of 5 mM glucose, in rat isolated intestinal loops.  
In this thesis, the AZ selective GPR119 agonists, Cpd. 42 and Cpd. 16 did not exhibit 
a GLP-1 secretory component to their responses in vitro.  However, in previously 
published studies both Cpd.42 and Cpd.16 increased plasma total GLP-1 levels in mice 
in vivo,  an effect that was elevated in the presence of sitagliptin (Scott et al., 2012; 
Scott et al., 2014).  These GPR119 preclinical studies have translated in human 
subjects as administration of GPR119 activators, 2-OG or C8-dietary oil (contains 2-
OG) have caused incretin secretion in vivo (Hansen et al., 2011; Mandøe et al., 2015).  
Thus, GPR119 agonism caused robust GLP-1 secretion in rodents and humans, but 
this was not observed in colonic mucosa in this PhD study in vitro.   
 
The absence of a GLP-1 secretory response may also be attributed to the recent 
discovery of differential peptide release from enteroendocrine L cells (Habib et al., 
2012; Cho et al., 2014; Cho et al., 2015; Grunddal et al., 2016).  In the past, various 
EECs were named according to their hormonal content using a letter code (L, K, I, N 
etc.).  Using this system, L cells contained GLP-1, GLP-2, PYY and OXM, K cells 
expressed GIP, I cells contained CCK and N cells secreted NTS.   Over the years, there 
has been a rise in evidence to suggest this system is less uniform than previously 
thought.  In 2012, Habib et al. (2012) utilised immunohistochemical analysis and 
FACs analysis to identify subsets of EECs.  Here, colonic L cells contained mRNA 
for PYY and GLP-1, whereas L cells in the small intestine contain mRNA for NTS, 
CCK, GIP and GLP-1 (Habib et al., 2012).  In 2015, Cho et al. investigated peptide 
localisation in colonic L cells in the mouse.  In addition to the classic GLP-1 and PYY 
containing L cells, various other peptide combinations were observed using triple 
labelling immunochemistry: GIP only cells, GIP/GLP-1, GLP-1 only, PYY only cells 
(Cho et al., 2015).  Cho et al. (2014) demonstrated that GLP-1 and PYY were also 
discovered in separate storage organelles in the same EEC, implying differential 
release may occur.  More recently, Grunddal et al. (2016) showed separate storage of 
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PYY, GLP-1, and NTS in murine distal small intestine, using super resolution 
structural illumination microscopy.  This differential PYY and GLP-1 release between 
L cells and peptide packaging within the same L cell vesicles, may contribute to the 
reason GPR119 agonism appeared to be mediated by a PYY Y1 epithelial mechanism, 
without the involvement of GLP-1, as shown previously with FFA2 agonism (Forbes 
et al., 2015).  Forbes et al. (2015) revealed FFA2 agonism in descending colon mucosa 
was PYY-Y1, not GLP-1-mediated in vitro.  This predominant PYY-Y1 signalling 
mechanism and the absence of a GLP-1 response to FFA2 agonism in vitro was also 
consistent with FFA1 and FFA4 signalling in this PhD study in vitro.   
 
4.5.4 FFA1 and FFA4 responses appeared GLP-1 independent  
Originally, it was reported that FFA1 and FFA4 were highly expressed in GLP-1-
containing L cells (Hirasawa et al., 2005; Edfalk et al., 2008).  Edfalk et al. (2008) 
demonstrated a HFD caused a rise in plasma GLP-1 (and GIP) concentrations in mice 
and these peptide secretions were reduced to basal levels in FFA1-/- mice.  This 
indicated a definitive role for the FFA1 receptor in GLP-1 secretion.  Later, Xiong et 
al. (2013) revealed a gavage of corn oil (containing linolenic and linoleic acid) evoked 
GLP-1 secretion and this was abolished in FFA1-/- mice, further confirming a major 
role for FFA1 in GLP-1 release  (Xiong et al., 2013).  Disappointingly, while the FFA1 
clinical candidate, TAK-875 improved glucose tolerance in diabetic Japanese human 
subjects, it did not evoke any incretin secretion (GLP-1 and GIP) in vivo (Kaku et al., 
2015).  Recently, mouse primary culture ex vivo preparations have been utilised to 
assess GLP-1 release upon application of endogenous LCFA or synthetic agonists.  In 
mouse colonic primary cultures, TAK-875 (1 µM) modestly elevated total GLP-1, 1.5-
fold above basal secretion, an effect that was eliminated in FFA1-/- cultures.  This 
modest increase in GLP-1 secretion was also observed in WT mice and was absent in 
FFA1-/- mice in vivo (Hauge et al., 2015).  In this thesis, the responses to the selective 
FFA1 agonists, TAK-875 and JTT (including the commercially available TUG424) 
were monophasic and lacked a GLP-1 component in descending colon mucosa.  Thus, 
FFA1 responses in this region of intestine appeared to be independent of a GLP-1-
mediated mechanism, which was consistent with the lack of TAK-875-induced 
incretin secretion observed in clinical trials.  Indeed, Ekberg et al. (2016) recently 
showed that the FFA1 receptor has a relatively small role in olive oil evoked incretin 
secretion (GLP-1 and GIP), by demonstrating loss of function in FFA1-/- mice.  
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Furthermore, TAK-875 was not an efficacious secretagogue of GLP-1 in ex vivo 
primary culture colonic preparations (Ekberg et al., 2016).  This suggested FFA1 on 
its own, did not have a major role in incretin secretion.   These findings and the lack 
of FFA1 GLP-1 response observed in this PhD study may also be attributed to 
potential partial Gαq-signalling activity of TAK-875 (Yabuki et al., 2013; Mancini et 
al., 2015) and TUG424 (Luo et al., 2012).  Unfortunately, the potential partial activity 
of these compounds could not be tested due to the unavailability of known full FFA1 
reference agonists.  Xiong et al. (2013) demonstrated a FFA1 partial agonist, AM-
6331 did not stimulate GLP-1 release ex vivo or in vivo in comparison to a full FFA1 
agonist, AM-8182 (Xiong et al., 2013).  Thus, in this thesis, a lack of a GLP-1 
component to FFA1 agonism may have been attributed to the partial activity of these 
AZ FFA1 agonists.  Whether the latter applies to FFA4 and GPR119 partial and full 
agonists has yet to be elucidated.  
 
The FFA4 receptor was identified in GLP-1 containing cells as the second 
characterised LCFA receptor (Hirasawa et al., 2005).  Hirasawa et al. (2005) measured 
portal vein and inferior vena cava plasma GLP-1 in response to α-linolenic acid in 
mice in vivo, implicating FFA4 in GLP-1 release.  However, α-linolenic acid also acts 
via FFA1 (Hara et al., 2011) and this experiment was not carried out in FFA4-/- mice 
to demonstrate GLP-1 release was FFA4, not FFA1-mediated (Hirasawa et al., 2005).  
Indeed, there has been an increasing body of evidence to suggest FFA4 has a relatively 
minor role, if any, in GLP-1 release in rodents (Xiong et al., 2013; Paulsen et al., 2014; 
Ekberg et al., 2016).  In the present study, like FFA1 agonism, the mucosal responses 
observed with the FFA4 selective agonists, namely Met-36, AZ423, were monophasic 
without any indication of a GLP-1 component.  These findings were consistent with 
those observed by Xiong et al. (2013) displaying corn oil-induced GLP-1 responses 
were not eliminated in FFA4-/- mice in vivo, indicating no role for FFA4 in GLP-1 
secretion (Xiong et al., 2013).  Additionally, Ekberg et al. (2016) recently 
demonstrated a previously efficacious FFA4 agonist, Metabolex-204, had no effect on 
GLP-1 release in ex vivo mouse primary colonic cultures and has a minor role (not 
significant) in GLP-1 release in vivo (Ekberg et al., 2016).  Taken together, the 
findings in this PhD study were similar to those previously published and suggested 




4.6 FFA1 and FFA4 antagonists revealed AZ agonists were highly selective  
4.6.1 ANT825 and GW1100 were selective FFA1 antagonists  
The potency of the AZ FFA1 competitive antagonist, ANT825 was not dissimilar from 
its potency (EC50 = 158.5 nM) obtained in a HEK293 cell line expressing human 
FFA1, measuring inositol monophosphate (Waring et al., 2015).  In this thesis, the 
commercially available FFA1 antagonist, GW1100 (IC50 = 1.0 µM; (Briscoe et al., 
2006)) abolished TUG424 responses but not TUG891 responses, showing FFA1 
selectivity, as seen previously (Briscoe et al., 2006).  Like GW1100, ANT825 
abolished FFA1 responses but both FFA1 antagonists also partially inhibited GW9508 
responses, indicating that at this concentration (1 µM); GW9508 exerted dual agonism 
via FFA1 and another receptor.  ANT825 had no effect on FFA4 or GPR119 agonism 
confirming the FFA1 selectivity of this FFA1 antagonist.   
 
4.6.2 AH-7614 was a selective FFA4 antagonist in mouse descending colon 
Interrogation of the selectivity of the FFA4 agonist, Met-36, with the FFA4 antagonist, 
AH-7614 in native mouse descending colon, revealed a concentration-dependent 
inhibition of the Met-36 response.  Notably, Met-36 is known to possess 100-fold 
higher selectivity for FFA4 in comparison to FFA1 (Stone et al., 2014).  This inhibition 
of FFA4 agonism was not as potent as the potency of AH-7614 observed in the original 
study (IC50 = 7.9 nM), utilising U2OS human osteosarcoma cells expressing mouse 
FFA4 (Sparks et al., 2014), and was not dissimilar from the IC50 of AH-7614 revealed 
at the mouse FFA4 receptor in the presence of TUG891 (500 nM), in a β-arrestin 
recruitment assay in HEK293T cells (IC50 = 11.7 nM (10.2 – 13.5)) (Watterson et al., 
2017).  These differences may be attributed to the fact that antagonist IC50 
measurements in different assays/studies were not directly comparable as the 
concentration of agonist utilised often varied between studies.  In this PhD study, 10 
µM AH-7614 did not completely inhibit FFA4 agonism (Met-36).  This finding was 
consistent with Watterson et al. (2017) demonstrating that FFA4 agonism (TUG891, 
3 µM) induced FFA4 internalisation, and this effect was not completely inhibited in 
the presence of 10 µM AH-7614.  This indicated that AH-7614 displayed negative 
allosteric modulator (NAM) properties when inhibiting the functional effect of 
TUG891 (Watterson et al., 2017).  Thus, Watterson et al. (2017) termed AH-7614 a 
NAM.  Having established the GW9508 response was partially FFA1-mediated, the 
GW9508 response was investigated in the presence of the FFA4 NAM, AH-7614 in 
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combination with and the FFA1 antagonist, ANT825.  The GW9508 response was 
significantly reduced, more so than the GW9508 response in the presence of ANT825 
alone.  Thus, GW9508 exerted dual FFA1 and FFA4 agonism, in the mouse 
descending colon.  Originally Briscoe et al. (2006) showed GW9508 raised [Ca2+]i in 
HEK293 cells expressing the human FFA4 receptor, a functional effect that was not 
affected by the FFA1 antagonist, GW1100 (Briscoe et al., 2006), demonstrating 
GW9508 was also FFA4 selective.  In this PhD study, GW9508 exerted dual agonism 
via FFA1 and FFA4 in mouse descending colon mucosa.   
 
4.6.3 FFA1 antagonism revealed FFA1 mucosal tone  
The FFA1 antagonists, namely ANT825 and GW1100, revealed for the first time a 
degree of endogenous FFA1 tonic activity in colonic mucosa.  Furthermore, ANT825 
revealed FFA1 tone was uniform along the length of the GI tract, as similarly observed 
in the tissue survey of FFA1 agonism in this thesis (Results, Figure 3.3).  The degree 
of FFA1 tonic activity was similar to that observed with the MC4 antagonist, HS014 
(Panaro et al. 2014) and the competitive GPR119 antagonist, AR436352 (Tough et al., 
2018b).  Since endogenous FFA1, MC4 and GPR119 agonism stimulates PYY release 
from L cells, blockade of these receptors inhibits endogenous PYY release and Y1 
activation, causing a consequent increase in Isc.  Thus, FFA1 agonism (as well as 
GPR119 or MC4 agonism) by endogenous mediators may underpin the tonic activity 
observed in the mucosa.  Tonic activity may also be an indicator of a constitutively 
active receptor.  Stoddart et al. (2007) reported FFA1 appeared as an apparent highly 
constitutively active receptor in HEK293 cells, utilising a 5’-O-(3-
[35S]thio)triphosphate([35S]GTPγS) binding assay.  However, bovine-serum albumin 
(BSA) reduced the basal [35S]GTPγS binding in the immunoprecipitates and this was 
attributed to the binding of BSA to FFAs.  Furthermore, binding was also eliminated 
by the FFA1 antagonist, GW1100 and the Gαq/Gα11 inhibitor, YM254890 (Stoddart et 
al., 2007).  As a result, the ‘FFA1 constitutive activity’ was more likely attributed to 
the binding of an unidentified endogenous mediator.  MCFA/LCFA are the 
endogenous activators of FFA1 (Itoh et al. 2003).  Thus, lipid metabolites hydrolysed 
during food intake (chow) that are present in the lamina propria, or an unidentified 




4.6.4 The absence of FFA4 tone may be attributed to FFA4 agonism in L cells and 
enterocytes 
Unlike, the FFA1 antagonists (ANT825 and GW1100), this PhD study revealed for 
the first time that the FFA4 NAM, AH-7614 had no effect on basal FFA4 tone.  The 
lack of FFA4 tone was surprising as most endogenous LCFAs non-selectively activate 
both FFA1 and FFA4 (Briscoe et al., 2003; Briscoe et al., 2006; Hara et al., 2011).  
While FFA4 was originally identified in GLP-1 containing L cells (Hirasawa et al., 
2005), two independent groups have revealed FFA4 is highly expressed in mouse and 
rat enterocytes, as well as L cells (Figure 4.4) (Paulsen et al., 2014; Ekberg et al., 
2016).   Assuming FFA4 was broadly expressed in the mucosal preparations in this 
PhD study and an unidentified endogenous ligand non-selectively activated both FFA1 
and FFA4, the FFA4 receptor may have been tonically active in L cells (like the FFA1 
receptor) and the surrounding enterocytes.  Theoretically, tonic L cell FFA4 activity 
could increase PYY-Y1 activity and thus reduce the Isc.  Assuming FFA4 also couples 
to Gαq in the neighbouring enterocytes, here activation of FFA4 may lead to the 
mobilisation of [Ca2+]i via the PLC-PKC/IP3 signalling pathway, to stimulate 
intermediate signalling cascades which increase Cl- secretion (presumably via CFTR) 
thus raising mucosal Isc  (Berger et al., 1993; Billet and Hanrahan, 2013a; Billet et al., 
2013b; Kunzelmann and Mehta, 2013).  Therefore, L cell FFA4 activity may be 
counteracted by enterocyte FFA4 activity (Figure 4.4).  In this way, in the presence of 
the FFA4 NAM, negative modulation of L cell FFA4 tonic activity would raise the Isc 
and this could be counteracted by the action of the FFA4 NAM at the enterocyte FFA4 
receptor i.e. a decrease in Isc (Figure 4.4).  As a result, no change in Isc would be 
190 
 
observed upon addition of the FFA4 NAM and this could appear as a lack of FFA4 
tone, as observed in this thesis.    
 
Figure 4.4: Proposed model of FFA1 and possible FFA4 tonic activity.  
Endogenous LCFAs activate FFA1 causing L cell PYY release, which activates 
epithelial Y1 receptors in a paracrine manner.  This causes inhibition of anion 
secretion.  In the presence of a FFA1 antagonist, ANT825 the basal Isc increased, 
indicating the FFA1 receptor was tonically active.  The FFA4 receptor is widely 
expressed in enterocytes and enteroendocrine L cells.  Thus, activation of FFA4 in L 
cells results in inhibition of anion secretion via a PYY-Y1 mechanism, whereas 
activation of FFA4 in the enterocytes stimulates anion secretion.   Y1 and Y2 receptors 
were blocked pharmacologically with the competitive Y1 (BIB03304) and Y2 
(BIIE2046) antagonists, respectively.  
 
The combination of the FFA4 NAM and FFA1 antagonist decreased basal Isc (but this 
was not significant) and eliminated the FFA1 tone that was previously observed in the 
presence of ANT825 alone.  Notably, L cells are outnumbered by the population of 
enterocytes in each mucosal preparation.  In this way, the activity of the FFA4 NAM 
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in the surrounding enterocytes (i.e. decreasing basal Isc) may counteract the increase 
in basal Isc attributed to FFA1 tonic activity (Figure 4.4).  As a result, an overall 
decrease in basal Isc may be observed upon application of the FFA4 NAM in 
combination with the FFA1 antagonist, as observed in this PhD study.  To investigate 
this hypothesis, the Y1 and Y2 receptors were selectively blocked with competitive Y 
antagonists, which eliminated the PYY-Y1/Y2 signalling attributed to L cell tonic 
activity (Figure 4.4). This allowed the effect of the FFA4 NAM to be further assessed 
specifically in enterocytes.  Firstly, FFA1 tonic activity was abolished in the presence 
of the Y antagonists, and thus FFA1 tone was PYY Y1/Y2-mediated.  Secondly, in the 
presence of both Y antagonists, the FFA4 NAM, AH-7614 significantly decreased the 
Isc, as the consequence of L cell tonic activity which previously counteracted this 
response, was abolished.   Furthermore, a significant decrease in Isc to ANT825 + AH-
7614 was observed in the presence of Y receptor blockade, further confirming FFA4 
enterocyte activity was limited by L cell tonic activity.  Taken together, FFA4 is 
expressed in enterocytes and L cells where it appears to be tonically active.  Notably, 
the AZ FFA4 agonists did not reveal any indication of an FFA4-mediated enterocyte 
secretory mechanism.  Thus, the FFA4 anti-secretory responses may be limited by a 
small secretory component that is not immediately evident in descending colon 
mucosa.  
 
4.7 FFA1, FFA4 and GPR119 responses were glucose-sensitive  
For the first time, selective activation of FFA1 and FFA4 in descending colon mucosa 
was shown to be glucose-sensitive.  Additionally, GPR119 agonism was also glucose-
sensitive, as shown previously.  These findings were consistent with previous glucose-
sensitivity observed in investigations of L cell-specific activation of GPR119 (Cox et 
al., 2010; Patel et al., 2014; Tough et al., 2018b), MC4 (Panaro et al., 2014), the 
calcium-sensing receptor (Joshi et al., 2013) and FFA2 (Forbes et al., 2015).  
Furthermore, PYY responses were glucose-insensitive, and therefore enterocyte Y1 
receptors were able to respond to PYY, in the absence of glucose as observed in 
previous studies (Cox et al., 2010; Joshi et al., 2013; Panaro et al., 2014; Patel et al., 
2014; Forbes et al., 2015; Tough et al., 2018b).  In this way, the presence of glucose 
regulates L cell FFA1, FFA4 and GPR119 agonism, but does not affect downstream 
PYY-Y1 signalling.  As a result, this signalling pathway should only occur in the 
presence of luminal postprandial nutrients, and thus could protect against 
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hypoglycaemia in vivo, a disadvantage of current T2DM anti-diabetics on the market, 
namely sulphonylureas and insulin.   
 
FFA1, FFA4 and GPR119 receptors were considered clinically favourable targets as 
they were not only co-expressed in GI L cells, but also differentially expressed in the 
pancreas.  FFA1 and GPR119 were identified in pancreatic β-cells (Itoh et al., 2003; 
Chu et al., 2007) and FFA4 was recently discovered in somatostatin-containing delta 
cells (Stone et al., 2014).  Thus, released L cell GLP-1 could prompt insulin release 
via GLP-1R on pancreatic β cells.  Additionally, in the pancreas, a FFA1 or GPR119 
agonist could simultaneously directly elevate insulin release postprandially.  While 
FFA4 agonism inhibits glucose-stimulated somatostatin-14 secretion from pancreatic 
delta cells in murine islets of Langerhans, a mechanism that was Gαi-coupled attributed 
to its pertussis-toxin sensitivity (Stone et al., 2014).  Physiologically, somatostatin 
inhibits β cell insulin secretion.  Therefore, FFA4 activation (Gαi) in delta cells inhibits 
somatostatin release, which could result in prolongation of insulin secretion.  
Certainly, the LCFA, DHA potentiated insulin secretion in murine islets, and this 
functional effect was lost in islets isolated from GPR120-/- mice (Stone et al., 2014).    
This combination of indirect and direct FFA1, FFA4 and GPR119 effects could 
improve glucose tolerance with minimal risk of hypoglycaemia.  Indeed, the FFA1 
agonist that progressed to Phase III clinical trials, TAK-875, improved glucose 
tolerance and presented with a low risk of hypoglycaemia, in Japanese patients with 
T2DM (Kaku et al., 2015).  This PhD study confirmed the glucose-sensitivity of TAK-
875 in native mouse colonic tissue in vitro. 
 
A lack of glucose-sensitivity has been displayed in primary canine L cells (Damholt 
et al., 1998) and fetal rat intestinal L cells (Roberge and Brubaker, 1991). These 
findings questioned the glucose responsiveness of the L cell in these species.   Several 
studies in GLUTags (Reimann and Gribble, 2002; Gribble et al., 2003), primary 
transgenic mouse L cell cultures (Reimann et al., 2008), isolated perfused rat colon 
(Plaisancié et al., 1995) and in humans in vivo (Herrmann et al., 1995) have shown 
glucose triggers GLP-1 secretion.  Initial investigations into the glucose-sensitivity of 
GLP-1 release in GLUTags has demonstrated that a high glucose-sensitivity in the 
range of 0 - 5 mM exists in this cell line (Reimann and Gribble, 2002; Gribble et al., 
2003).  A high glucose-sensitivity was also displayed in primary small intestine 
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cultures (EC50 = 4 mM) and colonic cultures (EC50 = 0.7 mM) (Reimann et al., 2008).  
As a result, GLP-1 release appeared glucose-sensitive and low millimolar glucose 
concentrations were required to elicit GLP-1 secretion.  Controversially, in a recent 
study GPR119 agonism appeared to be glucose-independent in primary mouse colonic 
cultures and in vivo (Lan et al., 2012).  Notably, Lan et al. (2012) utilised two 
independent GPR119 agonists, the first named B3 was tested in primary colonic 
cultures and the second GPR119 agonist, MBX-2982 was used in vivo.  Firstly, 
ablation of GLP-1 secretion to B3 was not tested in  primary colonic GPR119-/- 
cultures to confirm the glucose-insensitivity of its response was GPR119-mediated 
(Lan et al., 2012). Therefore, this functional effect of B3 may have been an off-target 
compound response.  Secondly, the GPR119 agonist, MBX-2982 increased GLP-1 in 
the absence of glucose after an overnight fast in vivo (Lan et al., 2012).  Notably, 
luminal (Kellett and Brot-Laroche, 2005) and plasma concentrations of glucose are 
around 5 mM after an overnight fast (Results, Figure 3.19).   In this way, after an 
overnight fast, the glucose concentration is still adequate to cause L cell GLP-1 
release, as the L cell glucose-sensitivity lies within a low millimolar range (Reimann 
and Gribble, 2002; Gribble et al., 2003; Reimann et al., 2008).  In this way, GPR119-
mediated (MBX-2982) GLP-1 secretion would be observed in the presence of “no 
glucose” in C57BL/6 mice.  In another study, Lan et al. (2009) demonstrated a 
glucose-load enhanced GLP-1 secretion in vivo and this effect was eliminated in 
GPR119-/- mice (Lan et al., 2009).  This further confirmed GPR119 responses were 
glucose-responsive, as shown previously (Chu et al., 2008; Cox et al., 2010; Patel et 
al., 2014; Tough et al., 2018b).   
 
The glucose-sensitivity of the L cell has been attributed to the glucose-sensing 
machinery, SGLT1 and GLUT2, both of which are highly expressed in mouse primary 
cultured intestinal/colonic cells.  Initial investigations of the low capacity/high affinity 
Na+ glucose co-transporter, SGLT1 in these primary cultures revealed SGLT1 was 
widely expressed from the mid-intestine to the colon.  The expression of the high 
capacity/low affinity facilitative glucose transporter, GLUT2 was high in the proximal 
GI tract and decreased along the length of the gut (Reimann et al., 2008).  In the mouse, 
SGLT1 has been suggested as the predominant glucose absorption transporter in the 




4.7.1 L cell glucose-sensitivity machinery: SGLT1 and GLUT2 and their involvement 
in FFA1, FFA4 and GPR119 agonism 
On basal Isc, the combination of the SGLT1 inhibitor, phloridzin and the GLUT2 
inhibitor, phloretin induced a time-dependent biphasic response.  Firstly, the intake of 
Na+ and glucose via apical SGLT1 increases Isc. Thus, the presence of phloridzin 
revealed a decrease in Isc, as observed previously (Cox et al., 2010; Joshi et al., 2013; 
Patel et al., 2014; Forbes et al., 2015; Panaro et al., 2014; Tough et al., 2018b).  
Secondly, uptake of glucose from the basolateral mucosal surface via GLUT2 
decreases the Isc and thus the GLUT2 inhibitor, phloretin is expected to increase the 
basal Isc.  In this way, the first component of the biphasic response observed under 
basal conditions was attributed to phloridzin and the second component to phloretin.  
 
In this PhD study, blockade of SGLT1 and GLUT2 with phloridzin and phloretin 
respectively, abolished FFA1, FFA4 and GPR119 agonism.  This implicated a critical 
requirement of SGLT1 and GLUT2 in FFA1, FFA4 and GPR119 L cell signalling.  In 
the mouse, SGLT1 and GLUT2 are both expressed in intestinal EECs and the 
surrounding enterocytes.  SGLT1 is trafficked to the luminal membrane (Reimann et 
al., 2008) and GLUT2 is located mainly in the basolateral membrane, but has also been 
identified in the apical membrane in mouse and rat (Gorboulev et al., 2012; Mace et 
al., 2012).  The facilitative transporter GLUT2 mediates a minor role in small intestinal 
glucose absorption when the luminal glucose concentration levels are low (i.e. during 
fasting periods) (Kellett and Brot-Laroche, 2005).  When the glucose concentration is 
low, GLUT2 is expressed minimally in the apical membrane.  As the luminal glucose 
concentration rises, apical GLUT2 expression is upregulated, under the control of 
SGLT1, a mechanism that is eliminated in SGLT1-/- mice (Gorboulev et al., 2012) 
(Figure 4.5).  A low level of GLUT2 expression in the apical membrane during fasting 
periods prevents glucose transport down its concentration gradient, from the plasma 
into the lumen via GLUT2.  In this way, minimal apical GLUT2 expression provides 
a protective mechanism to prevent unnecessary elimination of glucose during periods 
of low glucose intake, and thus GLUT2 regulation is an essential glucose transporter 
to maintain glucose homeostasis.  
SGLT1 and GLUT2 are critical regulators of incretin secretion.  Loss of SGLT1 
abolished the GLP-1 and GIP functional responses to an intragastric gavage of glucose 
in mice, demonstrating an important role of SGLT1 in L and K cell incretin release 
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(Röder et al., 2014).  In another study, a significant loss of GLP-1 release to a glucose 
load was revealed in GLUT2-/- mice (Cani et al., 2007), clearly linking GLUT2 to the 
regulation of incretin secretion.   Similarly, GLUT2 is essential for approximately 55 
% of incretin secretion in L and K cells in rats (Mace et al., 2012).  In this way, the 
glucose-sensing machinery, SGLT1 and GLUT2 of enteroendocrine L cells ensures 
peptide secretion is glucose-sensitive.   Approximately >80 % of D-glucose absorption 
in the luminal membrane occurs primarily via the Na+ glucose-cotransporter, SGLT1 
in mice (Gorboulev et al., 2012).  This was confirmed by Röder et al. (2014) as 
approximately 80 % loss of glucose uptake was demonstrated in SGLT1-/- mice.   As 
GLUT2 is trafficked in high glucose to the luminal membrane to ensure luminal and 
plasma glucose equilibrates, it is unlikely apical GLUT2 plays a major role in this PhD 
study as FFA1, FFA4 and GPR119 signalling was assessed in the presence of 11.1 
mM glucose, a concentration similar to the measured plasma glucose concentration 
before a 16 h overnight fast (at ~ 5.30 pm i.e. mice were satiated and resting) (Results, 
Figure 3.19).  Therefore, in this thesis, the glucose-sensitivity of FFA1, FFA4 and 
GPR119 was most likely primarily mediated by apical SGLT1 and basolateral 





Figure 4.5: FFA1, FFA4 and GPR119 glucose-sensitivity is mediated via SGLT1 
and GLUT2 in the L cell.  Activation of FFA1, FFA4 and GPR119 with selective 
agonists (apical application) stimulated Gαq (FFA1 and FFA4) and Gαs (GPR119) 
signalling, only in the presence of apical glucose.  Furthermore, in the presence of 
glucose, FFA1, FFA4 and GPR119 responses are eliminated in the presence of SGLT1 
inhibitor, phloridzin and the GLUT2 blocker, phloretin.  SGLT1 is the predominant 
glucose-transporter of the L cell and apical GLUT2 is expressed at low levels during 
fasting periods and is upregulated during high glucose, to equilibrate glucose levels in 
the plasma and lumen.  
 
4.8 Co-agonism of FFA1, FFA4 and GPR119 was additive, not synergistic in the 
descending colon 
Physiologically after a meal, triglycerides are hydrolysed by intestinal pancreatic 
lipase yielding, 2-MAG and FFAs, endogenous activators of enteroendocrine L cell 
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GPR119 and FFA1/FFA4, respectively (Figure 1.2).  In this way, postprandial 
concomitant activation of FFA1, FFA4 and GPR119 may act synergistically to 
enhance peptide release, particularly PYY release that could be measured indirectly 
via the Y1 epithelial response.  To probe for possible synergistic effects between FFA1, 
FFA4 or GPR119 activation, highly selective synthetic agonists (at EC80 
concentrations) were chosen to stimulate two or more receptors (triple receptor 
agonism discussed in section 4.10) at any one time, in descending colon mucosa.  The 
combined agonist responses were compared with the responses to single agonist 
application.  Notably, combined agonists were added to the mucosa in a single 
application to mimic experiments carried out in murine colonic primary culture 
preparations (Ekberg et al., 2016; Hauge et al., 2017).   
 
In this thesis, all the responses to the following co-agonism combinations of selective 
FFA1, FFA4 and GPR119 agonists: FFA1 + FFA4, FFA1 + GPR119 and FFA4 + 
GPR119, were additive but not synergistic, when compared with responses exhibited 
by single agonism.  This demonstrated that the combined agonism of two independent 
receptors increased the capability of the L cell to secrete PYY, as measured by the 
larger anti-secretory response.  Furthermore, the delayed maxima of the combined 
responses to GPR119 + FFA1 agonism and GPR119 + FFA4 agonism compared to 
the maxima of single agonism may be attributed to the integration of intracellular 
signalling pathways in the L cell and/or the surrounding enterocytes, as a consequence 
of coincident Gαs-sustained (GPR119) and Gαq-transient (FFA1 or FFA4) L cell 
activation.  The additive effects of combined agonism were consistent with the 
additive findings observed by Hauge et al. (2017) but were at odds with the synergistic 
effects observed by Ekberg et al. (2016).  In murine colonic cultures prepared from 
C57BL/6 mice, the synergistic effects of selective potent agonists were assessed by 
measuring GLP-1 secretion over a 3 h agonist incubation period, in the presence of 10 
mM glucose.  A synergistic response was defined as a response that was greater than 
an additive effect.  Ekberg et al. (2016) observed synergistic GLP-1 secretion when 
utilising a low concentration of a GPR119 agonist (AR231453, 10-9 M) along with a 
higher concentration of a FFA1 agonist (TAK-875, 10-5 or 10-6 M).  Furthermore, an 
additive, not a synergistic effect was revealed when combining the GPR119 agonist 
(AR231453, 10-9 M) with a FFA4 agonist (Metabolex-209, 10-5 or 10-6 M) (Ekberg et 
al., 2016), as seen in the current study.   The absence of a synergistic effect of the 
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combined FFA4 agonist (Metabolex-209) and GPR119 agonist to stimulate GLP-1 
secretion, confirms the minor role of the FFA4 receptor in GLP-1 release.   Later in a 
separate study, the combination of a GPR119 agonist (AR246881, 10-9 M) and a FFA1 
agonist (MK-2035, 10-8 – 10-7 M) in murine primary colonic cultures was additive and 
not synergistic (Hauge et al., 2017).  This was most likely attributed to the utilisation 
of a low concentration (nM range) of the FFA1 agonist, in comparison to the higher 
concentration (µM range) used by Ekberg et al. (2016).  It would appear certainly in 
these two studies, that a low concentration (nM range) of a GPR119 agonist (coupled 
to Gαs) and a higher concentration (µM range) of a FFA1 agonist (coupled to Gαq) is 
required to elicit synergistic GLP-1 release.   
 
In the present study, the concentration of the FFA1 agonist, TAK-875 was identical to 
the TAK-875 concentration (1 µM) utilised by Ekberg et al. (2016).  Thus, the absence 
of an observed synergistic effect in the present study may be attributed to the use of a 
rather high concentration (EC80, nM - µM) of a GPR119 agonist, Cpd.16 compared to 
the lower concentration of a GPR119 agonist (nM range) used in recent published 
investigations (Ekberg et al., 2016; Hauge et al., 2017).  Notably, differences in assay 
preparations (i.e. Ussing chamber mouse mucosal sheets versus mouse primary 
colonic cultures) may contribute to the observed lack of synergy in the current study.  
While both assays utilised the mouse colon in the presence of glucose, the present 
study specifically investigated mechanisms in the descending colon, in single mucosal 
preparations (exposed area, 0.14 cm2), whereas murine colonic cultures were created 
by mincing the entire mouse colon (Ekberg et al., 2016; Psichas et al., 2017).  In 
murine colonic cultures, active GLP-1 release was measured over a 3 h period in 
primary L cell cultures, whereas Ussing chamber mucosal responses to agonism or co-
agonism were monitored over 20 mins.  One could argue that the mucosal responses 
were measured in more of an acute setting in native tissue.  Furthermore, within this 
20 min period, mucosal responses represented a downstream PYY-Y1 paracrine 
mechanism (in the absence of DPPIV-inhibitor) and was not a direct measure of GLP-
1 release from L cells.  Hence, PYY is likely to undergo DPPIV hydrolysis before it 
can bind enterocyte Y1 receptors, limiting the Isc recording of the actual PYY-Y1 
response.  As a result, if co-agonism was indeed synergistic, PYY degradation limits 
this observation.  Moreover, co-agonism investigations in murine primary L cell 
cultures measured GLP-1 secretion, and in this present study a GLP-1 component was 
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not observed in FFA1, FFA4 or GPR119 agonism.   Therefore, this PhD study cannot 
rule out the fact that differences between the described additive responses and 
synergistic effects observed by Ekberg et al. (2016) may be attributed to the recent 
discovery of GLP-1 only and PYY only segregated L cells (Cho et al., 2015).  
Furthermore, GLP-1 and PYY storage has also been identified in separate vesicles in 
the same cell (Cho et al., 2014).  In this way, activation of the L cell with potent and 
selective FFA1, FFA4 or GPR119 agonists could lead to differential L cell GLP-1 and 
PYY release, which may also be dependent on the intestinal region under 
investigation.  
 
4.9 The dietary FFA, pinolenic acid was a dual FFA1 and FFA4 agonist  
The dietary FFA, pinolenic acid constitutes 15-20 % of PNO (Christiansen et al., 2015) 
and administration of PNO has been associated with a reduction in food intake 
(Hughes et al., 2008; Pasman et al., 2008) and weight gain (Le et al., 2012; Park et al., 
2013), and an increase in energy expenditure (Hughes et al., 2008).  Pasman et al. 
(2008) observed a 25 % rise in GLP-1 and a 60 % increase in CCK-8 in overweight 
post-menopausal woman after administration of PNO, compared to the control group. 
The rise in these two peptide hormones was thought to contribute to appetite 
suppression (Pasman et al., 2008).  The FFA1 and FFA4 receptors are expressed in 
GLP-1 containing L cells (Hirasawa et al., 2005; Edfalk et al., 2008) and CCK-
containing I cells (Liou et al., 2011; Sykaras et al., 2012).  Recently, pinolenic acid 
was described as a selective dual FFA1 and FFA4 agonist in HEK293 cells 
(Christiansen et al., 2015).  In this PhD study, the function and pharmacology of 
pinolenic acid was tested in mouse native descending colon for the first time.  Here, 
the potency and efficacy of pinolenic acid resembled that of the commercially 
available dual agonist, GW9508.  Moreover, the potency in native tissue was 
consistent with the potencies exhibited in HEK293 cells expressing mouse FFA1 or 
FFA4, in a Ca2+ mobilisation assay (Christiansen et al., 2015).  Christiansen et al. 
(2015) demonstrated pinolenic acid was similarly potent at the mouse FFA1 and FFA4 
receptors in a Ca2+ mobilisation study, with EC50 values of 2.8 µM and 3.6 µM, 
respectively (Christiansen et al., 2015).  In the current study, like GW9508, pinolenic 
acid was selective for both the FFA1 and FFA4 receptors, demonstrating dual agonism 
in native tissue.  The residual pinolenic acid mucosal response in the presence of the 
combined FFA1 antagonist and FFA4 NAM was attributed to the NAM properties of 
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AH-7614 (Watterson et al., 2017).  The pinolenic acid response was abolished in the 
presence of the competitive Y1 and Y2 antagonists, BIBO3304 and BIIE2046, 
respectively.  Therefore, L cell derived PYY acts via Y1 and presumably Y2, 
underpinning the pinolenic acid mucosal response.  Physiologically, the released PYY 
could potentially reduce GI motility (Pironi et al., 1993; Lin et al., 1996; Lin et al., 
2000; Tough et al., 2011), increase central satiety (PYY(3-36)) and reduce food intake 
and weight gain.  Thus, pinolenic acid may contribute to the beneficial effects of PNO 
administration described earlier in humans and rodents (Pasman et al., 2008; Le et al., 
2012; Park et al., 2013).  
 
4.10 Triple co-agonism of FFA1, FFA4 and GPR119 was not additive and potentially 
led to Y1 receptor desensitisation 
In the presence of the triglyceride, olive oil, Ekberg et al. (2016) utilised various 
knockout mice (FFA1-/-, FFA4-/-, GPR119-/- and double FFA1/FFA4-/-) to shown 
FFA1, FFA4 and GPR119 all contributed to GLP-1 release, but to different extents in 
vivo.  Ekberg et al. (2016) demonstrated that the GPR119 receptor and the FFA1 
receptor had a similar importance for GLP-1/GIP release after lipid ingestion, while 
FFA4 had a relatively minor contribution (Ekberg et al., 2016).   To date, this PhD 
study is the first to show concomitant agonism of L cell FFA1, FFA4 and GPR119 
with potent and selective synthetic agonists, in native mouse descending colon 
mucosal preparations in vitro.  These experiments display a more accurate 
representation of postprandial L cell activation compared to co-agonism.  Triple 
receptor agonism was assessed utilising EC80 concentrations of the dual FFA1 and 
FFA4 agonist, pinolenic acid in combination with a full GPR119 agonist, PSN632408 
or the AZ selective GPR119 agonist, Cpd.16.  Triple receptor agonism was 
hypothesised to result in an additive mucosal anti-secretory response, presumably 
larger than the co-addition mucosal responses.  However, the combined response to 
pinolenic acid with each GPR119 agonist was not additive.  Moreover, PSN632408 L 
cell signalling appeared limited when this agonist was added in combination with the 
dual agonist, pinolenic acid.  The concentration of PSN632408 was potentially too 
high, and a lower concentration (in the nM range) should ideally be assessed in 
accordance with previous studies (Ekberg et al., 2016; Hauge et al., 2017), to observe 




Notably, while L cell triple receptor agonism appeared ‘blunted’ it is possible that 
PYY release was additive.  However, mucosal anti-secretory responses are a 
measurement of the consequent paracrine effects of PYY release, involving further 
enterocyte downstream signalling.  In this way, a large increase in PYY release evoked 
by triple receptor agonism could potentially cause desensitisation and internalisation 
of the finite population of Y1 receptors in the surrounding enterocytes, in each mucosal 
preparation.  The neighbouring enterocyte Y1 receptors might be less responsive to the 
large increase in PYY and therefore conceal any potential additive effects (Figure 4.6).  
Indeed, Holliday and Cox (2003) demonstrated in colonic carcinoma epithelial layers 
that as the concentration of exogenous PYY increased (3 nM – 1 µM), the PYY 
response became more transient and this was possibly a consequence of Y1 receptor 
desensitisation (Holliday and Cox, 2003; Holliday et al., 2005).  Furthermore, the Y1 
receptor underwent agonist (NPY)-stimulated phosphorylation and the involvement of 
the G-protein coupled receptor kinase 2 (GRK2) was critical in this process.  
Phosphorylation of the Y1 receptor by GRK2 was required for β-arrestin 2 recruitment 
and this signalling pathway most likely underpinned Y1 receptor desensitisation.  
Furthermore, NPY (100 nM) induced rapid (within 5 min) internalisation of Y1 
receptors via clathrin-dependent endocytosis, and this was inhibited by the 
pretreatment of the competitive Y1 antagonist, BIBO3304, in HEK293 cells (Holliday 
et al., 2005).  In another study, the Y1 receptor was also shown to rapidly internalise 
upon agonist stimulation in HEK293 cells, via clathrin-dependent endocytosis 
(Gicquiaux et al., 2002).  Gicquiaux et al. (2002) revealed submembrane 
internalisation occurred within 5 min (Gicquiaux et al., 2002; Pheng et al., 2003) and 
endocytosed receptors recycled back to the submembrane region slowly, but within 60 
min (Gicquiaux et al., 2002).  More recently, using super-resolution imaging, NPY 
(100 nM) was shown to induce rapid clathrin-dependent Y1 internalisation (within 5 
min) in HEK293 cells (Kempf et al., 2015).  Thus, as the Y1 receptor undergoes rapid 
desensitisation and internalisation, it is possible that the increase in PYY release after 
triple receptor agonism (pinolenic acid + PSN632408) led to Y1 desensitisation and 
presumably subsequent internalisation.  As a result, the anti-secretory response would 





Figure 4.6: FFA1, FFA4 and GPR119 agonism in the L cell.  The GPR119 agonist, 
PSN632408 elicits a large PYY-Y1(Gαi) anti-secretory response.  However, additional 
application of the dual FFA1 and FFA4 agonist, pinolenic acid limits PSN632408-
induced L cell signalling, presumably as a consequence of a large increase in released 
PYY, which leads to PYY-Y1 desensitisation and internalisation via clathrin-
dependent endocytosis.  The endocytosed Y1 receptors are recycled back slowly to the 
plasma membrane.  
 
Taken together, in this thesis, the combination of two agonists (utilising an EC80 
concentration) resulted in additive responses.  However, an appropriate low 
concentration (nM range) of a GPR119 agonist applied concomitantly with a high 
concentration (µM range) of a FFA1 agonist, appears to act synergistically to release 
L cell peptides (i.e. GLP-1) (Ekberg et al., 2016).  Physiologically, a very low 
concentration of nutrients arrives in the distal intestine postprandially, as most 
nutrients are primarily absorbed and sensed in the proximal intestine.  The 
concentration of nutrients that arrive in the distal intestine may be low enough (nM - 
µM, Ekberg et al., 2016) to elicit co-agonism and synergistic GLP-1 and presumably 
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PYY release, in vivo.  In this way, these nutrients may act to prolong the slowing of 
transit and enhance satiety during fasting periods.  Pathophysiological conditions that 
induce steatorrhoea (as described in section 4.3.3), increase the intraluminal lipid 
content in the colon and this enhances PYY release (Adrian et al.,1986).  This rise in 
PYY levels may desensitise Y1 signalling (Holliday and Cox, 2003), and may also 
cause internalisation of the Y1 receptor (Holliday et al., 2005).  Thus, unresponsive 
PYY-Y1 signalling attributed to Y1 desensitisation and internalisation, may contribute 
to the reason steatorrhoea is associated with more frequent and liquid stools i.e. 
diarrhoea (Ung et al., 2000), despite PYY being a known defender against diarrhoea 
(Playford et al., 1990).   
 
4.11 FFA1 and FFA4 agonism slowed colonic motility in vitro  
FFA1 (TUG424, TAK-875) and FFA4 (TUG891, Met-36) agonists attenuated colonic 
motility in vitro to a similar degree, as seen previously with MC4 (Panaro et al., 2014) 
and GPR119 agonism (Tough et al., 2018b).  These agonists decreased colonic 
motility presumably via the release of PYY, a known mediator of the colonic brake 
(Lin et al., 1996; Tough et al., 2011).  Pretreatment with the FFA1 antagonist, 
GW1100 revealed basal colonic mucosal tone (as seen in Ussing chamber studies), 
indicative of endogenous FFA1 activity.  In the presence of the FFA1 antagonist 
GW1100, the colonic brake induced by the FFA1 agonist, TUG424 was disinhibited 
and therefore colonic transit increased, whereas transit induced by the FFA4 agonist, 
TUG891 remained unaffected, demonstrating the selectivity of GW1100 for the FFA1 
receptor. 
 
4.11.1 FFA4 not FFA1 agonism slowed colonic motility in vivo 
As the FFA1 agonist, TAK-875 and the FFA4 agonist, Met-36 slowed transit in vitro, 
the translation of these effects was investigated in vivo.   Following the overnight fast, 
plasma glucose levels were reduced to 5 mM, a concentration similarly observed by 
Han et al. (2008) after an overnight fast in C57BL/6J mice (6 mM).   However, when 
FFA1 and FFA4 signalling was assessed in the presence of 5 mM glucose, mucosal 
responses were no different when compared with signalling in the presence of 11.1 
mM glucose, confirming the reduction in plasma glucose after an overnight fast does 
not affect FFA1 or FFA4 signalling.  Reimann and Gribble (2002) demonstrated that 
GLP-1 secretion was elevated as glucose increased from 0 - 5 mM in GLUTags, but 
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secretion plateaued as the glucose concentration incrementally increased from 5 - 25 
mM.  This revealed a low micromolar glucose-sensitivity of GLP-1 secretion 
(Reimann and Gribble, 2002), which was also shown in mouse L cell primary cultures 
(Reimann et al., 2008).  Indeed, this was consistent with the findings in this thesis, as 
an incremental increase in the glucose concentration from 5 to 25 mM did not affect 
FFA1 and FFA4 agonism.   
 
Met-36 significantly slowed colonic transit presumably via PYY, whereas TAK-875 
failed to show significant inhibition of bead colonic transit (when administered orally 
or via i.p.) or UGIT (i.p only).  This apparent lack of efficacy may be due to the 
administration of TAK-875 as a suspension.  In the in vitro transit studies, the isolated 
colon is severed from the CNS and TAK-875 acts directly upon colonic FFA1 
receptors.  In the in vivo study, it’s possible that the ability of TAK-875 to release PYY 
is not sufficient to alter colonic motility, with the added complication of modulatory 
CNS pathways.  As ANT825 had no effect on colonic or upper intestinal transit, the 
observed FFA1 tonic activity in vitro (Ussing chamber studies) was presumably not 
sufficient to result in an increase in transit in vivo.  The positive control, loperamide 
HCL, significantly slowed colonic and UGIT, as shown previously (Myagmarjalbuu 
et al., 2013).  Notably, there are concerns in the literature that isoflurane interferes 
with GI transit.   In 2005, Torjman and colleagues reported that 6 min exposure to 
isoflurane in rats slows UGIT by 50 % (Torjman et al., 2005).  In this PhD study, it is 
important to note mice received a 2 min exposure of isoflurane 1 h after the drug, 
vehicle or positive control were administered, followed by bead insertion and 
excretion.  Therefore, this brief exposure of isoflurane in the protocol (at the time of 
maximal drug exposure) should have minimal effect on colonic motility.  Furthermore, 
there were no differences in colonic transit rates between different vehicle controls (po 
vs i.p.) in this study, compared with those in a previous investigation (Forbes et al., 
2012).   
 
4.11.2 The FFA4 agonist, Met-36 increased motility in the upper intestine 
Unexpectedly, Met-36 was pro-motile in the upper intestine in vivo, when utilising the 
same dose that slowed transit in the colon.  In the upper intestine, FFA4 is expressed 
by I cells, K cells and L cells, causing release of CCK, GIP and PYY respectively, via 
Gαq-signalling (Hirasawa et al., 2005; Tanaka et al., 2008; Sykaras et al., 2012; Iwasaki 
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et al., 2015).  FFA4 has also been identified in gastric ghrelin and somatostatin cells, 
however FFA4 signals via Gαi to inhibit peptide release in these cells (Engelstoft et al. 
2013, Egerod et al. 2015).  GIP (Ogawa et al., 2011)  and PYY (Lin et al., 1996) slow 
small intestinal transit, while CCK increases upper intestinal transit in mice (Wang et 
al., 2004).  In this way, activation of I cell FFA4 may have contributed to the observed 
increase in transit, and thus antagonising the CCK-1 and CCK-2 receptors should 
abolish this effect.  More recently, RT-PCR revealed FFA4 in duodenal and colonic 
enterochromaffin cells (ECCs), which are responsible for secreting 5-HT (Martin et 
al., 2017).  These ECCs were recently revealed as a heterogenous population in the 
mouse.  In the upper intestine, particularly the mouse duodenum and jejunum, almost 
all of the 5-HT was found colocalised with CCK (50 – 60 %) or CCK with secretin 
(40 – 50 %) (Reynaud et al., 2016).   To date, there are no studies that have investigated 
FFA4 G-protein signalling mechanisms in ECCs.  In isolated guinea pig ileum, 
luminal perfusion of the MCFA, decanoic acid (1 mM) evoked propulsion and 
segmentation via release of 5-HT and CCK.  This was inhibited by antagonists of the 
5-HT3, 5-HT4, CCK-1 and CCK-2 receptors, demonstrating critical roles for these four 
receptors in fatty acid-induced propulsion and segmentation (Ellis et al., 2013).  As 
the FFA4 receptor is expressed in duodenal enteroendocrine I cells (Sykaras et al., 
2012) and ECCs (Martin et al., 2017), activation of FFA4 here could prompt CCK and 
5-HT secretion, to enhance motility and segmentation (Diwakarla et al., 2017).  Taken 
together, this suggests that in this thesis, Met-36 potentially activated FFA4 on ECCs 
and I cells to evoke 5-HT and CCK release, which may have increased UGIT.  This 
stimulation of UGIT may aid duodenal digestion and absorption.  Additionally, CCK 
is known to stimulate distal L cell PYY release, which slows motility and enhances 
nutrient absorption in the proximal intestine, via the ileal and colonic brakes (Lin et 
al., 1996; Lin et al., 2000). Notably, there was no indication of a 5-HT- or CCK-
mediated component to the FFA4 mucosal response in the upper intestine (mid-ileum) 
in vitro, and thus this potential mechanism was only observed in vivo.  
 
4.12 The prospects for future FFA1, FFA4 and GPR119 agonists in the 
pharmaceutical industry 
The AZ FFA1, FFA4 and GPR119 selective agonists were synthesised to investigate 
the potential of the FFA1, FFA4 and GPR119 receptors as anti-diabetic therapeutic 
targets.  These three receptors are expressed in the pancreas (Itoh et al., 2003; Chu et 
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al., 2007; Stone et al., 2014) and also in intestinal GLP-1 containing L cells (Hirasawa 
et al., 2005; Chu et al., 2008; Edfalk et al., 2008).  Theoretically, due to their distinctive 
distribution, selective agonism could cause intestinal L cell peptide release, and FFA1 
or GPR119 agonism might stimulate β cell insulin secretion, via a glucose-sensitive 
pathway and thus limit hypoglycaemia.  Indeed, in the current study FFA1, FFA4 and 
GPR119 agonism was glucose-sensitive in L cells.  This characteristic provides an 
advantage over some anti-diabetic therapeutics that cause hypoglycaemia, namely 
sulfonylureas and insulin.   
 
Although several GPR119 and FFA1 agonists have been synthesised and progressed 
into clinical trials, only one has surpassed phase II clinical trials, the FFA1 agonist, 
TAK-875 (Kaku et al., 2015; Li et al., 2016; Ritter et al., 2016).  The FFA1 agonist, 
JTT-851 (Japan Tobacco) has recently completed phase II studies, however no clinical 
outcomes have been disclosed (NCT01699737).  Unfortunately, several agonists that 
have progressed to phase II clinical trials have been terminated, often without 
disclosure of the underlying reason.  The GPR119 agonist, GSK1292263 that reached 
phase II clinical trials exhibited no safety issues, however no alterations in glucose, 
insulin or glucagon were observed when this agonist was administered alone or in 
combination with metformin.  This clinical trial was terminated due to lack of 
GSK1292263 efficacy (Nunez et al., 2014).  In the present study the novel AZ 
compounds were selective and potent but displayed low maximal responses in native 
mouse colonic mucosa, whereas the GPR119 agonists displayed partial activity in 
comparison to the commercial GPR119 agonist, PSN632408.   The lack of efficacy of 
the AZ compounds may be attributed to potent β-arrestin recruitment and subsequent 
receptor desensitisation/internalisation, resulting in tachyphylaxis.  Full agonists 
should be taken into consideration in future chemical optimisation studies, as they 
exhibit greater efficacy.  However, full agonists are often accompanied by low 
potency, high lipophilicity and large molecular size, which limits compound 
absorption.  Agonists that are highly lipophilic increase the potential for systemic 
permeation, CYP enzyme and hERG inhibition, and other unwanted side effects 
attributed to the peripheral and central expression (excluding the gut) of FFA1, FFA4 
and GPR119.  Recently, the expression of GPR119 was identified in skeletal myotubes 
and cardiac myoblasts in vitro.  GPR119 agonism (PSN632408) induced detrimental 
fatty acid/glucose metabolism and oxidation in skeletal myotubes (Cornall et al., 
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2013b), and downregulated genes involved in nutrient metabolism and inflammation 
states in H9c2 cardiac myoblasts (Cornall et al., 2012).  To date, it remains unknown 
whether these unwanted GPR119 effects will translate into rodent and human studies 
in vivo.   A luminal-restricted GPR119 agonist may increase the safety profile of a 
potential GPR119 candidate and minimise the adverse systemic effects.   However, a 
luminal-restricted GPR119 agonist would limit direct β cell GPR119 signalling and 
therefore rely on L cell GPR119 activation alone to improve glucose tolerance.  That 
said, for the first time β cell GPR119 agonism (AR231453) resulted in no difference 
in insulin, GLP-1 levels and glucose tolerance in selective β cell GPR119-/- and WT 
mice (Panaro et al., 2017).  This suggested activation of β cell GPR119 does not 
mediate the beneficial effects of GPR119 agonism, and therefore these effects may be 
solely incretin-mediated.  Thus, a potent orally available GPR119 agonist, which is 
restricted to the gut lumen and can substantially elevate L cell GLP-1 release, could 
increase the success rate of future GPR119 therapeutics.  Whether this is also the case 
for the β cell FFA1 receptor has yet to be elucidated.  The TAK-875 clinical trial was 
terminated due to liver failure (Kaku et al., 2015), which has been attributed to possible 
inhibition of liver bile transporters (Otieno et al., 2017; Wolenski et al., 2017).  As 
FFA1 receptors are not expressed in hepatocytes, the liver toxicity may have been a 
specific TAK-875 compound effect, and therefore holds promise for future FFA1 
clinical candidates.  However, luminal-restricted FFA1 agonists should be considered 
in future investigations.  
 
To date the high rate of attrition of FFA1 and GPR119 clinical candidates has been 
disappointing.  This has been attributed to the lack of translatability between 
preclinical animal studies and human clinical trials.  Additionally, potential variation 
in human and rodent enteroendocrine receptor expression and signalling variation may 
contribute to this attrition rate.   In terms of the FFA1 agonist, TAK-875, while many 
in vitro studies in primary cultures demonstrated TAK-875 increased GLP-1 secretion 
(Hauge et al., 2015; Ekberg et al., 2016; Hauge et al., 2017), this functional effect was 
not observed in native colonic tissue in this PhD study, and also did not translate in 
human studies (Araki et al., 2012; Kaku et al., 2015).  This questioned the ability of 
these agonists to stimulate GLP-1 release in vivo.  Thus, there is a clear preclinical 
need for assays based in native tissue in vitro, before carrying out in vivo experiments.  
This approach might provide the best chance of observing an accurate and translatable 
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response in vivo.  Another confounding factor may be the fact that agonism of FFA1, 
FFA4 or GPR119 may not result in substantial GLP-1 and PYY secretion, to mimic 
the high GLP-1/PYY plasma levels observed in individuals after bariatric surgery, 
which are thought to underlie the successful weight loss and improvement in glucose 
tolerance in these individuals (Miras and le Roux, 2013).  Furthermore,  there has been 
an increasing body of evidence over the length of this PhD to suggest the FFA4 
receptor has a minor contribution to GLP-1 release (Xiong et al., 2013; Paulsen et al., 
2014; Ekberg et al., 2016).  Over the years, FFA4 has been identified in enterocytes 
and L cells.  Thus, FFA4 is more broadly expressed in the intestine compared to the 
other L cell lipid receptors, GPR119 and FFA1.  As a result, selectively targeting L 
cell FFA4 becomes problematic.  The complexity increases as FFA4 couples to Gαi in 
other EEC types in the gut (Egerod et al., 2015; Koyama et al., 2016).  In this way, 
agonists may possess stimulatory effects in one cell but counter inhibitory effects in 
another.  To date, no FFA4 agonists have progressed to clinical trials.  While the FFA4 
receptor was presented as an ideal target for T2DM in 2005 (Hirasawa et al., 2005), 
today the FFA4 receptor is not a suitable candidate for T2DM.  
 
Taken together, as co-agonism of FFA1 and GPR119 act synergistically to prompt 
GLP-1 secretion in mice (Hauge et al., 2015; Ekberg et al., 2016) and co-agonism of 
these receptors is additive in native descending colonic mucosa, future T2DM 
therapeutics should optimally target FFA1 and GPR119.  Luminal-restricted FFA1 
and GPR119 agonists that are potent, efficacious and improve glucose-tolerance while 




Selective FFA1, FFA4 and GPR119 agonism potently inhibited mucosal anion 
secretion via a PYY-Y1 paracrine mechanism.  Mucosal responses were bi-directional, 
and therefore these receptors are most likely expressed on both the luminal and serosal 
domains of the L cell.  The novel AZ agonists were selective and more potent than the 
commercially available agonists but induced low maximal responses.  The AZ 
GPR119 agonists displayed partial activity in comparison to PSN632408, indicative 
of potential β-arrestin recruitment.  This may have resulted in acute desensitisation 
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and might be a possible contributing factor to the failure of many GPR119 and FFA1 
clinical candidates in the past.  FFA1, FFA4 and GPR119 mucosal responses were 
greatest in the ileum, ascending colon and descending colon, respectively.  Thus, these 
three receptors may have a major role to play in pathophysiological malnutrition states 
e.g. steatorrhoea.  Furthermore, FFA1, FFA4 and GPR119 agonism was independent 
of enteric neurons, and therefore their responses were epithelial in origin.  The 
glucose-sensitivity of FFA1, FFA4 and GPR119 agonism was mediated by SGLT1 
and GLUT2, and may well provide protection against hypoglycaemia, a side effect of 
current T2DM therapeutics, namely sulphonylureas and insulin.  Dual agonism was 
additive in native tissue, while the signalling to triple receptor agonism appeared 
limited, a possible consequence of Y1 desensitisation.   
 
The competitive Y1 and Y2 antagonists revealed Y1 and Y2 tone respectively, an 
indicator of tonic PYY release.  Additionally, the FFA1 antagonists, ANT825 and 
GW1100 revealed tonic FFA1 activity.  This suggested an endogenous ligand was 
activating the FFA1 receptor.  The lack of FFA4 tone in the presence of the FFA4 
NAM, AH-7614 may have been attributed to the broad expression of the FFA4 
receptor in L cells and the surrounding enterocytes.   Agonism of FFA1 and FFA4 
inhibited colonic transit in vitro, and FFA4 agonism induced regional differences in 
transit in vivo.  In the colon, FFA4 agonism slowed transit presumably via PYY, 
whereas in the upper GI tract FFA4 agonism was pro-motile and potentially involved 
5-HT/CCK-containing ECCs in the mouse in vivo.   
 
Taken together, FFA1 and GPR119 co-agonism may be beneficial therapeutically in 
T2DM and obesity in the form of potent luminal-restricted agonists, while the FFA4 
receptor does not appear to be a suitable target for future anti-diabetic and anti-obesity 
therapeutics attributed to its widespread distribution along the length of the GI 
epithelium.  Co-agonism more closely mimics the combinatorial activity of 
triglyceride metabolites in the diet.  Therefore, a GPR119 agonist in combination with 
a FFA1 agonist may act synergistically to amplify hormone release, and thus improve 
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